Nucleic acids encoding anchor-modified antibodies and their use

By manipulating nucleic acids in non-human animals, we developed immunoglobulins that encode anchor-modified antibodies, solving the problem of monoclonal antibodies being unable to treat target diseases that are difficult to bind to, and improving treatment efficacy.

JP7949106B2Active Publication Date: 2026-11-11REGENERON PHARMACEUTICALS INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2025087440
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-07-08
Filing Date
2025-05-26
Publication Date
2026-11-11
Estimated Expiration
2041-12-20

AI Technical Summary

Technical Problem

Existing monoclonal antibody products are ineffective in treating diseases associated with targets that are difficult to bind to and/or approach, necessitating new treatment methods.

Method used

By manipulating nucleic acids in non-human animals, we developed immunoglobulins encoding anchor-modified proteins. These anchor-modified immunoglobulins were then used to increase their affinity for anchored receptors and improve their binding properties.

Benefits of technology

It enhances the binding ability of immunoglobulins to anchored receptors, thereby improving the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007949106000014
    Figure 0007949106000014
  • Figure 0007949106000015
    Figure 0007949106000015
  • Figure 0007949106000016
    Figure 0007949106000016
Patent Text Reader

Abstract

To provide nucleic acids encoding anchor modified antibodies and uses thereof.SOLUTION: Described herein are anchor-modified immunoglobulin polypeptides, wherein the anchor moors the immunoglobulin polypeptide to a receptor of interest. The anchor-modified immunoglobulin polypeptides are generally characterized at the N-terminus with an anchor, e.g., the receptor binding portion of a ligand that binds a receptor. Non-human animals genetically modified with recombinant immunoglobulin segments that encode the anchor-modified immunoglobulin polypeptides are capable of making the anchor-modified immunoglobulin polypeptides. Such non-human animals also provided, along with methods and compositions for making and using the non-human animals. Methods for producing anchor-modified immunoglobulins from non-human animals are also provided, as well as anchor-modified immunoglobulins generated therefrom.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims the interests of U.S. Provisional Patent Application No. 63 / 129,893, filed on 23 December 2020, and U.S. Provisional Patent Application No. 63 / 219,402, filed on 8 July 2021, pursuant to Section 119(e) of the U.S. Patent Act, which are incorporated herein by reference, respectively.

[0002] Sequence List The sequence listing described in the file 10507WO01_ST25.txt is 47 kilobytes in size, was created on December 17, 2021, and is incorporated herein by reference in its entirety. [Background technology]

[0003] Monoclonal antibody products have revolutionized the biopharmaceutical industry, bringing about significant advances in the treatment of several diseases. Despite these advancements and the knowledge gained from using monoclonal antibodies for therapeutic purposes, diseases associated with targets that are difficult for monoclonal antibodies to bind to and / or access still exist, and it is believed that different approaches are needed to develop effective treatments. [Overview of the project] [Means for solving the problem]

[0004] This specification discloses the recognition that it is desirable to manipulate non-human animals as an improved in vivo system for identifying and developing novel antibody-based therapeutics, in some embodiments antibodies (e.g., monoclonal antibodies and / or fragments thereof), which can be used to treat a variety of diseases. The nucleic acids, non-human animals, methods, and polypeptides disclosed herein relate to anchor-modified immunoglobulins. The anchors described herein generally consist of a receptor-binding portion of a non-immunoglobulin polypeptide that binds to a congener receptor. The anchor attached to the immunoglobulin helps to increase the affinity of the immunoglobulin to the congener receptor of the anchor, thereby improving the binding properties of the immunoglobulin. This specification describes nucleic acid molecules encoding anchor-modified immunoglobulins, and / or nucleic acid molecules that can be used to modify a non-human animal so that the non-human animal can novelly generate anchor-modified immunoglobulins.

[0005] The anchor-modified immunoglobulins described herein are modified, at least in part, to encode an anchor between the Ig reader sequence and the framework (FR) and complementarity-determining region (CDR) of the germline V segment, and in a responsive linkage thereto, for example, the immunoglobulin (Ig) heavy chain variable region (V H ) segment or light chain variable region (V L ) may be coded by variable region (V) segments such as segments.

[0006] Therefore, nucleic acid molecules including targeted vectors and non-human animal genomes containing unreconstituted or reconstituted modified Ig V segments are also described. Furthermore, non-human animal genomes, non-human animal cells, and non-human animals containing the nucleic acid molecules described herein are also described herein.

[0007] The recombinant nucleic acid molecules described herein may include a modified immunoglobulin (Ig) variable (V) segment encoding an anchor-modified Ig polypeptide, wherein the modified Ig V segment includes a nucleic acid sequence encoding an anchor between a nucleic acid sequence encoding an Ig signal peptide and a nucleic acid sequence encoding a framework region (FR)1, complementarity-determining region (CDR1), FR2, CDR2, FR3, and CDR3 of a germline Ig V segment or a variant thereof, wherein the anchor-modified Ig polypeptide comprises, in a functional linkage, (i) an Ig signal peptide, (ii) an anchor, and (iii) FR1, CDR1, FR2, CDR2, FR3, and CDR3 of a germline Ig V segment or a variant thereof, wherein the anchor includes a receptor-binding portion of a target non-immunoglobulin polypeptide that binds to a congener receptor, and optionally, in this case, the recombinant nucleic acid molecule lacks any other V segment. The recombinant nucleic acid molecules described herein may include one or more (non)reconstituted Ig diversity (D) segments, one or more (non)reconstituted Ig binding (J) segments, and / or one or more Ig constant region (C) genes.

[0008] In some embodiments, the Ig signal peptide is an Ig signal peptide of the germline Ig V segment or a variant thereof. In some embodiments, the Ig signal peptide comprises the sequence MDWTWRFLFVVAAATGVQS (SEQ ID NO: 7). In some embodiments, the anchor comprises a linker that links the receptor-binding portion of the non-immunoglobulin polypeptide of interest to FR1, CDR1, FR2, CDR2, FR3, and CDR3 of the germline Ig V segment or a variant thereof. In some embodiments of the linker, the linker comprises the sequence GGGGS (SEQ ID NO: 5).

[0009] In some embodiments, the germline Ig V segment or its variant is the germline Ig heavy chain variable (V H)segment or a variant thereof, for example, a human (h) germline Ig V segment or a variant thereof, for example, germline human (h)V H 1-2 segment, germline hV H 1-3 segment, germline hV H 1-8 segment, germline hV H 1-18 segment, germline hV H 1-24 segment, germline hV H 1-45 segment, germline hV H 1-46 segment, germline hV H 1-58 segment, germline hV H 1-69 segment, germline hV H 2-5 segment, germline hV H 2-26 segment, germline hV H 2-70 segment, germline hV H 3-7 segment, germline hV H 3-9 segment, germline hV H 3-11 segment, germline hV H 3-13 segment, germline hV H 3-15 segment, germline hV H 3-16 segment, germline hV H 3-20 segment, germline hV H 3-21 segment, germline hV H 3-23 segment, germline hV H 3-30 segment, germline hV H 3-30-3 segment, germline hV H 3-30-5 segment, germline hV H 3-33 segment, germline hV H 3-35 segment, germline hV H 3-38 segment, germline hV H 3-43 segment, germline hV H 3-48 segment, germline hV H 3-49 segment, germline hV H 3-53 segment, germline hVH 3-64 segments, germline hV H 3-66 segments, germline hV H 3-72 segments, germline hV H 3-73 segments, germline hV H 3-74 segments, germline hV H 4-4 segment, germline hV H 4-28 segments, germline hV H 4-30-1 segment, germline hV H 4 30-2 segments, germline hV H 4-30-4 segment, germline hV H 4-31 segments, germline hV H 4-34 segments, germline hV H 4-39 segments, germline hV H 4-59 segments, germline hV H 4-61 segments, germline hV H 5-51 segments, germline hV H 6-1 segment, germline hV H 7-4-1 segment, germline hV H 7-81 segments, or variants thereof. In some embodiments, the germline IgV segment or its variant is the germline hV H 1-69 is a segment or a variant thereof. In some embodiments, the variant is an allele variant.

[0010] In some embodiments, recombinant nucleic acid molecules may include heavy chain variable region loci, for example, a movable linkage, oriented from 5' to 3', including: (I) Modified Ig V H Segment, (II) one or more Ig heavy chain diversity (D H ) segment, and (III) one group Ig heavy chain bond (J H ) segment. In some embodiments, (II) Ig D H One or more of the segments are human IgD HIncluding one, more, or all of the segments and / or (III) Ig J H One or more of the segments are human Ig J H Includes one, more, or all of the segments. In some embodiments, (II) Ig D H One or more of the segments, and (III) Ig J H One or more gene segments are recombinant and rearranged into Ig D H / J H It forms a sequence. Thus, the recombinant nucleic acid molecule has a functional linkage and, from 5' to 3', includes: modified Ig V H Gene segment and reconstituted Ig D H / J H array.

[0011] In some embodiments, modified IgV H Gene segment and reconstituted Ig D H / J H The sequence is rearranged and reconstructed Ig V H / D H / J H A sequence is formed, which encodes an anchor-modified Ig heavy chain variable domain, in which case the anchor-modified Ig heavy chain variable domain is a functional linkage comprising (i) an Ig signal peptide, (ii) an anchor, and (iii) a reconstituted Ig V H / D H / J H It includes FR1, complementarity determination region (CDR1), FR2, CDR2, FR3, CDR3, and FR4, which are encoded by the sequence.

[0012] In some embodiments, modified IgV H The segment is an unreconstructed modified Ig V H It is a gene segment.

[0013] In some embodiments, the recombinant nucleic acids disclosed herein have an Ig heavy chain constant region (C H) further comprises a nucleic acid sequence encoding, in this case Ig C H the nucleic acid sequence encoding is downstream of (I) the modified Ig V H segment, (II) one or more of the Ig D H segments, and (III) one or more of the Ig J H segments, and is operably linked thereto. In some embodiments, the nucleic acid sequence encoding Ig C H comprises an Igμ gene encoding an IgM isotype, an Igδ gene encoding an IgD isotype, an Igγ gene encoding an IgG isotype, an Igα gene encoding an IgA isotype, and / or an Igε gene encoding an IgE isotype. In some embodiments, the recombinant nucleic acid molecules described herein comprise a nucleic acid sequence encoding an anchor-modified Ig heavy chain, wherein said anchor-modified Ig heavy chain is, in operable linkage, (i) an Ig signal peptide, (ii) an anchor, (iii) a rearranged Ig V H / D H / J H Ig heavy chain variable domain comprising FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 encoded by the sequence, and (iv) Ig C H , In some embodiments, Ig C H is a non-human Ig C H , such as a rodent Ig C H , such as a rat Ig C H or a mouse Ig C H .

[0014] In some embodiments, the germline Ig V segment or variant thereof is a germline Ig light chain variable (V L ) segment or variant thereof. In some embodiments, the recombinant nucleic acid molecule may comprise a light chain variable region locus, for example, in operable linkage, and may comprise the following from 5' to 3': (I) a modified Ig V L segment, and (II) one or more of the Ig light chain joining (J L ) segments.

[0015] In some embodiments, modified IgV L Segments, and Ig J L One or more of the segments are rearranged and reconstructed Ig V L / J L The sequence is formed. The sequence encodes an anchor-modified Ig light chain variable domain, in which the anchor-modified Ig light chain variable domain is a functional linkage comprising (i) an Ig signal peptide, (ii) an anchor, and (iii) a reconstituted Ig V. L / J L Includes FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4, which are encoded by the array.

[0016] In some embodiments, the recombinant nucleic acid molecule has a light chain variable region locus and an Ig light chain constant region (C L It may include a nucleic acid sequence encoding the Ig C, in which case the Ig C L The nucleic acid sequences encoding are downstream of the following, and are operablely ligated to them: (I) Modified Ig V L Segment, and (II)Ig light chain binding (J L ) One or more of the segments. In some embodiments, the anchor-modified Ig light chain is a operable linkage containing (i) an Ig signal peptide, (ii) an anchor, and (iii) a reconstituted Ig V. L / J L The Ig light chain variable domains include FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 encoded by the sequence, and (iv) Ig C L , including. In some embodiments, Ig C L is non-human Ig C L For example, IgC in rodents L For example, rat Ig C L or mouse Ig C L That is the case.

[0017] In some embodiments of light chain variable region loci, germline Ig V LThe segment or its variant is a germline Ig light chain variable kappa (Vκ) segment or its variant. Thus, in some embodiments, the recombinant nucleic acid molecule described herein comprises, in a operable linkage and from 5' to 3', one or more of the following: (I) a modified Ig Vκ segment, and (II) one or more Ig light chain-binding kappa (Jκ) segments. In some embodiments, the recombinant nucleic acid molecule described herein comprises, in a operable linkage and from 5' to 3', one or more of the following: (I) a modified Ig Vκ segment, (II) one or more Ig light chain-binding kappa (Jk), and (III) a nucleic acid sequence encoding an Ig light chain constant kappa region (Cκ).

[0018] In some embodiments of light chain variable region loci, germline Ig V L The segment or its variant is a germline Ig light chain variable lambda (Vλ) segment or its variant. Thus, in some embodiments, the recombinant nucleic acid molecule described herein comprises, in a operable linkage and from 5' to 3', one or more of the following: (I) a modified Ig Vλ segment, and (II) one or more Ig light chain bound lambda (Jλ) segments. In some embodiments, the recombinant nucleic acid molecule described herein comprises, in a operable linkage and from 5' to 3', one or more of the following: (I) a modified Ig Vλ segment, (II) one or more Ig light chain bound lambda (Jλ) segments, and a nucleic acid sequence encoding the Ig light chain constant lambda region (Cλ).

[0019] In some embodiments, the recombinant nucleic acid molecules described herein include the sequence described as SEQ ID NO: 8 or a degenerate variant thereof, or SEQ ID NO: 10 or a degenerate variant thereof.

[0020] Targeted vectors containing nucleic acid molecules, non-human animal cells (e.g., host cells, embryonic stem cells, etc.), and non-human animals are also described.

[0021] Targeting vectors, including embodiments of recombinant nucleic acid molecules disclosed herein, are also described. In some embodiments of targeting vectors, the targeting vector further includes 5' and 3' homologous arms, which target a non-human Ig heavy chain locus, thereby, during homologous recombination between the targeting vector and the non-human Ig heavy chain locus, the targeted non-human Ig heavy chain locus recombines the recombinant nucleic acid molecule with the non-human Ig C at the non-human Ig heavy chain locus. H Upstream of and including therein in a operable linkage, optionally in this case, the non-human Ig heavy chain locus is an endogenous rodent Ig heavy chain locus, and / or in this case, the non-human Ig heavy chain locus includes a human or humanized immunoglobulin heavy chain variable region and endogenous Ig V H , D H and / or J H This includes deletions of gene segments, or combinations thereof. In some embodiments, during homologous recombination between the targeting vector and a non-human Ig heavy chain locus, the recombinant nucleic acid molecule is recombined with non-human Ig heavy chain locus at the non-human Ig heavy chain locus. H The segment is replaced. In some embodiments, during homologous recombination between the targeting vector and a non-human Ig heavy chain locus, the recombinant nucleic acid molecule replaces one or more non-human V at the non-human Ig heavy chain locus. H Segment, all non-human D H Segments, and all non-human J H The segment is replaced. In some embodiments, during homologous recombination between the targeting vector and a non-human Ig heavy chain locus, the recombinant nucleic acid molecule replaces one non-human V at the non-human Ig heavy chain locus. H All or all non-human V segments other than the segment H Segment, all non-human D H Segments, and all non-human J HThe segment is replaced. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig heavy chain locus, the targeted non-human Ig heavy chain locus includes a recombinant nucleic acid molecule operably linked to a non-human Ig heavy chain control sequence at the non-human Ig heavy chain locus. In some embodiments, the targeting vector comprises a recombinant nucleic acid molecule as described herein, as well as 5' and 3' homologous arms, the arms targeting a non-human Ig heavy chain locus, thereby, upon homologous recombination between the targeting vector and the non-human Ig heavy chain locus, the targeted non-human Ig heavy chain locus contains the recombinant nucleic acid molecule in an operable linkage to the non-human Ig heavy chain control sequence of the non-human Ig heavy chain locus, optionally in this case the non-human Ig heavy chain locus is an endogenous rodent Ig heavy chain locus in rodents or rodent cells (e.g., rodent embryonic stem cells), and / or in this case the non-human Ig heavy chain locus comprises a human or humanized immunoglobulin heavy chain variable region and endogenous Ig V H , D H and / or J H This includes deletions of gene segments, or combinations thereof, and optionally, in this case, upon homologous recombination between the targeting vector and a non-human Ig heavy chain locus, the recombinant nucleic acid molecule has one or more non-human V at the non-human Ig heavy chain locus. H Segment, all non-human D H Genetic segment, all non-human J H Genetic segments, and one or more non-human C H A gene is replaced. In some embodiments, the 5' homologous arm contains the sequence described as SEQ ID NO: 11, and / or the 3' homologous arm contains the sequence described as SEQ ID NO: 12.

[0022] In some embodiments of the targeting vector, the targeting vector comprises a recombinant nucleic acid molecule as described herein and 5' and 3' homologous arms, the arms targeting a non-human Ig light chain locus, thereby, upon homologous recombination between the targeting vector and the non-human Ig light chain locus, the targeted non-human Ig light chain locus contains the recombinant nucleic acid molecule upstream of the non-human Ig CL of the non-human Ig light chain locus and operably linked thereto, optionally in this case the non-human Ig light chain locus is an endogenous rodent Ig light chain locus and / or in this case the non-human Ig light chain locus contains a human or humanized immunoglobulin light chain variable region and endogenous Ig V L and / or J L This includes deletions of gene segments, or combinations thereof. In some embodiments, during homologous recombination between the targeting vector and a non-human Ig light chain locus, the recombinant nucleic acid molecule is recombined with non-human Ig at the non-human Ig light chain locus. L The segment is replaced. In some embodiments, during homologous recombination between the targeting vector and a non-human Ig light chain locus, the recombinant nucleic acid molecule replaces one or more non-human Ig light chain loci at the non-human Ig light chain locus. L Segments and all non-human J L The segment is replaced. In some embodiments, during homologous recombination between the targeting vector and the non-human Ig light chain locus, the recombinant nucleic acid molecule replaces all non-human Ig light chain loci at the non-human Ig light chain locus. L Segments and all non-human J HThe segment is replaced. In some embodiments, upon homologous recombination between the targeting vector and a non-human Ig light chain locus, the targeted non-human Ig heavy chain locus includes a recombinant nucleic acid molecule operably linked to a non-human Ig light chain control sequence at the Ig light chain locus. In some embodiments, the targeting vector described herein includes the nucleic acid molecule described herein, as well as 5' and 3' homologous arms, the arms targeting a non-human Ig light chain locus, thereby, upon homologous recombination between the targeting vector and the non-human Ig light chain locus, the targeted non-human Ig light chain locus includes the recombinant nucleic acid molecule operably linked to the non-human Ig light chain control sequence at the non-human Ig light chain locus, optionally in this case the non-human Ig light chain locus is an endogenous rodent Ig light chain locus, and / or in this case the non-human Ig light chain locus includes a human or humanized immunoglobulin light chain variable region and endogenous Ig V L and / or J L This includes deletions of gene segments, or combinations thereof, and optionally, in this case, upon homologous recombination between the targeted vector and a non-human Ig light chain locus, the recombinant nucleic acid molecule is non-human V at the non-human Ig light chain locus. L Segment, J L Replace the gene segment and the non-human CL gene.

[0023] In some embodiments of the targeted vector, the targeted vector comprises a recombinant nucleic acid molecule as described herein and 5' and 3' homologous arms, the arms targeting a non-human Ig light chain κ locus, thereby, upon homologous recombination between the targeted vector and the non-human Ig light chain κ locus, the targeted non-human Ig light chain κ locus contains the recombinant nucleic acid molecule upstream of the non-human Ig Cκ of the non-human Ig light chain κ locus and in a operable linkage thereto, optionally in this case the non-human Ig light chain κ locus is an endogenous rodent Ig light chain κ locus and / or in this case the non-human Ig light chain κ locus contains a human or humanized immunoglobulin light chain variable region, contains a deletion of an endogenous Ig Vκ and / or Jκ gene segment, or a combination thereof. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain κ locus, the recombinant nucleic acid molecule replaces a non-human Vκ segment at the non-human Ig light chain κ locus. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain κ locus, the recombinant nucleic acid molecule replaces one or more non-human Vκ segments and all non-human Jκ segments at the non-human Ig light chain κ locus. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain κ locus, the recombinant nucleic acid molecule replaces all non-human Vκ segments and all non-human Jκ segments at the non-human Ig light chain κ locus. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain κ locus, the targeted non-human Ig light chain κ locus includes a recombinant nucleic acid molecule operably linked to a non-human Ig light chain κ control sequence at the Ig light chain κ locus.In some embodiments of the targeted vector, the targeted vector comprises a nucleic acid molecule as described herein, as well as 5' and 3' homologous arms, the arms targeting a non-human Ig light chain κ locus, thereby, upon homologous recombination between the targeted vector and the non-human Ig light chain κ locus, the targeted non-human Ig light chain κ locus contains the recombinant nucleic acid molecule in an operable linkage to the non-human Ig light chain κ regulatory sequence of the Ig light chain κ locus, and optionally, in this case, upon homologous recombination between the targeted vector and the non-human Ig light chain κ locus, the recombinant nucleic acid molecule replaces the non-human Vκ segment, all Jκ gene segments, and the non-human Cκ gene at the non-human Ig light chain κ locus.

[0024] In some embodiments of the targeted vector, the targeted vector comprises a recombinant nucleic acid molecule as described herein and 5' and 3' homologous arms, the arms targeting a non-human Ig light chain λ locus, thereby, upon homologous recombination between the targeted vector and the non-human Ig light chain λ locus, the targeted non-human Ig light chain λ locus contains the recombinant nucleic acid molecule upstream of the non-human Ig Cλ of the non-human Ig light chain locus and in a operable linkage thereto, optionally in this case the non-human Ig light chain λ locus is an endogenous rodent Ig light chain λ locus and / or in this case the non-human Ig light chain λ locus contains a human or humanized immunoglobulin light chain variable region, contains a deletion of an endogenous Ig Vλ and / or Jλ gene segment, or a combination thereof. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain λ locus, the recombinant nucleic acid molecule replaces a non-human Vλ segment at the non-human Ig light chain λ locus. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain λ locus, the recombinant nucleic acid molecule replaces one or more non-human Vλ segments and all non-human Jλ segments at the non-human Ig light chain locus. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain λ locus, the recombinant nucleic acid molecule replaces all non-human Vλ segments and all non-human Jλ segments at the non-human Ig light chain λ locus. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain λ locus, the targeted non-human Ig light chain λ locus includes a recombinant nucleic acid molecule operably linked to a non-human Ig light chain λ control sequence at the Ig light chain λ locus. In some embodiments, the targeting vector comprises a nucleic acid molecule as described herein, as well as 5' and 3' homologous arms that target a non-human Ig light chain λ locus, thereby, in homologous recombination between the targeting vector and the non-human Ig light chain λ locus, the targeted non-human Ig light chain λ locus comprises a recombinant nucleic acid molecule operably linked to a non-human Ig light chain λ control sequence at the Ig light chain λ locus.In some embodiments, during homologous recombination between the targeted vector and the non-human Ig light chain λ locus, the recombinant nucleic acid molecule replaces the non-human Vλ segment, all non-human Jλ gene segments, and the non-human Cλ gene at the said non-human Ig light chain λ locus.

[0025] In this specification, non-human animal genomes comprising recombinant nucleic acid molecules and / or targeted vectors described herein are also described. In some embodiments of non-human animal genomes, the non-human animal genome comprises recombinant nucleic acid molecules described herein at the endogenous Ig locus of the non-human animal genome, for example, the non-human animal genome comprises a targeted vector described herein, in which case the targeted vector comprises 5' and 3' homologous arms targeting the endogenous Ig locus. In some embodiments, the non-human animal genome is a rodent genome. In some embodiments, the non-human animal genome is a rat genome. In some embodiments, the non-human animal genome is a mouse genome.

[0026] In this specification, non-human animals or non-human animal cell genomes, including recombinant nucleic acid molecules, targeted vectors, and / or non-human animal genomes described herein, are also described. In some embodiments of non-human animals, the non-human animals described herein include recombinant nucleic acid molecules, targeted vectors, or non-human animal genomes described herein in their germline, such as germ cells, and can, for example, pass on the recombinant nucleic acid molecules, targeted vectors, and / or non-human animal genomes described herein to their offspring.

[0027] Methods for producing non-human cells, non-human embryos, and / or non-human animals using recombinant nucleic acid molecules, such as targeted vectors, described herein, in vitro are also described. In some embodiments, the in vitro method for modifying isolated cells includes introducing the recombinant nucleic acid molecules described herein into the isolated cells, for example, by contacting the cells with the targeted vectors described herein. In some embodiments of the method, the cells are host cells. In some embodiments, the cells are embryonic stem (ES) cells. In some embodiments, the cells described herein, or cells produced according to the methods described herein, are rodent cells, for example, in this case, rat cells or mouse cells.

[0028] Methods for producing anchor-modified antigen-binding proteins using nucleic acid molecules, non-human cells, and / or non-human animals described herein are also described. Non-human animal embryos and non-human animals that may include and / or can be developed (e.g., produced) from embryonic stem cells described herein are also described. Such embryos or non-human animals may be developed by methods including transplanting ES cells described herein into an embryo and / or transplanting an embryo containing ES cells into a suitable host, and maintaining the host under suitable conditions to produce viable offspring during the development of the ES cells or the embryo.

[0029] In some embodiments of non-human animals described herein (for example, embodiments in which the non-human animal comprises a recombinant nucleic acid molecule, targeted vector, and / or genome described herein, and / or is produced according to the method described herein), the non-human animal comprises, compared to a control non-human animal, (a) an equivalent number of mature B cells in the spleen, (b) an equivalent number of kappa-positive B cells in the spleen, (c) an equivalent number of lambda-positive B cells in the spleen, (d) an equivalent level of serum IgG, and / or (e) an equivalent level of serum IgM. In some embodiments, the non-human animals described herein can initiate an immune response comparable to that of a control non-human animal. In some embodiments, the non-human animals described herein comprises a plurality of antigen-binding proteins, each protein comprising an anchor, and / or derived from a recombinant nucleic acid molecule, targeted vector, and / or non-human animal described herein. In some embodiments, the non-human animals described herein further comprises a homologous receptor of the non-immunoglobulin polypeptide of interest, the receptor-binding portion of the non-immunoglobulin polypeptide of interest functions as an anchor. In some embodiments of non-human animals, the non-human animals described herein comprise a plurality of antigen-binding proteins, each of which specifically binds to a homologous receptor of the non-immunoglobulin polypeptide of interest, and the receptor-binding portion of the non-immunoglobulin polypeptide of interest functions as an anchor.

[0030] As described herein, the non-immunoglobulin polypeptide of interest (the receptor-binding portion of the non-immunoglobulin polypeptide of interest functions as an anchor) may include atrial natriuretic peptide (ANP). In some embodiments, the c-terminal tail of ANP (e.g., NSFRY (SEQ ID NO: 3)) may function as an anchor for a congener receptor. In some embodiments, the congener receptor includes a natriuretic peptide receptor (NPR), e.g., NPR3, or a portion thereof.

[0031] In some embodiments of non-human animals, if the non-human animal described herein is immunized with a congener receptor of the target non-immunoglobulin polypeptide (optionally in this case, the congener receptor includes a natriuretic peptide receptor (NPR), e.g., NPR3) whose receptor-binding portion (e.g., NSFRY(SEQ ID NO: 3)) functions as an anchor described herein, the non-human animal described herein further comprises several antigen-binding proteins, the proteins of which bind to the congener receptors, each of which has 1x10 9 KD less than 30 minutes and / or t 1 / 2 The system comprises: In some embodiments, at least 15% of the antigen-binding proteins can block and / or block the binding of the congeneral receptor to the non-immunoglobulin polypeptide of interest. In some embodiments, more than 50% of the antigen-binding proteins bind to the congeneral receptor expressed on the cell surface.

[0032] In some embodiments of non-human animals described herein, the non-human animal is a rodent. In some embodiments of non-human animals described herein, the non-human animal is a rat. In some embodiments of non-human animals, the non-human animal is a mouse.

[0033] Furthermore, anchor-modified antigen-binding proteins encoded by nucleic acid molecules described herein or produced by non-human animals described herein are also described.

[0034] This specification describes methods for producing antigen-binding proteins or obtaining nucleic acids encoding such proteins, the methods comprising (i) immunizing a non-human animal as described herein with an antigen (e.g., a homologous receptor of a non-immunoglobulin polypeptide of interest, wherein the receptor-binding portion of the non-immunoglobulin polypeptide of interest functions as an anchor), or immunizing a non-human animal produced according to the methods described herein (e.g., a non-human animal comprising a modified immunoglobulin (Ig) variable (V) segment encoding an anchor-modified Ig polypeptide), and (ii) inducing an immune response in the non-human animal to the antigen, comprising an antibody that binds to the antigen, or a nucleic acid encoding such antibody. Some embodiments further include recovering an antigen-binding protein or nucleic acid encoding such protein from a non-human animal or non-human animal cells such as B cells, and optionally fusing the B cells with myeloma cells to form a hybridoma. Some embodiments further include cloning the recovered nucleic acid into an expression construct and optionally expressing the expression construct in a host cell. In some embodiments of the cloning, the method further comprises cloning the recovered nucleic acid, in which case the recovered nucleic acid encodes a sequence encoding the human Ig constant region and an Ig variable domain in frame. Also described herein are B cells, hybridomas fused with B cells, or host cells expressing nucleic acids recovered from B cells. In some embodiments, the mass of each antigen-binding protein confirms the presence of an anchor-modified Ig polypeptide. In some embodiments, the mass of each antigen-binding protein is determined by matrix-assisted laser desorption / ionization-time-of-flight mass spectrometry. In some embodiments, the mass of each antigen-binding protein confirms the presence of an anchor-modified Ig polypeptide, and the mass of each antigen-binding protein is determined by matrix-assisted laser desorption / ionization-time-of-flight mass spectrometry.

[0035] Also described herein are anchor-modified Ig polypeptides which are (a) encoded by a recombinant nucleic acid molecule, a targeted vector, or a non-human animal genome as described herein, (b) expressed by a non-human animal or non-human animal cell as described herein, (c) expressed by a non-human animal or non-human animal cell prepared according to the method described herein, and / or (d) prepared by any of the methods described herein.

[0036] Other features, purposes, and advantages of the non-human animals, cells, nucleic acids, and compositions disclosed herein will become apparent in the detailed descriptions of the specific embodiments shown below. However, it should be understood that the following detailed descriptions illustrate specific embodiments but are for illustrative purposes only and not limiting. [Brief explanation of the drawing]

[0037] The drawings included in this specification, consisting of the following figures, are for illustrative purposes only and are not intended to limit the scope of this specification.

[0038] [Figure 1] Figure 1 shows a non-limiting example of an embodiment of an ANP-modified VH gene segment useful as donor DNA for Cas9 / GA modification, not to exact scale. Restriction enzyme recognition sites (XhoI, Mrel, EcoRI, AvrII, Mrel) and the spectinomycin resistance gene (SPEC) are also shown. In this non-limiting embodiment, the human VH1-69 gene segment is modified with a sequence encoding the C-terminal tail of atrial natriuretic protein (ANP) (NSFRY, SEQ ID NO: 3) to form donor DNA containing the ANP-modified VH1-69 gene segment. Generally, unfilled sequences represent human sequences, and filled sequences represent mouse sequences. Dotted sequences represent non-human, non-mouse sequences.

[0039] [Figure 2-1]Figure 2 shows an example of a non-limiting embodiment of a DNA donor (described as Sequence ID No. 10) used to modify the VH1-69 gene in BAC clone VI504.The following characteristics are shown: -Sense DNA sequence including: (a) the last seven codons of a bipartite signal peptide encoded by the germline human VH1-69 segment (see the “signal peptide” traveled split arrow); the nucleotide sequence encoding the entire signal polypeptide is described as SEQ ID NO: 6; and the amino acid sequence of the entire signal polypeptide is described as SEQ ID NO: 7; (b) the germline Ig VH1-69 segment including exon 1, intron 1, and exon 2 (see the “VH” traveled split arrow immediately above the DNA sequence); (c) germline Ig (d) Intron 1 of the VH1-69 segment ("Intron"), (e) Nucleotide sequences encoding the C-terminal tail of atrial natriuretic peptide (ANP) (SEQ ID NO: 3) and the G4S linker (SEQ ID NO: 5), (e) Germline portions of the VH1-69 segment encoding FR1, CDR1 (patterned box), FR2, CDR2 (patterned box), FR3, and CDR3 (patterned box), and the amino acid sequences of the same portion (see split arrow labeled IgHV1-69), as well as (e) Recombination signal sequence of 23mer (RS-23 split), - Conceptual translation of the ANP-modified VH1-69 segment (labeled ANP-G4S-VH1-69) including the leader sequence, - crRNA binding site used to cleave VI504 in vitro using Cas9 (labeled 5'VH1-69 Cas9 and PAM), - VI504 and donor Gibson 5' and 3' duplications used for assembly (black arrow lines labeled "5'VH1-69 duplication" and "3'VH1-69" respectively) - restriction enzyme sites indicated by shaded boxes below the sequence: EcoRI and AvrII sites used to ligate the spectinomycin-resistant cassette to the donor, XhoI site used to remove the donor from the pUC vector skeleton, and MreI site used to remove the Spec cassette from the modified BAC before seamless repair by Joiner oligo-mediated Gibson assembly. [Figure 2-2] Same as above.

[0040] [Figure 3] Figure 3 shows a non-limiting, exemplary embodiment, not to exact scale, in which the ANP-modified VH1-69 segment was inserted into BAC clone VI504 according to Example 1 to produce the targeted vector VI748. Generally, unfilled elements represent human sequences (e.g., unfilled triangles represent human VH1-69 segments, human DH segments, and human JH segments), filled elements represent mouse sequences (e.g., filled triangles represent endogenous mouse VH segments (unlabeled), filled arrows represent mouse Adam6a "a" and Adam6b "b" genes, filled ovals represent Ig enhancers, and filled arrows represent mouse Igμ genes "IgM"), and stippled elements represent non-human and non-mouse sequences (e.g., chloramphenicol resistance gene "CM", site-specific recombinase recognition site "Frt", hygromycin resistance gene "HYG", and spectinomycin resistance gene "SPEC").

[0041] [Figure 4]Figure 4 shows a non-scalar diagram of an example of a non-limiting embodiment in which a targeted vector is inserted into an immunoglobulin heavy chain variable region locus within the genome of mouse ES cells by electroporation. After electroporation, this example of a non-limiting embodiment retains the endogenous VH segment, shown as a filled triangle upstream of the Adam6a("a") gene. Generally, unfilled elements represent human sequences (e.g., unfilled triangles represent human VH1-69 segments, human DH segments, and human JH segments), filled elements represent mouse sequences (e.g., filled triangles represent endogenous mouse VH segments (unlabeled), filled arrows represent mouse Adam6a "a" and Adam6b "b" genes, filled ovals represent Ig enhancers, and filled arrows represent mouse Igμ genes "IgM"), and stippled elements represent non-human and non-mouse sequences (e.g., chloramphenicol resistance gene "CM", site-specific recombinase recognition site "Frt", hygromycin resistance gene "HYG", and spectinomycin resistance gene "SPEC").

[0042] [Figure 5A]Figures 5A-5F show graphs comparing spleen cell populations from ANP-VH1-69 modified mice with control VELOCIMMUNE® mice, which are results related to non-limiting embodiments of the present invention. Figures 5A-B show (A) total number of cells per spleen (y axis), number of CD19+ cells / spleen (y axis), or (B) percentage of lymphocytes (CD19+ cells) per spleen (y axis) for mice modified with the ANP-modified VH1-69 segment (ANP) or control VELOCIMMUNE® animals containing the humanized Ig locus (control). Figures 5C-5D show (C) the total number of mature B cells (CD19+IgDhiIgMint) and transitional B cells (CD19+IgDintIgMhi) per spleen (y axis) or (D) the percentage of mature B cells (CD19+IgDintIgMhi) per spleen (y axis) in mice modified with the ANP-modified VH1-69 segment (ANP) or in VELOCIMMUNE® animals (control) containing a humanized Ig locus. Figures 5E-F show (E) the total number of CD19+ kappa+ cells and CD19+ lambda+ cells per spleen (y axis) or (F) the proportion of CD19+ κ+ cells and CD19+ λ+ cells per spleen (y axis) in mice modified with the ANP-modified VH1-69 segment (ANP) or control VELOCIMMUNE® animals containing the humanized Ig locus (control). [Figure 5B] Same as above. [Figure 5C] Same as above. [Figure 5D] Same as above. [Figure 5E] Same as above. [Figure 5F] Same as above.

[0043] [Figure 6A]Figures 6A-6F show graphs comparing bone marrow cell populations isolated from the femurs of ANP-VH1-69 modified mice with those of control VELOCIMMUNE® mice, which are results related to non-limiting embodiments of the present invention. Figures 6A-B show (A) the total number of cells per femur (y axis) and the number of CD19+ B cells per femur (y axis), or (B) the percentage of lymphocytes (CD19+ cells) per femur (y axis), for mice modified with the ANP-modified VH1-69 segment (ANP) or control VELOCIMMUNE® animals containing the humanized Ig locus (control). Figures 6C-D show (C) the total number of CD43+ckit+ pro-B cells per femur (y axis) and the number of CD43-ckit-pre-B cells per femur (y axis), or (D) the percentage of CD43+ckit+ pro-B cells or CD43-ckit-pre-B cells per femur, for mice modified with the ANP-modified VH1-69 segment (ANP) or control VELOCIMMUNE® animals containing the humanized Ig locus (control). Figures 6E-F show (E) the total number of immature and mature B cells per femur (y axis), or (F) the percentage of immature and mature B cells per femur (y axis), for mice modified with the ANP-modified VH1-69 segment (ANP) or control VELOCIMMUNE® animals containing the humanized Ig locus (control). [Figure 6B] Same as above. [Figure 6C] Same as above. [Figure 6D] Same as above. [Figure 6E] Same as above. [Figure 6F] Same as above.

[0044] [Figure 7] Figure 7 shows serum IgG levels from ANP-VH1-69 modified animals and serum IgG levels from control animals of VELOCIMMUNE®, as analyzed by Western blot analysis, which are results related to a non-limiting embodiment of the present invention.

[0045] [Figure 8A]Figures 8A and 8B show the concentrations (μg / mL, y axis) of (A) serum mouse (m)IgG or (B) serum mIgM isolated from ANP-VH1-69 modified animals (ANP) or control VELOCIMMUNE® animals (control) containing a humanized Ig locus, which are results related to non-limiting embodiments of the present invention. [Figure 8B] Same as above.

[0046] [Figure 9] Figure 9 shows a graph comparing the immune response (antibody titer, y axis) to protein antigens in ANP-VH1-69 modified animals (ANP) or VELOCIMMUNE® animals containing a humanized Ig locus (control), which are results related to non-limiting embodiments of the present invention. Of the serum samples tested, for ANP-VH1-69 modified mice, three samples were collected after the third boost and one sample was collected after the fifth boost. For VELOCIMMUNE® control mice, two serum samples were collected after the sixth boost and one sample was collected after the ninth boost.

[0047] [Figure 10] Figure 10 shows a graph comparing the immune response (antibody titer, y axis) to protein antigens in ANP-VH1-69 modified animals (ANP) or VELOCIMMUNE® animals containing a humanized Ig locus (control), which are results related to non-limiting embodiments of the present invention. Of the serum samples tested, for ANP-VH1-69 modified mice, three samples were collected after the third boost and one sample was collected after the fifth boost. For VELOCIMMUNE® control mice, two serum samples were collected after the sixth boost and one sample was collected after the ninth boost.

[0048] [Figure 11]Figure 11 shows a box plot comparing the KD values ​​(y-axis) of hNPR3-MMH binding to NPR3 monoclonal antibodies (mAbs) isolated from ANP-VH1-69 modified mice (ANP) or control VELOCIMMUNE® animals (controls) containing a humanized Ig locus against protein antigens at 25°C, representing results related to a non-limiting embodiment of the present invention.

[0049] [Figure 12] Figure 12 shows a box plot comparing the t1 / 2 values ​​(y-axis) of hNPR3-MMH binding to NPR3 monoclonal antibodies (mAbs) isolated from ANP-VH1-69 modified mice (ANP) or control VELOCIMMUNE® animals (controls) containing a humanized Ig locus, against protein antigens at 25°C, which is a result related to a non-limiting embodiment of the present invention. [Modes for carrying out the invention]

[0050] definition The scope of the present invention is defined by the claims appended to this specification and is not limited by the specific embodiments described herein. Those skilled in the art will recognize, by reading this disclosure, a variety of modifications that may be equivalent to the embodiments described herein, or that may be within the scope of the claims by other means. In general, technical terms are used in the sense understood in the art unless explicitly suggested otherwise. Explicit definitions of certain terms are provided herein and below, but the meanings of these and other terms in specific examples throughout this specification will be evident to those skilled in the art from the context. Further definitions of the following and other terms are provided throughout this specification. References cited herein or in relevant parts thereof are incorporated herein by reference in their entirety.

[0051] The use of sequential terms such as “first,” “second,” and “third” in a claim to modify a claim does not in itself imply superiority, precedence, or sequence of one claim element over another, or a temporal order in which the actions of the method are performed, but is used solely as a distinguishing mark to differentiate one claim element having a particular name from another element having the same name (other than the use of sequential terms).

[0052] In this specification and in these claims, the articles “a” and “an” should be understood to include multiple referents unless it is explicitly stated otherwise. Claims or statements containing “or” between one or more elements of a group are satisfied if one, two or more, or all elements of the group are present, used, or otherwise related to a given product or process, unless it is indicated otherwise or otherwise obvious from the context. The present invention includes embodiments in which exactly one element of a group is present, used, or otherwise related to a given product or process. The present invention also includes embodiments in which two or more, or all elements of a group, are present, used, or otherwise related to a given product or process. Furthermore, it should be understood that the present invention covers all variations, combinations, and reorders in which one or more limitations, elements, phrases, descriptive terms, etc., from one or more of the described claims are introduced into another claim (or any other related claim) that depends on the same basic claim, unless otherwise specified or unless it is obvious to a person skilled in the art that a contradiction or inconsistency would occur. Where elements as described exist (e.g., in the form of a Markush group or similar), each subgroup of the elements is also disclosed, and any element can be removed from the group. Naturally, when the present invention or an aspect of the present invention is referred to as including certain elements, features, etc., the embodiments or aspects of the present invention consist of, or substantially consist of, such elements, features, etc. For brevity, these embodiments are not specifically described herein in many terms in all cases. Naturally, any embodiment or aspect of the present invention may be expressly excluded from the claims, whether or not certain exclusions are enumerated in the specification.

[0053] As used herein, the terms “about” and “approximately” are used synonymously. Any figures used herein, with or without “about” or “approximately,” are intended to cover any normal variation as understood by those skilled in the art, e.g., + / - 5%.

[0054] Administration: This refers to the administration of a composition to a target or system (e.g., cells, organs, tissues, organisms, or related components or groups thereof). Those skilled in the art will recognize that the route of administration may vary depending on, for example, the target or system to which the composition is administered, the properties of the composition, and the purpose of administration.

[0055] For example, in some embodiments, administration to an animal subject (e.g., human or rodent) may be by bronchial administration (including bronchial infusion), oral administration, intraenteral administration, interdermal administration, intra-arterial administration, intradermal administration, gastric administration, intramedullary administration, intramuscular administration, intranasal administration, intraperitoneal administration, intrathecal administration, intravenous administration, intraventricular administration, mucosal administration, nasal administration, oral administration, rectal administration, subcutaneous administration, sublingual administration, local administration, tracheal administration (including intratracheal infusion), transdermal administration, vaginal administration, and / or intravitreal administration. In some embodiments, administration may include intermittent dosing. In some embodiments, administration may include continuous dosing (e.g., perfusion) over at least a selected period. In some embodiments, antibodies produced by non-human animals disclosed herein may be administered to a subject (e.g., human subject or rodent). In some embodiments, the pharmaceutical composition includes antibodies produced by non-human animals disclosed herein. In some embodiments, the pharmaceutical composition may comprise a buffer, diluent, excipient, or any combination thereof. In some embodiments, the pharmaceutical composition comprising antibodies produced by non-human animals as disclosed herein may be contained in a container for storage or administration, such as a vial, syringe (e.g., an IV syringe), or bag (e.g., an IV bag).

[0056] Affinity refers to the strength of the interaction between an antigen-binding protein and its binding partner, for example, the interaction between an antibody and a specific epitope. Antibodies that specifically bind to an epitope typically have an affinity of about 10 with respect to their target epitope. -9 M or less (for example, approximately 1 x 10) -9 M, 1x10 -10 M, 1x10 -11 M, or approximately 1x10 -12 M)'s KD It has. K D This can be measured by surface plasmon resonance, for example, BIACORE®, enzyme-linked immunosorbent assay (ELISA), or other known methods.

[0057] An antibody refers to an immunoglobulin antigen-binding protein. A tetrameric antibody contains four polypeptide immunoglobulin (Ig) chains, for example, two Ig heavy chains (H) and two Ig light chains (L) interconnected by disulfide bonds. Each heavy chain contains an Ig heavy chain variable domain and an Ig heavy chain constant region or domain (C). H ) includes. The heavy chain constant region is C H 1. C H 2, and C H It contains three domains. Each light chain consists of an Ig light chain variable domain and an Ig light chain constant region (C L ) includes.

[0058] The Ig heavy chain variable domain and the Ig light chain variable domain can each be further subdivided into a hypervariable region called the complementarity-determining region (CDR), which is inserted into a more conserved region called the framework region (FR). The Ig heavy chain variable domain and the light chain variable domain each contain three CDRs and four FRs, which are arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (the heavy chain CDRs may be abbreviated as HCDR1, HCDR2, and HCDR3, and the light chain CDRs may be abbreviated as LCDR1, LCDR2, and LCDR3).

[0059] Antigen-binding proteins refer to immunoglobulins, antibodies, and binding proteins such as monoclonal antibodies, polyspecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, single-chain Fv(scFv), single-chain antibodies, Fab fragments, F(ab′) fragments, disulfide-bonded Fv(sdFv), intrabodies, minibodies, diabodies, and anti-idiotype (anti-Id) antibodies, as well as any of the epitope-binding fragments described above. The terms “antibody” and “antibodies” also refer to covalent diabodies disclosed in U.S. Patent 20070004909, and Ig-DARTS disclosed in, for example, U.S. Patent 20090060910, which are incorporated herein by reference in their entirety.

[0060] Biological activity refers to the characteristic of any agent that is active in a biological system, in vitro, or in vivo (e.g., in a living organism). For example, if an agent is present in a living organism, and it has a biological effect within that organism, it is considered biologically active.

[0061] In certain embodiments, if a protein or polypeptide is biologically active, the portion of that protein or polypeptide that gives rise to at least one biological activity is generally referred to as the “biologically active” portion.

[0062] The term "homogeneous" typically refers to two interacting biomolecules (for example, a receptor and its ligand).

[0063] Equivalent means two or more drugs, entities, situations, conditions, etc., that are not identical to one another but are similar enough to allow for a comparison that enables reasonable conclusions to be drawn based on observed differences or similarities. A person skilled in the art will understand, in context, the degree of identity required for two or more such drugs, entities, situations, conditions, etc., to be considered equivalent in a given situation.

[0064] Conservative amino acid substitution refers to the substitution of an amino acid residue with another amino acid residue that has a side-chain R group with similar chemical properties (e.g., charge or hydrophobicity). Generally, conservative amino acid substitutions do not substantially alter the functional properties of the protein in question, such as its ability to bind to its homologous receptors. Examples of amino acid groups with side chains having similar chemical properties include: aliphatic side chains such as glycine, alanine, valine, leucine, and isoleucine; aliphatic-hydroxyl side chains such as serine and threonine; amide-containing side chains such as asparagine and glutamine; aromatic side chains such as phenylalanine, tyrosine, and tryptophan; basic side chains such as lysine, arginine, and histidine; acidic side chains such as aspartic acid and glutamic acid; and sulfur-containing side chains such as cysteine ​​and methionine. Conservative amino acid substituents include, for example, valine / leucine / isoleucine, phenylalanine / tyrosine, lysine / arginine, alanine / valine, glutamic acid / aspartic acid, and asparagine / glutamine.

[0065] In some embodiments, a conserved amino acid substitution may be a substitution of any undenatured residue in an alanine-containing protein, for example, used in alanine scanning mutagenesis. In some embodiments, a conserved substitution with a positive value in the PAM250 log-likelihood matrix is ​​performed, as disclosed in Gonnet, GH et al., 1992, Science 256:1443-1445 (this document is incorporated herein by reference in its entirety). In some embodiments, the substitution is a moderately conserved substitution, in which case the substitution has a non-negative value in the PAM250 log-likelihood matrix.

[0066] A control, as known in the art, refers to a "control" that serves as a baseline for comparison of results. Generally, controls are used to increase the integrity of an experiment by isolating such variables in order to draw conclusions about them. In some embodiments, a control is a reaction or assay performed concurrently with the test reaction or assay to provide a comparator. A "control" may also refer to a "control animal." A "control animal" may have the modifications described herein, modifications different from those described herein, or be unmodified (i.e., wild-type). In one experiment, the "test" (i.e., the variable being tested) is applied. In a second experiment, which is the "control," the variable being tested is not applied. A control may be a positive control or a negative control.

[0067] In some embodiments, the control is a historical control (i.e., a previously performed test or assay, or a previously known quantity or result). In some embodiments, the control is a printed or otherwise preserved record, or includes one.

[0068] A degenerate variant of a reference nucleic acid molecule has the same amino acid sequence as the amino acid sequence encoded by the reference nucleic acid, and has a substantially identical nucleic acid sequence to the reference nucleic acid molecule, but encodes a polypeptide that has differences due to the degeneracy of the genetic code.

[0069] Disruption refers to the result of homologous recombination events with DNA molecules (e.g., endogenous homologous sequences such as genes or loci).

[0070] In some embodiments, disruption may achieve or demonstrate an insertion, deletion, substitution, exchange, missense mutation, or frameshift of a DNA sequence, or any combination thereof. Insertions may include insertions of an entire gene or a fragment of a gene (e.g., an exon), which may be of a non-endogenous origin (e.g., a heterologous sequence) or a coding sequence derived from or isolated from the specific gene of interest. In some embodiments, disruption may increase the expression and / or activity of a gene or gene product (e.g., a protein encoded by the gene). In some embodiments, disruption may decrease the expression and / or activity of a gene or gene product. In some embodiments, disruption may alter the sequence of a gene or a gene product (e.g., a encoded protein). In some embodiments, disruption may alter the sequence of a chromosome or chromosomal location within the genome. In some embodiments, disruption may cleave or fragment a gene or a gene product (e.g., a encoded protein). In some embodiments, disruption may elongate a gene or a gene product. In some such embodiments, disruption may result in the assembly of a fusion protein. In some embodiments, damage may affect the level of a gene or gene product but not its activity. In some embodiments, damage may affect the activity of a gene or gene product but not its level. In some embodiments, damage may have no significant effect on the level of a gene or gene product. In some embodiments, damage may have no significant effect on the activity of a gene or gene product. In some embodiments, damage may have no significant effect on either the level or activity of a gene or gene product. In some embodiments, a significant effect can be measured, for example, by a Student's T test, though not limited to these methods.

[0071] An endogenous locus or endogenous gene means a gene locus that exists in the parent or reference organism (or cell) prior to the introduction of any modification, disruption, deletion, insertion, alteration, substitution, or exchange described herein.

[0072] In some embodiments, the endogenous locus contains, in whole or in part, a sequence found in nature. In some embodiments, the endogenous locus is a wild-type locus. In some embodiments, the reference organism is a wild-type organism. In some embodiments, the reference organism is a genetically modified organism. In some embodiments, the reference organism is a laboratory-bred organism (wild-type or genetically modified).

[0073] An endogenous promoter refers to a promoter that is naturally associated with an endogenous gene or gene locus, for example, in a wild-type organism.

[0074] "Manipulated" generally means a form of manipulation performed by human hands. As is common and as is understood by those skilled in the art, a manipulated polynucleotide or cellular progeny is also usually considered "manipulated," even if the actual manipulation was performed on a past entity. Furthermore, as is recognized by those skilled in the art, various techniques are available through which the "manipulations" described herein can be performed. A polynucleotide may be considered "manipulated" if two or more sequences that are not linked together in their natural order are manipulated by human hands and directly linked to each other in the manipulated polynucleotide. In some embodiments, the manipulated polynucleotide may include a control sequence that exists in nature operatively bound to a first coding sequence but not to a second coding sequence, and is linked by human hands to operatively bind to the second coding sequence. Alternatively, or further, in some embodiments, a first nucleic acid sequence and a second nucleic acid sequence, each encoding polypeptide elements or domains that are not linked to each other in nature, may be linked to each other in a single manipulated polynucleotide. Similarly, in some embodiments, a cell or organism may be considered "manipulated" if it is manipulated in such a way that its genetic information is altered (for example, by introducing new genetic material that was not previously present, or by changing or removing previously present genetic material).

[0075] For example, in some embodiments, “Operation” may include selecting or designing (e.g., nucleic acid sequences, polypeptide sequences, cells, tissues and / or organisms) via the use of a computer system programmed to perform analysis or comparison, or to analyze recommended and / or selected sequences by other means. Alternatively, or further, in some embodiments, “Operation” may include the use of in vitro chemical synthesis techniques and / or recombinant nucleic acid techniques, such as nucleic acid amplification hybridization (e.g., via polymerase chain reactions), mutation, transformation, transfection, etc., and / or the use of various arbitrary controlled crossing methods. As will be recognized by those skilled in the art, various such established techniques (e.g., recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection, etc.)) are publicly known in the art and are described in various general and detailed references, which are cited and / or discussed throughout this specification. For example, see Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989 (which is incorporated herein in its entirety by reference).

[0076] A gene is defined as a DNA sequence in a chromosome that codes for a product (e.g., an RNA product and / or a polypeptide product). For clarity, the term “gene” generally refers to a portion of a nucleic acid that codes for a polypeptide; the term may optionally include a regulatory sequence, which should be evident from the context to those skilled in the art. This definition is not intended to exclude the application of the term “gene” to non-protein-coding expression units, but rather to clarify that as used herein, the term often refers to a nucleic acid that codes for a polypeptide.

[0077] In some embodiments, the gene includes a coding sequence (i.e., a sequence that codes for a particular product). In some embodiments, the gene includes a non-coding sequence. In some embodiments, the gene includes both a coding sequence (e.g., an exon sequence) and a non-coding sequence (e.g., an intron sequence). In some embodiments, the gene may include one or more regulatory sequences (e.g., promoters, enhancers, etc.) and / or an intron sequence that can control or influence one or more aspects of gene expression (e.g., cell type-specific expression, induced expression, etc.).

[0078] For example, the variable domain of immunoglobulin antigen receptors such as antibodies is encoded by a set of gene segments, also referred to herein as “segments.” These segments are arranged contiguously along chromosomes and, through somatic recombination, form complete variable domain exons. The configuration of inheritable human gene segments, e.g., the germline arrangement of human gene segments, e.g., the order of human gene segments in the human germline genome (e.g., the genome passed on to the next generation), is found in Lefranc, M.-P., Exp. Clin. mmunogenet., 18, 100-116 (2001), which is incorporated herein by reference in its entirety and also shows the functional gene segments and pseudogenes found within the human immunoglobulin heavy chain loci in the germline arrangement. Gene segments are classified as variable (V) gene segments (each of which may also be individually referred to as a V segment), diversity (D) gene segments (each of which may also be individually referred to as a D segment), or binding (J) segments (each of which may also be individually referred to as a J segment). Germline DNA contains multiple copies of each type of gene segment, but in receptor-carrying lymphocytes, only one copy is expressed for each type of receptor chain.

[0079] A series of recombination phenomena involving several genetic components help assemble immunoglobulins from ordered sequences of gene segments (e.g., V, D, and J). This assembly of gene segments is known to be imprecise; therefore, immunoglobulin diversity is achieved both by the combination of different gene segments and by the formation of unique bindings through imprecise binding. Furthermore, diversity is generated through a process known as somatic hypermutation, in which the variable region sequence of an immunoglobulin is modified to increase its affinity and specificity for an antigen. The Ig gene segment as used herein, e.g., the Ig V segment, includes variants of the germline Ig V segment. Variants of the germline Ig segment, e.g., variants of the germline Ig V segment, include polymorphisms, e.g., alleles, their variants, their somatic hypermutant variants, their recombinant variants, and their degenerate variants.

[0080] Sequence polymorphisms in the coding region of Ig segments, such as allele variants of germline Ig segments, are described in Palares, N. et al. (1998) Exp. Clin. Immunogenet., 15, 8-18; Barbie, V. and Lefranc, M.-P. (1998) Exp. Clin. Immunogenet., 15, 171-183; Martinez, C. and Lefranc, M.-P. (1998) Exp. Clin. Immunogenet., 15, 184-193; Palares, N. et al. (1999) Exp. Clin. Immunogenet., 16, 36-60 (1999); and Ruiz, M. et al. (1999) Exp. Clin. Immunogenet., 16, 173-184. Each of these references is incorporated herein by reference in its entirety. Representations of allele germline Ig segments can also be found in two formats on the web at imgt.org / IMGTrepertoire / Proteins / #B and imgt.org / IMGTrepertoire / Proteins / #C. The former presents the alignment of all known sequences assigned to various alleles by comparison with allele*01, while the latter provides a description of nucleotide variations and corresponding amino acid changes of various alleles by comparison with allele*01. See also European Patent No. 3128009, which is incorporated herein by reference in its entirety.

[0081] An Ig V segment may be considered a recombinant or somatic hypermutant variant of a germline Ig V segment if it contains at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% nucleic acid sequence homology with respect to one or more of the FR1, FR2, and / or FR3 regions, and encodes amino acids that have at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% amino acid sequence homology with respect to the amino acid sequence encoded by the germline Ig V segment.

[0082] In some embodiments, an Ig V segment may be considered a recombinant or somatic hypermutant variant of a germline Ig V segment if it has 80% to 99% nucleic acid sequence homology to a germline segment with respect to one or more regions of FR1, FR2, and / or FR3. In some embodiments, an Ig V segment may be considered a recombinant or somatic hypermutant variant of a germline Ig V segment if it has 85% to 99% nucleic acid sequence homology to a germline segment with respect to one or more regions of FR1, FR2, and / or FR3. In some embodiments, an Ig V segment may be considered a recombinant or somatic hypermutant variant of a germline Ig V segment if it has 90% to 99% nucleic acid sequence homology to a germline segment with respect to one or more regions of FR1, FR2, and / or FR3. In some embodiments, an Ig V segment may be considered a recombinant or somatic hypermutant variant of a germline Ig V segment if it has 95% to 99% nucleic acid sequence homology with respect to one or more regions of FR1, FR2, and / or FR3 with respect to a germline segment.

[0083] An Ig V segment may be considered a recombinant or somatic hypermutant variant of a germline Ig V segment if it encodes amino acids that have 80% to 99% amino acid sequence homology with the amino acid sequence encoded by the germline Ig V segment with respect to one or more regions of FR1, FR2, and / or FR3. An Ig V segment may be considered a recombinant or somatic hypermutant variant of a germline Ig V segment if it encodes amino acids that have 85% to 99% amino acid sequence homology with the amino acid sequence encoded by the germline Ig V segment with respect to one or more regions of FR1, FR2, and / or FR3. An Ig V segment may be considered a recombinant or somatic hypermutant variant of a germline Ig V segment if it encodes amino acids that have 90% to 99% amino acid sequence homology with the amino acid sequence encoded by the germline Ig V segment with respect to one or more regions of FR1, FR2, and / or FR3. An Ig V segment may be considered a recombinant or somatic hypermutant variant of a germline Ig V segment if it encodes amino acids that have 95% to 99% amino acid sequence homology with respect to one or more of the FR1, FR2, and / or FR3 regions of the germline Ig V segment.

[0084] Immunoglobulin molecules are Y-shaped polypeptides composed of two identical heavy chains and two identical light chains, each having two structural components: one variable domain and one constant domain. The variable domains of the heavy and light chains are formed by the assembly of gene segments, while the constant domain is fused to the variable domain through RNA splicing. The mechanisms for assembling (or binding) gene segments are similar for the heavy and light chains, but only one binding event is required for the light chain (i.e., V to J), while two events are required for the heavy chain (i.e., D to J and V to DJ).

[0085] Generally speaking, the immunoglobulin heavy chain variable domain is related to immunoglobulin heavy chain diversity (DH ) Gene segment (D H (Also called segments) and immunoglobulin heavy chain binding J H Gene segment (J H Variable immunoglobulin heavy chains (V) are rearranged together with segments (also called segments). H ) Gene segment (V H It is encoded by a variable domain exon formed by somatic recombination of the immunoglobulin light chain (also called a segment). Generally, the immunoglobulin light chain variable domain is encoded by immunoglobulin light chain binding (J L ) Gene segment (J L (Also called segments) along with immunoglobulin light chain variable (V L ) Gene segment (V L It is encoded by variable domain exons formed by somatic cell recombination of segments (also called segments).

[0086] The assembly of gene segments for the heavy and light chain variable regions (referred to as VDJ recombination and VJ recombination, respectively) is induced by conserved non-coding DNA sequences adjacent to each gene segment, called recombination signal sequences (RSS), which ensure DNA rearrangement at the precise location compared to the V, D, and J coding sequences (see, e.g., Ramsden, DA et al., 1994, Nuc. Acids Res. 22(10):1785-96; the entire text is incorporated herein by reference). Each RSS consists of a coding sequence (e.g., V, D, or J segment), followed by a conserved block of seven nucleotides (heptamers) contiguous with a spacer (either 12 bp or 23 bp), and a second conserved block of nine nucleotides (nonamers). While considerable sequence variation in the 12 bp or 23 bp spacer is tolerated between individuals, the lengths of these sequences typically do not vary. Recombination between immunoglobulin gene segments follows a rule commonly referred to as the 12 / 23 rule, where a gene segment adjacent to a 12 bp RSS with a 12 bp spacer (or 12 mer) typically binds to a gene segment adjacent to a 23 bp spacer (or 23 mer, see, for example, Hiom, K. and M. Gellert, 1998, Mol. Cell., 1(7):1011-9, the entire text of which is incorporated herein by reference).

[0087] Unless otherwise indicated, or unless it is obvious to those skilled in the art that a contradiction or inconsistency would arise, an unreconstructed gene segment is presumed to include two RSSs that are naturally related, e.g., adjacent, or possibly operably linked. In some embodiments, an unreconstructed gene segment as herein is a gene segment of its germline (e.g., wild-type) configuration, e.g., germline V, each having 23-mer RSSs adjacent at both ends. H Genetic segments and germline J H It may include gene segments. In contrast, germline D HGene segments, for example, unreconstructed D H Each gene segment has 12-mer RSSs adjacent to each other at its ends.

[0088] Therefore, an unreconstructed gene segment also refers to the gene segment of that germline configuration, including any RSS associated with such germline configuration. Furthermore, multiple gene segments in that germline configuration generally refer not only to each individual gene segment of that germline (e.g., unreconstructed) configuration, but also to the order and / or position of the functional gene segments. See, for example, Lefranc, M.-P., Exp. Clin. Immunogenet., 18, 100-116 (2001). This document, concerning the germline configuration of human V, D, and J gene segments, is incorporated herein by reference in its entirety.

[0089] Each V segment contains a nucleic acid sequence encoding an Ig signal or Ig reader (L) peptide operably bound to nucleic acid sequences encoding FR1, CDR1, FR2, CDR2, FR3, and a portion of CDR3 of the immunoglobulin variable domain. Each D gene segment contributes to CDR3 of the immunoglobulin heavy chain variable domain. Each J gene segment also contributes to CDR3 and FR4 of the immunoglobulin variable domain. The amino acid positions of FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 are based on the unique numbering described in Lefranc et al. (2003) Dev. Comp. Immunol. 27:55-77 and can also be viewed at www.imgt.org.

[0090] Heterogeneous: This refers to substances or entities from different sources. For example, when used in relation to polypeptides, genes, or gene products present in a particular cell or organism, the term clarifies that the relevant polypeptide or its fragment, gene or its fragment, or gene product or its fragment is (1) genetically engineered by humans, (2) introduced into a cell or organism (or its precursor) by humans (e.g., by genetic engineering), and / or (3) not naturally produced by or present in the relevant cell or organism (e.g., the relevant cell type or organism type). Another example includes polypeptides or their fragments, genes or their fragments, or gene products or their fragments that are not naturally associated and, in some embodiments, are non-endogenous, normally present in certain native cells or organisms under the control of regulatory elements (e.g., promoters), but are modified, for example, by mutation or substitution.

[0091] A host cell means a cell into which a different (e.g., exogenous) nucleic acid or protein has been introduced. A person skilled in the art will understand that such a term is used not only to refer to a specific subject cell but also to refer to the offspring of such a cell. Since certain modifications can occur in subsequent generations due to mutation or environmental influences, such offspring may not be identical to the parent cell, but they still fall within the scope of the term “host cell.”

[0092] In some embodiments, the host cell is a prokaryotic cell or a eukaryotic cell, or includes one. In some embodiments, the host cell is a mammalian cell, or includes one. Generally, the host cell is any cell suitable for receiving and / or producing heterologous nucleic acids or proteins, regardless of the species of cell specified. Examples of cells include prokaryotic and eukaryotic (unicellular or multicellular) cells, bacterial cells (e.g., Escherichia coli), and Examples include strains of *C. coli*, *Bacillus* spp., *Streptomyces* spp., etc., mycobacterial cells, fungal cells, yeast cells (e.g., budding yeast (Saccharomyces cerevisiae), fission yeast (Schizosaccharomyces pombe), *Pichia pastoris*, *Pichia methanolica*, etc.), plant cells, insect cells (e.g., SF-9, SF-21, baculovirus-infected insect cells, nettle moth (Trichoplusia ni), etc.), non-human animal cells, human cells, or cell fusions such as hybridomas or quadromas.

[0093] In some embodiments, the cells are human, monkey, ape, hamster, rat, or mouse cells. In some embodiments, the cells are eukaryotic cells and are selected from the following cells: CHO (e.g., CHO K1, DXB-11 CHO, Veggie-CHO), COS (e.g., COS-7), retinal cells, Vero, CV1, kidney (e.g., HEK293, 293 EBNA, MSR 293, MDCK, HaK, BHK), HeLa, HepG2, WI38, MRC 5, Colo205, HB 8065, HL-60, (e.g., BHK21), Jurkat, Daudi, A431 (epidermal), CV-1, U937, 3T3, L cells, C127 cells, SP2 / 0, NS-0, MMT 060562, Sertoli cells, BRL 3A cells, HT1080 cells, myeloma cells, tumor cells, and cell lines derived from the aforementioned cells. In some embodiments, the cells include one or more viral genes, for example, retinal cells expressing viral genes (e.g., PER.C6® cells). In some embodiments, the host cells are isolated cells or include isolated cells. In some embodiments, the host cells are part of a tissue. In some embodiments, the host cells are part of an organism.

[0094] Humanization refers to a molecule (e.g., nucleic acids, proteins, etc.) of non-human origin in which a corresponding portion is replaced with a corresponding portion of a corresponding human molecule so that the modified (e.g., humanized) molecule retains and / or maintains the structure that performs such retained biological functions. In contrast, "human," etc., encompasses molecules that have human nucleotides or proteins that are of human origin only, e.g., molecules containing only human nucleotides and amino acid sequences, respectively. The term "human (humanized)" is used to reflect whether the human (humanized) molecule can be (a) a human molecule or (b) a humanized molecule.

[0095] Identity: This refers to the identity determined by various algorithms known in the art that can be used to measure nucleotide and / or amino acid sequence identity in relation to sequence comparison.

[0096] In some embodiments, the identity described herein is determined using ClustalW v.1.83(slow) alignment with a Gonnet similarity matrix (MACVECTOR® 10.0.2, MacVector Inc., 2008) with a gap start penalty of 10.0 and a gap extension penalty of 0.1.

[0097] Immunoglobulins refer to certain polypeptides that are present in serum or expressed on B cells of the immune system and function as antibodies, such as antigen-binding proteins, as well as the nucleic acids that encode such polypeptides.

[0098] Non-immunoglobulin polypeptides refer to ligands, such as polypeptides, that bind to congener receptors. Exemplary and known non-immunoglobulin polypeptides include, but are not limited to, pairs of congener receptors, non-immunoglobulin polypeptides that bind to congener G protein-coupled receptors (GPCRs). Examples of GPCRs, but are not limited to, chemokine receptors, glucagon receptors (e.g., GLP1:GLP1R), calcitonin receptors, and melanocortin receptors. These, and other congener GPCRs, including non-immunoglobulin polypeptides that bind to these receptors, are known in the art. For example, Wu See et al. (2017) J.Mol.Biol.429:2726-45. This document is incorporated herein by reference in its entirety. Additional, non-limiting, and exemplary non-immunoglobulin polypeptides (ligands): Examples of homologous receptor pairs include: a. Ligands that bind to tyrosine kinases of the same receptor, such as, but not limited to, epidermal growth factor (EGF), insulin, platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), etc. b.DLL:Notch receptor pair, c.B7: CD28 / CLTA4 / PD1 receptor pair, d. Semaphorin: Plexin receptor pair, e.PCSK9 / LDLR pair, f.HLA:LILR pair, g.HLA:KIR pair, h.RGD-ligand:integrin pair, i. Amilyn: CALCR / RAMP, e.g., RAMP1 / 2 / 3 pairs j. Natriuretic peptides (e.g., ANP, BNP, CNP): Pairs of natriuretic peptide receptors (NPR, NPR3, etc.). Ligand:receptor pairs can also include proteases and inhibitors.

[0099] "In vitro" refers to events that occur not within a multicellular organism, but in an artificial environment such as a test tube, reaction vessel, or cell culture.

[0100] In vivo refers to events occurring within multicellular organisms, such as humans and / or non-human animals. In the context of cell-based systems, the term may also be used to refer to events occurring within living cells (as opposed to, for example, in vitro systems).

[0101] "Isolated" means (1) a substance and / or entity separated from at least some of the components to which it was originally associated when it was first produced (either in a natural environment or / or a laboratory environment), and / or (2) a substance and / or entity designed, produced, prepared, and / or manufactured by human hands. Isolated substances and / or entities may be separated from about 10 or more other components to which they were originally associated. In some embodiments, isolated factors are at least about 80% pure. A substance is "pure" if it is substantially free of other components. In some embodiments, as those skilled in the art will understand, a substance may still be considered "isolated" or even "pure" after being combined with certain other components, such as one or more carriers or excipients (e.g., buffers, solvents, water, etc.), and in such embodiments, the percentage of isolation or purity of the substance is calculated without including such carriers or excipients.

[0102] For example, in some embodiments, a naturally occurring biomolecule such as a polypeptide or polynucleotide is considered “isolated” if (a) its origin or source of derivation is not related to some or all of the components that accompany it in its natural state, (b) it substantially does not contain other polypeptides or nucleic acids of the same species that produces it in nature, or (c) it is expressed by a cell or other expression system that is not the species that produces it in nature, or otherwise related to components from there. Thus, for example, in some embodiments, a polypeptide that is chemically synthesized or synthesized in a cell system different from the one that produces it in nature is considered an “isolated” polypeptide. Or, additionally, in some embodiments, a polypeptide that has undergone one or more purification techniques may be considered an “isolated” polypeptide insofar as it is a) separated from the other components to which it accompanies it in nature and / or b) separated from the other components to which it accompanies it when it was first produced.

[0103] A leader sequence or signal peptide refers to an immunoglobulin signal or leader (L) peptide that induces immunoglobulin heavy or light chains in the endoplasmic reticulum and is subsequently cleaved from the heavy or light chains before the final antibody assembly. It may also refer to a nucleic acid sequence encoding a signal peptide or leader peptide. Each V gene segment contains a leader sequence encoded by exons 1 and 2 of the segment (see, e.g., Figure 2), located immediately upstream of the exon 2 sequences encoding FR1, CDR1, FR2, CDR2, FR3, and CDR3 of the germline Ig V segment. Ig signal sequences or Ig leader sequences are publicly known in this art. See, for example, Lefranc et al. (2003) Dev. Comp. Immunol. 27:55-77. This literature is incorporated herein in its entirety by reference and is also available online at imgt.org. See also Lefranc and Lefranc (2020) Biomedicines 8(9):1-117.

[0104] Non-human animals mean any vertebrate organism that is not human. Non-human animals may also be cyclostomes, bony fish, cartilaginous fish (e.g., sharks or rays), amphibians, reptiles, mammals, and birds. In some embodiments, non-human mammals may also be primates, goats, sheep, pigs, dogs, cattle, or rodents. In some embodiments, non-human animals may also be rats or mice.

[0105] In its broadest sense, nucleic acid refers to any compound and / or substance that is incorporated into or can be incorporated into an oligonucleotide chain, and is generally interchangeable with nucleic acid molecule, nucleic acid sequence, nucleotide molecule, and nucleotide molecule; these terms are interchangeable.

[0106] In some embodiments, “nucleic acid” is an oligonucleotide chain or a compound and / or substance into which an oligonucleotide chain can be incorporated via a phosphodiester bond. As is evident from the context, in some embodiments, “nucleic acid” refers to individual nucleic acid residues (e.g., nucleotides and / or nucleosides), and in some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising individual nucleic acid residues. In some embodiments, “nucleic acid” is or contains RNA, and in some embodiments, “nucleic acid” is or contains DNA. In some embodiments, “nucleic acid” contains or consists of one or more native nucleic acid residues. In some embodiments, “nucleic acid” contains or consists of one or more nucleic acid analogs. In some embodiments, nucleic acid analogs differ from “nucleic acid” in that they do not utilize a phosphodiester backbone. For example, in some embodiments, “nucleic acid” is, contains or consists of one or more “peptide nucleic acids” known in the art and having peptide bonds instead of phosphodiester bonds in their backbone, and they are considered to be within the scope of the invention. Or, further, in some embodiments, “nucleic acid” has one or more phosphorothioate and / or 5'-N-phosphoramidite bonds instead of phosphodiester bonds. In some embodiments, the “nucleic acid” is one or more natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine) or consists of one or more natural nucleosides.In some embodiments, “nucleic acid” is one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynylcytidine, C-5 propynyluridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyluridine, C5-propynylcytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, 2-thiocytidine, methylated bases, intercalated bases, and combinations thereof) or consists thereof. In some embodiments, the "nucleic acid" contains one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) compared to those of natural nucleic acids. In some embodiments, the "nucleic acid" has a nucleotide sequence encoding a functional gene product such as RNA or a protein. In some embodiments, the "nucleic acid" has a nucleotide sequence encoding a polypeptide fragment (e.g., a peptide). In some embodiments, the "nucleic acid" contains one or more introns. In some embodiments, the "nucleic acid" contains one or more exons. In some embodiments, the "nucleic acid" contains one or more coding sequences. In some embodiments, the "nucleic acid" is prepared by one or more of the following: isolation from a naturally occurring product, enzymatic synthesis by polymerization based on a complementary template (in vivo or in vitro), replication in recombinant cells or systems, and chemosynthesis. In some embodiments, the "nucleic acid" is at least three or more residues long. In some embodiments, the "nucleic acid" is single-stranded, and in some embodiments, the "nucleic acid" is double-stranded. In some embodiments, the "nucleic acid" has a nucleotide sequence containing at least one element that encodes a polypeptide or a fragment thereof, or is a complement to a sequence that encodes such a sequence. In some embodiments, the "nucleic acid" has enzymatic activity.

[0107] "Operablely coupled" means that the components described are in a relationship that allows them to function in the manner they are intended.

[0108] In other embodiments, the operable linkage does not require continuity. For example, unreconstructed variable region gene segments that are "operably linked" to each other can be reconstructed to form a reconstructed variable region gene, and such unreconstructed variable region gene segments are not necessarily contiguous to each other. Unreconstructed variable region gene segments that are operablely linked to each other and to contiguous constant region genes have the ability to be reconstructed to form a reconstructed variable region gene that is expressed by binding to the constant region gene as a polypeptide chain of an antigen-binding protein. A control sequence "operably linked" to a coding sequence is linked in such a way that expression of the coding sequence is achieved under conditions that are compatible with the control sequence. The "operably linked" sequence includes both an expression regulatory sequence adjacent to the gene of interest and an expression regulatory sequence that acts in trans or at a distance to regulate the gene of interest.

[0109] The term "regulatory sequences" refers to polynucleotide sequences necessary for the expression and processing of the coding sequences to which they are ligated. Regulatory sequences include appropriate transcription start, termination, promoter, and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak sequences); sequences that enhance protein stability; and, if desired, sequences that enhance protein secretion. The nature of such regulatory sequences varies depending on the host organism. For example, in prokaryotes, these regulatory sequences generally include promoters, ribosome binding sites, and transcription termination sequences, while in eukaryotes, these regulatory sequences typically include promoters and transcription termination sequences. The term "regulatory sequence" is intended to include elements whose presence is essential for expression and processing, but may also include additional elements whose presence is advantageous, such as leader sequences and fusion partner sequences.

[0110] Physiological conditions include the meaning known in the art relating to the conditions under which a cell or organism survives and / or reproduces. In some embodiments, the term means external or internal environmental conditions that may occur naturally for an organism or cell system. In some embodiments, physiological conditions are conditions within the body of a human or non-human animal, particularly those at and / or within a surgical site. Physiological conditions typically include, for example, a temperature in the range of 20–40°C, 1 atmosphere, pH 6–8, glucose concentration of 1–20 mM, atmospheric oxygen concentration, and gravity occurring on Earth. In some embodiments, laboratory conditions are manipulated and / or maintained to physiological conditions. In some embodiments, physiological conditions are those that occur within an organism (e.g., a non-human animal).

[0111] A polypeptide refers to any polymer chain of amino acids.

[0112] In some embodiments, the polypeptide has an amino acid sequence that exists in nature. In some embodiments, the polypeptide has an amino acid sequence that does not exist in nature. In some embodiments, the polypeptide has an amino acid sequence that includes parts that exist separately in nature (i.e., from two or more different organisms, such as human and non-human parts). In some embodiments, the polypeptide has a genetically engineered amino acid sequence in the sense that it is designed and / or produced through human intervention. In some embodiments, the polypeptide may contain or consist of multiple fragments, each of which is found in the same parent polypeptide in a spatial arrangement different from that found in the polypeptide of interest (for example, fragments that are directly linked in the parent polypeptide may be spatially separated in the polypeptide of interest, or vice versa, and / or fragments may be in a different order in the polypeptide of interest than in the parent polypeptide), and the polypeptide of interest is thus a derivative of its parent polypeptide.

[0113] Recombination means nucleic acids and / or polypeptides designed, manipulated, prepared, expressed, generated, or isolated by recombinant means, such as polypeptides expressed using recombinant expression vectors transfected into host cells, polypeptides isolated from recombinant combinatorial human polypeptide libraries (Hoogenboom HR, 1997 TIB Tech. 15:62-70; Hoogenboom H., and Chames P., 2000, Immunology Today 21:371-378; Azzazy H., and Highsmith WE, 2002, Clin. Biochem. 35:425-445; Gavilondo JV, and Larrick JW, 2002, BioTechniques 29:128-145), and antibodies isolated from animals (e.g., mice) that are transgenic to human immunoglobulin genes (e.g., Taylor, LD, et al., 1992, Nucl. Acids). Res.20:6287-6295;Little See M. et al., 2000, Immunology Today 21:364-370; Kellermann SA and Green LL, 2002, Current Opinion in Biotechnology 13:593-597; Murphy, AJ, et al., 2014, Proc. Natl. Acad. Sci. USA 111(14):5153-5158 (each of which is incorporated herein by reference), or any other means involving cross-splicing of selected sequence elements to mean polypeptides prepared, expressed, produced or isolated.

[0114] In some embodiments, one or more such selected sequence elements exist in nature. In some embodiments, one or more such selected sequence elements are designed in silico. In some embodiments, one or more such selected sequence elements arise, for example, from the induction (e.g., in vivo or in vitro) of known sequence elements of natural or synthetic origin. For example, in some embodiments, the recombinant polypeptide contains a sequence found in the genome (or polypeptide) of the source organism of interest (e.g., human, mouse, etc.). In some embodiments, the recombinant polypeptide contains a sequence that occurs naturally and separately from each other in two different organisms (e.g., human and non-human organisms) (i.e., derived from two or more different organisms, such as human and non-human parts). In some embodiments, the recombinant polypeptide has an amino acid sequence resulting from induction (e.g., in vitro or in vivo in non-human animals), and therefore the amino acid sequence of the recombinant polypeptide is a sequence that originates from and is related to the polypeptide sequence, but may not naturally exist in vivo in the genome of a non-human animal.

[0115] A reference refers to a standard or control agent, animal, cohort, individual, population, sample, sequence, or value compared to the agent, animal, cohort, individual, population, sample, sequence, or value of interest. "Reference" or "control" may also refer to a "reference animal" or "control animal." The "reference animal" may have the modifications described herein, modifications different from those described herein, or be unmodified (i.e., wild-type). Generally, as will be understood by those skilled in the art, the reference agent, animal, cohort, individual, population, sample, sequence, or value is determined or characterized under conditions equivalent to those used to determine or characterize the agent, animal (e.g., mammal), cohort, individual, population, sample, sequence, or value of interest.

[0116] In some embodiments, a reference drug, animal, cohort, individual, population, sample, sequence, or value is tested and / or calculated substantially concurrently with the test or calculation of the drug, animal, cohort, individual, population, sample, sequence, or value of interest. In some embodiments, the reference drug, animal, cohort, individual, population, sample, sequence, or value is, as may be, a known reference embodied in tangible media. In some embodiments, a reference may refer to a control. For example, "VELOCIMMUNE® control" or "control" as a reference animal refers to a VELOCIMMUNE® mouse containing humanized heavy chain and kappa variable region locus, in which case the mouse may be bred. These VELOCIMMUNE® control mice are outlined in Macdonald et al (2014) Proc. Natl. Acad. Sci. USA 111:5147-52 and Supplemental Information. That literature is incorporated herein by reference in its entirety.

[0117] Somatic cell recombination refers to the V-14 at the immunoglobulin heavy chain locus. H , D H , and J H Recombination of gene segments, or V at immunoglobulin light chain loci L and J L This refers to the recombination of gene segments. Somatic recombination occurs in the bone marrow before antigen contact during B cell development. At heavy chain loci, one DJ junction occurs in a process called DJ junction. H and one J H The DNA is randomly rejoined, and all intervening DNA is removed. Next, random V H The segment is reconstructed D H J H Recombination occurs in the segment. Recombination at immunoglobulin light chain loci occurs in a similar manner. During a process called VJ binding, V L Gene segment and J L Genetic segments are joined, then rejoined, and all the DNA between them is removed.

[0118] "Substantially" means a qualitative condition indicating the complete or near-complete range or degree of the feature or characteristic in question. Those skilled in the biological art will understand that biological and chemical phenomena rarely, if any, proceed to completion and / or to a complete state, or achieve or avoid absolute results. Therefore, the term "substantially" is used to capture the potential lack of completeness inherent in many biological and chemical phenomena.

[0119] Substantial homology refers to the similarity between amino acid sequences or nucleic acid sequences. As those skilled in the art will understand, two sequences are generally considered "substantial homologous" if they contain homologous residues in their corresponding positions. Homologous residues may be identical residues. Alternatively, homologous residues may be non-identical residues with moderately similar structural and / or functional characteristics. For example, as is well known to those skilled in the art, certain amino acids are generally classified as "hydrophobic" or "hydrophilic" amino acids, and / or as having "polar" or "nonpolar" side chains. Often, the substitution of one amino acid with another amino acid of the same type can be considered a "homologous" substitution. A general classification of amino acids is summarized below. [Table 1] [Table 2]

[0120] As is well known in the art, amino acid or nucleic acid sequences can be compared using any of the various algorithms available, including those available in commercially available computer programs such as BLASTN and BLASTP for nucleotide sequences, gapped BLAST, and PSI-BLAST for amino acid sequences. Examples of such programs are described in Altschul, SF et al., 1990, J.Mol.Biol., 215(3):403-410; Altschul et al., 1996, Methods Enzymol. 266:460-80; Altschul, SF et al., 1997, Nucleic Acids Res., 25:3389-402; Baxevanis, AD and BFFOuellette (eds.), Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley, 1998; and Misener et al. (eds.), Bioinformatics Methods and Protocols (Methods in Molecular Biology, Vol.132), Humana Press, 1998. In addition to identifying homologous sequences, the above programs typically provide an indicator of the degree of homology.

[0121] In some embodiments, two sequences are considered substantially homologous if at least 95% of their corresponding residues are homologous across a relevant interval of residues. In some embodiments, the relevant interval is a complete sequence. In some embodiments, the relevant interval consists of at least nine residues. In some embodiments, the relevant interval includes adjacent residues along the complete sequence. In some embodiments, the relevant interval includes discontinuous residues along the complete sequence, such as non-adjacent residues attracted by a folded structure of a polypeptide or a part thereof. In some embodiments, the relevant interval consists of at least ten residues.

[0122] Substantial identity means similarity between amino acid or nucleic acid sequences. As those skilled in the art will understand, two sequences are generally considered "substantial" if they contain identical residues at corresponding positions. As known in the art, amino acid or nucleic acid sequences can be compared using any of the various algorithms available, including those available in commercially available computer programs such as BLASTN and BLASTP for nucleotide sequences, gapped BLAST, and PSI-BLAST for amino acid sequences. Examples of such programs are described in Altschul, SF et al., 1990, J.Mol.Biol., 215(3):403-410; Altschul et al., 1996, Methods Enzymol. 266:460-80; Altschul, SF et al., 1997, Nucleic Acids Res., 25:3389-3402; Baxevanis, AD and BFFOuellette (eds.), Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley, 1998; and Misener et al. (eds.), Bioinformatics Methods and Protocols (Methods in Molecular Biology, Vol.132), Humana Press, 1998. In addition to identifying identical sequences, the above programs typically provide an indicator of the degree of identity.

[0123] In some embodiments, two sequences are considered substantially identical if at least 95% of the corresponding residues are identical across a relevant interval of residues. In some embodiments, the relevant interval is a complete sequence. In some embodiments, the relevant interval consists of at least 10 residues.

[0124] A targeted vector or targeted construct refers to a polynucleotide molecule containing a targeted region. The targeted region contains a sequence identical or substantially identical to that of a target cell, tissue, or animal, and integrates the targeted construct into its location within the genome of the cell, tissue, or animal by homologous recombination. This also includes targeted regions that are targeted using site-specific recombinase recognition sites (e.g., loxP or Frt sites).

[0125] In some embodiments, the targeted construct described herein further includes a nucleic acid sequence or gene of particular interest, a selectable marker, a regulatory sequence and / or modulating sequence, and other nucleic acid sequences that enable recombination mediated by the external addition of proteins that assist or promote recombination involving such sequences. In some embodiments, the targeted construct described herein further includes all or part of the gene of interest, which is a heterologous gene encoding all or part of a polypeptide having a function similar to that of a protein encoded by an endogenous sequence. In some embodiments, the targeted construct described herein further includes all or part of the humanized gene of interest, which encodes all or part of a polypeptide having a function similar to that of a polypeptide encoded by an endogenous sequence. In some embodiments, the targeted construct (or targeted vector) may include a human-engineered nucleic acid sequence. For example, in some embodiments, the targeted construct (or targeted vector) may be constructed to include an engineered polynucleotide or recombinant polynucleotide comprising two or more sequences that are not bound to each other in nature but have been human-engineered to be directly bound to each other in the engineered polynucleotide or recombinant polynucleotide.

[0126] A transgene or transgene construct means a nucleic acid sequence (e.g., a sequence encoding all or part of a polypeptide of interest) introduced into a cell by human intervention (e.g., by the method described herein). The transgene may be partially or entirely heterologous, i.e., exogenous to the transgenic animal or cell into which it is introduced. The transgene may contain one or more transcriptional regulatory sequences, such as introns or promoters, and any other nucleic acids, which may be required for the expression of the selected nucleic acid sequence. The transgene may contain one or more selection markers that enable the subsequent selection of offspring (e.g., cells) that have incorporated the transgene.

[0127] Transgenic animals, transgenic non-human animals, or Tg + In this specification, "interchangeable" means any non-natural non-human animal in which one or more cells of the non-human animal contain heterologous nucleic acids and / or genes encoding all or part of the polypeptide in question.

[0128] In some embodiments, heterologous nucleic acid sequences and / or genes are introduced into cells directly or indirectly by planned genetic engineering, such as by microinjection or by infection with recombinant viruses, into precursor cells. The term genetic engineering refers to the introduction of recombinant DNA molecules, rather than traditional mating techniques. These molecules may be incorporated into chromosomes or may be DNA that replicates outside of chromosomes. + The term "animals" includes animals that are heterozygous or homozygous to heteronucleotides and / or genes, as well as animals that have a single copy or multiple copies of heteronucleotides and / or genes.

[0129] A targeted vector is a nucleic acid molecule that can transport an associated target nucleic acid, specifically for the purpose of targeted insertion of the target nucleic acid into another nucleic acid molecule, such as a donor plasmid or a non-human animal genome.

[0130] In some embodiments, the vector can perform extrachromosomal replication and / or express ligated nucleic acids in host cells such as eukaryotic cells and / or prokaryotic cells. A vector capable of inducing the expression of a functionally ligated gene is referred to herein as an “expression vector” or “construct.”

[0131] The term "wild-type" has a meaning known in the art that refers to an entity with a structure and / or activity that exists in a "normal" state (as opposed to mutation, disease, manipulation, or alteration). Those skilled in the art will understand that wild-type genes and polypeptides often exist in multiple different forms (e.g., alleles).

[0132] Other features, purposes, and benefits of the present invention will become apparent in the detailed description of some embodiments below. However, it should be understood that while the detailed description shows some embodiments of the present invention, they are presented for illustrative purposes only and not for limiting purposes. Various changes and modifications within the scope of the present invention will become apparent to those skilled in the art from the modes for carrying out the invention. [Modes for carrying out the invention]

[0133] Antibody-based therapies have offered great hope for the treatment of several diseases, but the development of particularly effective antibodies that bind to troublesome targets remains a challenge. This specification describes an anchor-modified immunoglobulin (Ig) and a modified IgV segment encoding it, where the anchor comprises at least a receptor-binding portion of a ligand (e.g., a non-immunoglobulin polypeptide) that binds to a congener receptor. Animals possessing the modified IgV segment may produce a diverse repertoire of anchor-modified immunoglobulins in response to immunization of the anchor with a congener receptor.

[0134] While not constrained by theory, anchors act to increase the affinity of newly generated antibodies in animals responding to antigen challenges using a congener receptor by, for example, binding to the congener receptor simultaneously with an antibody that specifically binds to the congener receptor, and / or in response to an antigen challenge using the congener receptor, thereby causing affinity maturation of the antibody that would not normally be expanded without the anchor. Therefore, the diverse repertoire of immunoglobulins produced by non-human animals disclosed herein includes anchor-modified immunoglobulins that bind to congener receptors with high affinity, thereby increasing the immunoglobulin population from which lead candidates against previously problematic targets may be discovered. Nucleic acid molecules, including targeted vectors and animal genomes.

[0135] The anchor-modified immunoglobulins described herein are modified, at least in part, to encode an anchor between the Ig reader sequence and the framework (FR) and complementarity-determining region (CDR) of the germline Ig V segment, and in a responsive linkage thereto, for example, the heavy chain variable region (V) of immunoglobulin (Ig). H ) segment or light chain variable region (V L The immunoglobulin (Ig) signal peptide may be encoded by a variable region (V) segment, such as the ) segment. The nucleic acid sequences encoding immunoglobulin (Ig) signal peptides and germline V segments, such as the human germline V segment, are well known in the art, as are the encoded amino acid sequences. See, for example, Lefranc, M.-P., Exp. Clin. Immunogenet., 18, 100-116 (2001). This document is incorporated herein by reference in its entirety. See also the website accessible at the address imgt.org on the web (www).

[0136] Nucleic acid molecules containing a targeted vector, and animal genomes described herein, may include nucleic acid sequences encoding any Ig signal peptide of a germline V segment. In some embodiments, a modified Ig V segment includes a nucleic acid sequence encoding the signal peptide of a first germline Ig V segment, a nucleic acid sequence encoding an anchor, and nucleic acids encoding the framework region (FR) 1, complementarity-determining region (CDR) 1, FR2, CDR2, FR3, and CDR3 of a second germline Ig V segment, in which case the first germline Ig V segment and the second germline Ig V segment are different germline Ig V segments. In some embodiments, a modified Ig V segment includes a nucleic acid sequence encoding the signal peptide of a first germline Ig V segment, a nucleic acid sequence encoding an anchor, and nucleic acids encoding the framework region (FR) 1, complementarity-determining region (CDR) 1, FR2, CDR2, FR3, and CDR3 of a second germline Ig V segment, in which case the first germline Ig V segment and the second germline Ig V segment are the same germline Ig V segment. In some embodiments, the Ig signal peptide includes the sequence MDWTWRFLFVVAAATGVQS (SEQ ID NO: 7).

[0137] Human (h) germline V segment (e.g., human germline variable heavy chain (hV) H The amino acid sequences of the (hV) segment, the human germline variable kappa (hVκ or hIGKV) segment, and the human germline variable lambda (hVλ or hIGLV) segment, and the mouse (m) germline V segment (e.g., mouse germline variable heavy chain (mV) HThe amino acid sequences of the (mIGVH) segment, the mouse germline variable kappa (mVκ or mIGKV) segment, and the mouse germline variable lambda (mVλ or mIGLV) segment are available at the web addresses imgt.org / IMGTrepertoire / Proteins / SequenceLogos / human / and imgt.org / IMGTrepertoire / Proteins / SequenceLogos / mouse / , each of which is incorporated herein by reference in its entirety.

[0138] In some embodiments, the germline IgV segment or its variant (for example, variants encoding FR1, CDR1, FR2, CDR2, FR3, and CDR3 of the modified IgV segments described herein) is a human (h) germline IgV segment or its variant, for example, germline human (h)V H 1-2 segments, germline hV H 1-3 segments, germline hV H 1-8 segments, germline hV H 1 18 segments, germline hV H 1-24 segments, germline hV H 1-45 segments, germline hV H Segments 1-46, germline hV H 1-58 segments, germline hV H Segments 1-69, germline hV H 2-5 segments, germline hV H 2-26 segments, germline hV H 2 70 segments, germline hV H 3-7 segments, germline hV H 3-9 segments, germline hV H 3 11 segments, germline hV H 3 13 segments, germline hV H 3-15 segments, germline hV H 3-16 segments, germline hV H 3-20 segments, germline hVH 3-21 segments, germline hV H 3-23 segments, germline hV H 3-30 segments, germline hV H 3-30-3 segment, germline hV H 3-30-5 segment, germline hV H 3-33 segments, germline hV H 3-35 segments, germline hV H 3-38 segments, germline hV H 3-43 segments, germline hV H 3-48 segments, germline hV H 3-49 segments, germline hV H 3-53 segments, germline hV H 3-64 segments, germline hV H 3-66 segments, germline hV H 3-72 segments, germline hV H 3-73 segments, germline hV H 3-74 segments, germline hV H 4-4 segment, germline hV H 4-28 segments, germline hV H 4-30-1 segment, germline hV H 4 30-2 segments, germline hV H 4-30-4 segment, germline hV H 4-31 segments, germline hV H 4-34 segments, germline hV H 4-39 segments, germline hV H 4-59 segments, germline hV H 4-61 segments, germline hV H 5-51 segments, germline hV H 6-1 segment, germline hV H 7-4-1 segment, germline hV H 7-81 segments, or variants thereof. In some embodiments, the germline IgV segment or variant thereof is the germline hV H It is segment 1-69 or a variant thereof.

[0139] In some embodiments, the nucleic acid molecules described herein are modified Ig hV H Includes only segments, for example, any additional hV H This does not include segments or their variants.

[0140] In some embodiments, the nucleic acid molecules described herein are modified Ig hV H In addition to segments, additional hV H Segments, for example, V H 1-2, hV H 1-3, hV H 1-8, hV H 1 18, hV H 1-24, hV H 1-45, hV H 1-46, hV H 1-58, hV H 1-69, hV H 2-5, hV H 2-26, hV H 2 70, hV H 3-7, hV H 3-9, hV H 3 11, hV H 3 13, hV H 3-15, hV H 3-16, hV H 3-20, hV H 3-21, hV H 3-23, hV H 3-30, hV H 3-30-3, hV H 3-30-5, hV H 3-33, hV H 3-35, hV H 3-38, hV H 3-43, hV H 3-48, hV H 3-49, hV H 3-53, hV H 3-64, hV H 3-66, hV H 3-72, hV H 3-73, hV H 3-74, hV H 4-4, hVH 4-28、hV H 4-30-1、hV H 4 30-2、hV H 4-30-4、hV H 4-31、hV H 4-34、hV H 4-39、hV H 4-59、hV H 4-61、hV H 5-51、hV H 6-1、hV H 7-4-1、hV H 7-81 H 1-2、hV H 1-3、hV H 1-8、hV H 1 18、hV H 1-24、hV H 1-45、hV H 1-46、hV H 1-58、hV H 1-69、hV H 2-5、hV H 2-26、hV H 2 70、hV H 3-7、hV H 3-9、hV H 3 11、hV H 3 13、hV H 3-15、hV H 3-16、hV H 3-20、hV H 3-21、hV H 3-23、hV H 3-30、hV H 3-30-3、hV H 3-30-5、hV H 3-33、hV H 3-35、hV H 3-38、hV H 3-43、hV H 3-48、hV H 3-49、hV H 3-53、hV H 3-64、hV H 3-66、hV H 3-72、hV H 3-73、hVH 3-74, hV H 4-4, hV H 4-28, hV H 4-30-1, hV H 4 30-2, hV H 4-30-4, hV H 4-31, hV H 4-34, hV H 4-39, hV H 4-59, hV H 4-61, hV H 5-51, hV H 6-1, hV H 7-4-1, and hV H In some embodiments, including multiple or each of the 7-81 segments, hV H A segment is the arrangement of germlines.

[0141] In some embodiments, the nucleic acid molecules described herein (e.g., targeted vectors, non-human animal genomes, etc.) may include an Ig heavy chain variable region, for example, an additional (non-)reconstituted V segment in addition to the anchor-modified V segment. H , D H and / or J H It may include gene segments, and in some embodiments, additional (non)reconstituted hV H , hD H and / or hJ H It may include gene segments. In some embodiments, the nucleic acid molecules described herein (e.g., targeted vectors, non-human animal genomes, etc.) are (non)reconstituted hV H Only one segment, (un)reconstructed hD H One or more segments and (non)reconstructed hJ H A hV containing one or more segments, in this case only one of which is (un)reconstructed. H The segment is a modified hV containing a nucleic acid sequence encoding the anchor described herein. H It is a segment.

[0142] In some embodiments, the recombinant nucleic acids described herein (e.g., targeted vectors, non-human animal genomes, etc.) are one or more human D H Includes segments, for example, hD H 1-1, hD H 1-7, hD H 1-14, hD H 1-20, hD H 1-26, hD H 2-2, hD H 2-8, hD H 2-15, hD H 2-21, hD H 3-3, hD H 3-9, hD H 3-10, hD H 3-16, hD H 3-22, hD H 4-4, hD H 4-11, hD H 4-17, hD H 4-23, hD H 5-5, hD H 5-12, hD H 5-18, hD H 5-24, hD H 6-6, hD H 6-13, hD H 6-19, hD H 6-25, hD H Includes 7-27, and one, more, or each of their variants. In some embodiments, hD H 1-1, hD H 1-7, hD H 1-14, hD H 1-20, hD H 1-26, hD H 2-2, hD H 2-8, hD H 2-15, hD H 2-21, hD H 3-3, hD H 3-9, hD H 3-10, hD H 3-16, hD H 3-22, hD H 4-4, hD H 4-11, hD H 4-17, hDH 4-23, hD H 5-5, hD H 5-12, hD H 5-18, hD H 5-24, hD H 6-6, hD H 6-13, hD H 6-19, hD H 6-25, and hD H In some embodiments including several of 7-27, or each of them, hD H The segment is located in the arrangement of the germline.

[0143] In some embodiments, the recombinant nucleic acids described herein (e.g., targeted vectors, non-human animal genomes, etc.) are used in relation to one or more human J H Includes segments, for example, hJ H 1. hJ H 2. hJ H 3. hJ H 4. hJ H 5. hJ H 6, and one, more, or each of their variants. hJ H 1. hJ H 2. hJ H 3. hJ H 4. hJ H 5, and hJ H In some embodiments, which include multiple or each of the 6 segments, hJ H The segment is located in the arrangement of the germline.

[0144] In some embodiments, recombinant nucleic acid molecules (e.g., targeted vectors, non-human animal genomes, etc.) may include heavy chain variable region loci, for example, a movable linkage, oriented from 5' to 3', including: (I) Modified Ig V H Segment, (II) one or more Ig heavy chain diversity (D H ) segment, and (III) one or more Ig heavy chain bonds (J H ) segment. In some embodiments, (II) Ig D H One or more of the segments are human IgD HIncluding one, more, or all of the segments and / or (III) Ig J H One or more of the segments are human Ig J H Includes one, more, or all of the segments. In some embodiments, (II) Ig D H One or more of the segments, and (III) Ig J H One or more gene segments are recombinant and rearranged into Ig D H / J H It forms a sequence. Thus, the recombinant nucleic acid molecule has a functional linkage and, from 5' to 3', includes: modified Ig V H Gene segment and reconstituted Ig D H / J H array.

[0145] In some embodiments, Ig V H Gene segment and reconstituted Ig D H / J H Ig V with rearranged and reconstructed sequences H / D H / J H A sequence is formed, and the sequence encodes an anchor-modified Ig heavy chain variable domain. In this case, the anchor-modified Ig heavy chain variable domain is a functional linkage comprising (i) an Ig signal peptide, (ii) an anchor, and (iii) a reconstituted Ig V. H / D H / J H It includes FR1, complementarity determination region (CDR1), FR2, CDR2, FR3, CDR3, and FR4, which are encoded by the sequence.

[0146] In some embodiments, modified IgV H The segment is an unreconstructed modified Ig V H It is a gene segment.

[0147] In some embodiments, the recombinant nucleic acids described herein (e.g., targeted vectors, non-human animal genomes, etc.) have a constant Ig heavy chain region (CH The nucleic acid sequence further comprises a sequence encoding ) in this case Ig C H The nucleic acid sequence encoding (I) modified Ig V H Segment, (II) Ig D H One or more of the segments, and (III) Ig J H It lies downstream of one or more segments and is operably ligated to them. In some embodiments, the nucleic acid sequence is Ig C H The recombinant nucleic acid molecules described herein include an Igμ gene encoding the IgM isotype, an Igδ gene encoding the IgD isotype, an Igγ gene encoding the IgG isotype, an Igα gene encoding the IgA isotype, and / or an Igε gene encoding the IgE isotype. In some embodiments, the recombinant nucleic acid molecules described herein include a nucleic acid sequence encoding an anchor-modified Ig heavy chain, in which case the anchor-modified Ig heavy chain is a operable linkage comprising (i) an Ig signal peptide, (ii) an anchor, and (iii) a reconstituted Ig V H / D H / J H The sequence encodes Ig heavy chain variable domains including FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4, as well as (iv) Ig C H , including. In some embodiments, Ig C H is non-human Ig C H For example, IgC in rodents H For example, rat Ig C H or mouse Ig C H That is the case.

[0148] In some embodiments, the germline Ig V segment or its variants (e.g., variants encoding FR1, CDR1, FR2, CDR2, FR3 and CDR3 of the modified Ig V segment described herein) is germline Ig light chain variable (V L) is a segment or a variant thereof. In some embodiments, the recombinant nucleic acid molecule may include a light chain variable region locus, for example, a movable linkage, oriented from 5' to 3', including: (I) a modified Ig V L Segment, and (II)Ig light chain binding (J L ) One or more of the segments. In some embodiments, a modified Ig V L Segments, and Ig J L One or more of the segments are rearranged and reconstructed Ig V L / J L The sequence is formed. The sequence encodes an anchor-modified Ig light chain variable domain, in which the anchor-modified Ig light chain variable domain is a functional linkage comprising (i) an Ig signal peptide, (ii) an anchor, and (iii) a reconstituted Ig V. L / J L The sequence includes FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4, which are encoded by the sequence. In some embodiments, the recombinant nucleic acid molecule includes a light chain variable region locus and an Ig light chain constant region (C L It may include a nucleic acid sequence encoding the Ig C, in which case the Ig C L The nucleic acid sequences encoding are downstream of the following, and are operablely ligated to them: (I) Modified Ig V L Segment, and (II)Ig light chain binding (J L ) One or more of the segments. In some embodiments, the anchor-modified Ig light chain is a operable linkage containing (i) an Ig signal peptide, (ii) an anchor, and (iii) a reconstituted Ig V. L / J L The Ig light chain variable domains include FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 encoded by the sequence, and (iv) Ig C L , including. In some embodiments, Ig C L is non-human Ig C L For example, IgC in rodents L For example, rat Ig C L or mouse Ig C LThat is the case.

[0149] In some embodiments, the germline Ig V segment or its variants (e.g., variants encoding FR1, CDR1, FR2, CDR2, FR3, and CDR3 of the modified Ig V segment described herein) is the germline Ig light chain variable kappa (Vκ) segment or its variants, e.g., the human Vκ segment, e.g., the hVκ1-5 segment, hVκ Segments 1-6, hVκ1-8, hVκ1D-8, hVκ1-9, hVκ1-12, hVκ1D-12, hVκ1-13, hVκ1D-13, hVκ1-16, hVκ1D-16, hVκ1-17, hVκ1D-17, hVκ1-27, hVκ1-33, hVκ1D-33, hVκ1-37, hVκ1D-37, hVκ1-39, hVκ1D-39, a hVκ1-NL1 segment, hVκ1D-42 segment, hVκ1D-43 segment, hVκ2-4 segment, hVκ2-18 segment, hVκ2D-18 segment, hVκ2-24 segment, hVκ2D-24 segment, hVκ2-28 segment, hVκ2D-28 segment, hVκ2-29 segment, hVκ2D-29 segment, hVκ2-30 segment, hVκ2D-30 segment, hVκ2-40 segment, hVκ2D-40 segment These include the hVκ2D-26 segment, hVκ3-7 segment, hVκ3D-7 segment, hVκ3-11 segment, hVκ3D-11 segment, hVκ3-15 segment, hVκ3D-15 segment, hVκ3-20 segment, hVκ3D-20 segment, hVκ4-1 segment, hVκ5-2 segment, hVκ6-21 segment, hVκ6D-21 segment, hVκ6D-41 segment, hVκ7-3 segment, and their variants. In some embodiments, the nucleic acid molecules described herein are modified Ig In addition to the hVκ segments, it further includes additional hVκ segments, for example, hVκ1D-8 segments, hVκ1-9 segments, hVκ1-12 segments, hVκ1D-12 segments, hVκ1-13 segments, hVκ1D-13 segments, hVκ1-16 segments, hVκ1D-16 segments, hVκ1-17 segments, hVκ1D-17 segments, hVκ1-27 segments, hVκ1-33 segments, hVκ1D-33 segments, hVκ1-37 segments, hVκ1D-37 segments, hVκ1-39 segments, hVκ1D-39,a hVκ1-NL1 segment, hVκ1D-42 segment, hVκ1D-43 segment, hVκ2-4 segment, hVκ2-18 segment, hVκ2D-18 segment, hVκ2-24 segment, hVκ2D-24 segment, hVκ2-28 segment, hVκ2D-28 segment, hVκ2-29 segment, hVκ2D-29 segment, hVκ2-30 segment, hVκ2D-30 segment, hVκ2-40 segment, hVκ2 The following segments are included: D-40 segment, hVκ2D-26 segment, hVκ3-7 segment, hVκ3D-7 segment, hVκ3-11 segment, hVκ3D-11 segment, hVκ3-15 segment, hVκ3D-15 segment, hVκ3-20 segment, hVκ3D-20 segment, hVκ4-1 segment, hVκ5-2 segment, hVκ6-21 segment, and hVκ6D-21 segment, one or more of each of these, or each of them.hVκ1D-8 segment, hVκ1-9 segment, hVκ1-12 segment, hVκ1D-12 segment, hVκ1-13 segment, hVκ1D-13 segment, hVκ1-16 segment, hVκ1D-16 segment, hVκ1-17 segment, hVκ1D-17 segment, hVκ1-27 segment, hVκ1-33 segment, hVκ1D-33 segment, hVκ1-37 segment, hVκ1D-37 segment, hVκ1-39 segment, hVκ1D-39,a hVκ1-NL1 segment, hVκ1D-42 segment, hVκ1D-43 segment, hVκ2-4 segment, hVκ2-18 segment, hVκ2D-18 segment, hVκ2-24 segment, hVκ2D-24 segment, hVκ2-28 segment, hVκ2D-28 segment, hVκ2-29 segment, hVκ2D-29 segment, hVκ2-30 segment, hVκ2D-30 segment, hVκ2-40 segment, hVκ2D-40 segment, hV In some embodiments, which include several or each of the following segments: κ2D-26, hVκ3-7, hVκ3D-7, hVκ3-11, hVκ3D-11, hVκ3-15, hVκ3D-15, hVκ3-20, hVκ3D-20, hVκ4-1, hVκ5-2, hVκ6-21, and hVκ6D-21, the hVκ segments are located in the germline arrangement.

[0150] In some embodiments, the nucleic acid molecules described herein (e.g., targeted vectors, non-human animal genomes, etc.) may include an Ig light chain κ variable region, for example, an anchor-modified hVκ segment plus an additional (non)reconstructed Jκ segment, and in some embodiments, an additional (non)reconstructed hJκ gene segment may be included. Thus, in some embodiments, the recombinant nucleic acid molecules described herein include, in a operable linkage, and from 5' to 3', one or more of the following: (I) a modified Ig Vκ segment, and (II) an Ig light chain-bound kappa Jκ segment. In some embodiments, the recombinant nucleic acid molecules described herein (e.g., targeted vectors, non-human animal genomes, etc.) may include one or more human J κ The segment includes, for example, one, more, or each of the hJκ1, hJκ2, hJκ3, hJκ4, hJκ5, and their variants. In some embodiments that include more or each of the hJκ1, hJκ2, hJκ3, hJκ4, and hJκ5 segments, the hJκ segment is located in the germline arrangement.

[0151] Furthermore, in some embodiments, the recombinant nucleic acid molecule described herein comprises, in a movable linkage, from 5' to 3', (I) a modified Ig Vκ segment, and (II) one or more Ig light chain-binding kappa (Jκ) and a nucleic acid sequence encoding an Ig light chain constant kappa region (Cκ).

[0152] In some embodiments, germline Ig V segment or its variant (e.g., modified Ig as described herein) The variants encoding FR1, CDR1, FR2, CDR2, FR3, and CDR3 of the V segment are germline Ig light chain variable lambda (Vλ) segments or their variants, for example, human Vλ segments, such as hVλ1-36 segments, hVλ1-40 segments, hVλ1-41 segments, hVλ1-44 segments, hVλ1-47 segments, hVλ1-50 segments, hVλ1-51 segments, hVλ1-62 segments, hVλ2-5 segments, hVλ2-8 segments, hVλ2-11 segments, hVλ2-14 segments, hVλ2-18 segments, hVλ2-23 segments, hVλ2-33 segments, hVλ2-34 segments, hVλ3-1 segments, hVλ3-9 segments, hVλ3-10 segments These are segments hVλ3-12, hVλ3-13, hVλ3-16, hVλ3-19, hVλ3-21, hVλ3-22, hVλ3-25, hVλ3-27, hVλ3-31, hVλ3-32, hVλ4-3, hVλ4-60, hVλ4-69, hVλ5-37, hVλ5-39, hVλ5-45, hVλ5-48, hVλ5-52, hVλ6-57, hVλ7-43, hVλ7-46, hVλ8-61, hVλ9-49, hVλ10-54, hVλ11-55, and their variants.In some embodiments, the nucleic acid molecules described herein further include additional hVλ segments in addition to the modified Ig hVλ segments, for example, hVλ1-36 segments, hVλ1-40 segments, hVλ1-41 segments, hVλ1-44 segments, hVλ1-47 segments, hVλ1-50 segments, hVλ1-51 segments, hVλ1-62 segments, hVλ2-5 segments, hVλ2-8 segments, hVλ2-11 segments, hVλ2-14 segments, hVλ2-18 segments, hVλ2-23 segments, hVλ2-33 segments, hVλ2-34 segments, hVλ3-1 segments, hVλ3-9 segments, hVλ3-10 segments, hVλ3-12 segments, hVλ3-13 segments, hVλ3-16 segments The segment further includes one or more or each of the following segments: hVλ3-19, hVλ3-21, hVλ3-22, hVλ3-25, hVλ3-27, hVλ3-31, hVλ3-32, hVλ4-3, hVλ4-60, hVλ4-69, hVλ5-37, hVλ5-39, hVλ5-45, hVλ5-48, hVλ5-52, hVλ6-57, hVλ7-43, hVλ7-46, hVλ8-61, hVλ9-49, hVλ10-54, and hVλ11-55.hVλ1-36 segment, hVλ1-40 segment, hVλ1-41 segment, hVλ1-44 segment, hVλ1-47 segment, hVλ1-50 segment, hVλ1-51 segment, hVλ1-62 segment, hVλ2-5 segment, hVλ2-8 segment, hVλ2-11 segment, hVλ2-14 segment, hVλ2-18 segment, hVλ2-23 segment, hVλ2-33 segment, hVλ2-34 segment, hVλ3-1 segment, hVλ3-9 segment, hVλ3-10 segment, hVλ3-12 segment, hVλ3-13 segment, hVλ3-16 segment, hVλ3-19 segment, hVλ3-21 segment, h In some embodiments, which include several or each of the following segments: Vλ3-22, hVλ3-25, hVλ3-27, hVλ3-31, hVλ3-32, hVλ4-3, hVλ4-60, hVλ4-69, hVλ5-37, hVλ5-39, hVλ5-45, hVλ5-48, hVλ5-52, hVλ6-57, hVλ7-43, hVλ7-46, hVλ8-61, hVλ9-49, hVλ10-54, and hVλ11-55, the hVλ segments are located in the germline arrangement.

[0153] In some embodiments, the nucleic acid molecules described herein (e.g., targeted vectors, non-human animal genomes, etc.) may include an Ig light chain λ variable region, for example, an anchor-modified hVλ segment plus an additional (non)reconstructed Jλ segment, and in some embodiments, an additional (non)reconstructed hJκλ gene segment may be included. Thus, in some embodiments, the recombinant nucleic acid molecules described herein include, in a operable linkage and from 5' to 3', one or more of the following: (I) a modified Ig Vλ segment, and (II) one or more Ig light chain-bound kappa Jλ segments. In some embodiments, the recombinant nucleic acid molecules described herein (e.g., targeted vectors, non-human animal genomes, etc.) include one or more human Jλ segments, for example, one or more of the hJλ1, hJλ2, hJλ3, hJλ4, hJλ5, hJλ6, hJλ7 segments, and their variants, or each of them. In some embodiments, which include several or each of the hJλ1, hJλ2, hJλ3, hJλ4, hJλ5, hJλ6, and hJλ7 segments, the hJλ segments are in germline arrangement. In some embodiments, the recombinant nucleic acid molecule described herein includes, in a movable linkage, from 5' to 3', (I) a modified Ig Vλ segment, (II) one or more Ig light chain-binding lambda (Jλ) segments, and a nucleic acid sequence encoding an Ig light chain constant lambda region (Cλ).

[0154] anchor

[0155] As described herein, the anchor comprises a ligand (or a portion thereof) that binds to a congener receptor. In some embodiments, the ligand may be a non-immunoglobulin polypeptide. Thus, as described herein, the anchor may comprise a non-immunoglobulin polypeptide, for example, a receptor-binding portion of a non-immunoglobulin polypeptide. The anchor modifications described herein may be useful for increasing the affinity between an antigen-binding protein, such as an antibody, and a troublesome receptor.

[0156] Exemplary and known non-immunoglobulin polypeptides: Examples of non-immunoglobulin polypeptides that bind to, but are not limited to, congeneral receptor pairs, include non-immunoglobulin polypeptides that bind to congeneral G protein-coupled receptors (GPCRs). Examples of GPCRs, but are not limited to, include chemokine receptors, glucagon receptors (e.g., GLP1:GLP1R), calcitonin receptors, and melanocortin receptors. These, and other congeneral GPCRs, including non-immunoglobulin polypeptides that bind to these receptors, are known in the art. See, for example, Wu et al. (2017) J.Mol.Biol.429:2726-45. That document is incorporated herein by reference in its entirety. Additional, non-exclusive, and exemplary non-immunoglobulin polypeptides (ligands): Examples of congeneral receptor pairs include: a. Ligands that bind to tyrosine kinases of the same receptor, such as, but not limited to, epidermal growth factor (EGF), insulin, platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), etc. b.DLL:Notch receptor pair, c.B7: CD28 / CLTA4 / PD1 receptor pair, d. Semaphorin: Plexin receptor pair, e.PCSK9 / LDLR pair, f.HLA:LILR pair, g. HLA:KIR pair, h. RGD-ligand:integrin pair, i. Natriuretic peptides (e.g., ANP, BNP, CNP): Pairs of natriuretic peptide receptors (NPR, NPR3, etc.). Ligand:receptor pairs can also include proteases and inhibitors.

[0157] In some embodiments, the anchor includes a natriuretic peptide (NP), for example, the receptor-binding portion of the NP. NP comprises at least eight structurally related amino acid peptides and is conserved as three distinct prohormones: atrial natriuretic peptide (ANP) prohormone, B-type natriuretic peptide (BNP) prohormone, and C-type natriuretic peptide (CNP) prohormone. Recently, D-type natriuretic peptide (DNP), a dendroaspis natriuretic peptide, has been discovered, and its role in humans remains unclear.

[0158] ANP prohormone (proANP) is a 126-amino acid polypeptide primarily expressed by cardiomyocytes, producing several peptides with hypotensive, natriuretic, diuretic, and / or potassium diuretic properties. These peptides derived from ANP prohormone are identified by the amino acid sequence beginning at the N-terminus of the ANP prohormone. For example, proANP 1-30 contains long-acting NP, proANP 31-67 possesses vasodilatory properties, proANP 79-98 contains potassium diuretic peptides, and amino acids 99-126 (also called ANP) are present. In the kidney, proANP undergoes different processing, with an additional four amino acids added to the N-terminus, such as proANP 95-126 (also called urodilatin).

[0159] BNP prohormone (proBNP) is a 108-amino acid polypeptide primarily expressed by cardiomyocytes. BNP prohormone is processed within the human heart to form BNP (e.g., amino acids 77-108 of its 108-amino acid prohormone) and NT-proBNP (e.g., amino acids 1-76, both of which circulate in humans). BNP is a reliable biomarker of ventricular dilation. Pandit et al. (2011) Ind. J. Endocrinol. Metab. 15(4) S345-53. This reference is incorporated herein by reference in its entirety.

[0160] Unlike ANPs and BNPs, CNPs are primarily expressed by endothelial and renal epithelial cells. Two types of CNP molecules have been identified in circulation. Although CNPs appear to lack natriuretic function, there are several indications that they may function as regulators of vascular tone and paracrine or autocrine proliferation, and that CNPs may play a role in bone growth.

[0161] NPs exert their biological functions by specifically binding to cell surface receptors. Three specific receptors have been identified in mammalian tissues: two guanylyl cyclase-binding receptors (GC-A and GC-B, also referred to as NP receptor (NPR)-A and NPR-B, respectively). NPR-A and NPR-B act via activation of the cGMP-dependent signaling cascade. In contrast, a third type C receptor (also called NPR-C) does not bind to guanylyl cyclase and is thought to be primarily involved in NP clearance. All three receptors bind to ANP, BNP, and CNP with different affinities. The ranking of ligand selectivity for GC-A is ANP ≥ BNP ≫ CNP, for GC-B it is CNP ≫ ANP ≥ BNP, and for NPR-C it is ANP > CNP > BNP. Jaubert et al. (1999) PNAS 96(18)10278-283. This document is incorporated herein by reference in its entirety.

[0162] NP receptors may be useful targets for the treatment of hypertension and cardiovascular disease. However, ANP and BNP have important diuretic, natriuretic, and hypotensive properties, while CNP may play a role in bone growth. Therefore, antibody-based targeting of NP receptors must take into account the differential binding affinity of the receptors to NP.

[0163] In some embodiments, the anchor comprises the ANP sequence or a portion thereof. The nucleic acid sequence encoding human ANP is described with NCBI accession number NM_006172.4 and hereafter as Sequence ID 1. The amino acid sequence of human ANP is described with NCBI accession number NP_006163 and hereafter as Sequence ID 2. In some embodiments, the anchor described herein comprises the receptor-binding portion of ANP, for example, the C-terminal tail of ANP. In some embodiments, the receptor-binding portion of ANP comprises the amino acid sequence NSFRY (Sequence ID 3).

[0164] Linker

[0165] In some embodiments, the anchor includes a linker that links the receptor-binding portion of the target non-immunoglobulin polypeptide to FR1, CDR1, FR2, CDR2, FR3, and CDR3 of the germline Ig V segment or its variant. In some embodiments, the linker may be 1 amino acid long. In some embodiments, the linker may be 2 amino acids long. In some embodiments, the linker may be 3 amino acids long. In some embodiments, the linker may be 4 amino acids long, for example, the linker may include the sequence GLSG (SEQ ID NO: 13). In some embodiments, the linker may be 5 amino acids long, for example, the sequence GGGGS (SEQ ID NO: 5). In some embodiments, the linker may be 6 amino acids long, for example, the sequence GLSGSG (SEQ ID NO: 14). In some embodiments, the linker may be 7 amino acids long. In some embodiments, the linker may include the sequence GLSGLSGS (SEQ ID NO: 15). In some embodiments, the linker may be 9 amino acids long. In some embodiments, the linker length may be 10 amino acids, and may include, for example, the sequence GLSGLSGLSG (SEQ ID NO: 16) or the sequence GLSGGSGLSG (SEQ ID NO: 17). In some embodiments, the first and second linkers are identical in length, and each is longer than 10 amino acids.

[0166] In some embodiments, the recombinant nucleic acid molecules described herein include the sequence described as SEQ ID NO: 8 or a degenerate variant thereof, or SEQ ID NO: 10 or a degenerate variant thereof.

[0167] Targeted vectors

[0168] Furthermore, targeted vectors are provided which are employed in methods for producing genetically modified non-human animals, cells, tissues, or embryos.

[0169] In one embodiment, a targeting vector is provided that includes an inserted nucleic acid, such as a recombinant nucleic acid molecule containing a modified Ig V segment described herein, adjacent to 5' and 3' homologous arms, the arms capable of homologous recombination with a target site, such as an Ig heavy chain or light chain variable region locus. Examples of targeting vectors and their components (i.e., inserted nucleic acids, target polynucleotides, expression cassettes, etc.) are described in detail below herein.

[0170] A homologous arm and a target site (i.e., a homologous genomic region) are "complementary" or "complementary" to each other if the two regions share a sufficient level of sequence identity and act as substrates for homologous recombination. "Homologous" means a DNA sequence that is identical to, or shares sequence identity with, a corresponding or "complementary" sequence. The sequence identity between a given target site and the corresponding homologous arm present on the targeting vector may be any degree of sequence identity to which homologous recombination can occur. For example, the amount of sequence identity shared by the homologous arm (or fragment thereof) of the targeting vector and the target site (or fragment thereof) may be at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity, such that the sequence undergoes homologous recombination. Furthermore, the homologous complementary region between the homologous arm and the complementary target site may be of any length sufficient to facilitate homologous recombination at the cleaved recognition site. For example, given homologous arms and / or complementary target sites have lengths of at least 5-10kb, 5-15kb, 10-20kb, 20-30kb, 30-40kb, 40-50kb, 50-60kb, 60-70kb, 70-80kb, 80-90kb, and 90-100kb, so that the homologous arms have sufficient homology to perform homologous recombination with the corresponding target sites in the cell genome. b may include homologous complementary regions of 100-110kb, 110-120kb, 120-130kb, 130-140kb, 140-150kb, 150-160kb, 160-170kb, 170-180kb, 180-190kb, 190-200kb, and 200kb-300kb or more (as described, for example, in vectors otherwise described herein). For ease of reference, homologous arms are referred to herein as 5' and 3' homologous arms. These terms relate to the relative position of the homologous arms to the inserted nucleic acid within the targeted vector.

[0171] Therefore, the homologous arms of a targeting vector are designed to be complementary to the target site having the target locus. Thus, the homologous arms may be complementary to a locus native to the cell, or to a region of a heterogeneous or exogenous DNA segment integrated into the cell genome, including, but not limited to, a transgene, expression cassette, or heterogeneous or exogenous region of genomic DNA. Alternatively, the homologous arms of a targeting vector may be complementary to a region of a human artificial chromosome, or to any other manipulated genomic region contained in a suitable host cell. Furthermore, the homologous arms of a targeting vector may be complementary to, or derived from, a region of a BAC library, cosmid library, or P1 phage library. Therefore, in certain embodiments, the homologous arms of a targeting vector are complementary to a genomic locus that is native, heterogeneous, or exogenous to a given cell, such as a eukaryotic, non-human, mammalian, non-human mammalian, human, rodent, mouse, or rat. In one embodiment, the homologous arms are derived from synthetic DNA.

[0172] In some embodiments of the targeting vector, the targeting vector further includes 5' and 3' homologous arms, which target a non-human Ig heavy chain locus, thereby enabling homologous recombination between the targeting vector and the non-human Ig heavy chain locus to recombinate with recombinant nucleic acid molecules (e.g., modified Ig V). H Segments, and optionally Ig D H Segment and / or Ig J H Recombinant nucleic acid molecules containing segments are used at the non-human Ig heavy chain locus of the non-human Ig C H Upstream of and including therein in a operable linkage, optionally in this case, the non-human Ig heavy chain locus is an endogenous rodent Ig heavy chain locus, and / or in this case, the non-human Ig heavy chain locus includes a human or humanized immunoglobulin heavy chain variable region and endogenous Ig V H , D H and / or J HThis includes deletions of gene segments, or combinations thereof. In some embodiments, during homologous recombination between the targeting vector and a non-human Ig heavy chain locus, the recombinant nucleic acid molecule is recombined with non-human Ig heavy chain locus at the non-human Ig heavy chain locus. H The segment is replaced. In some embodiments, during homologous recombination between the targeting vector and a non-human Ig heavy chain locus, the recombinant nucleic acid molecule replaces one or more non-human V at the non-human Ig heavy chain locus. H Segment, all non-human D H Segments, and all non-human J H The segment is replaced. In some embodiments, during homologous recombination between the targeting vector and a non-human Ig heavy chain locus, the recombinant nucleic acid molecule replaces one non-human V at the non-human Ig heavy chain locus. H All or all non-human V segments other than the segment H Segment, all non-human D H Segments, and all non-human J H The segment is replaced. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig heavy chain locus, the targeted non-human Ig heavy chain locus includes a recombinant nucleic acid molecule operably linked to a non-human Ig heavy chain control sequence at the non-human Ig heavy chain locus.

[0173] In some embodiments, the targeting vector comprises a recombinant nucleic acid molecule as described herein, as well as 5' and 3' homologous arms that target a non-human Ig heavy chain locus, thereby enabling homologous recombination between the targeting vector and the non-human Ig heavy chain locus to recombinate with the recombinant nucleic acid molecule (e.g., modified Ig V). H Segments, and optionally Ig D H Segment, Ig J H Segment and / or Ig C HA recombinant nucleic acid molecule (containing a gene) is included in an operable linkage to the non-human Ig heavy chain regulatory sequence of the non-human Ig heavy chain locus, and optionally in this case the non-human Ig heavy chain locus is an endogenous rodent Ig heavy chain locus in rodents or rodent cells (e.g., rodent embryonic stem cells), and / or in this case the non-human Ig heavy chain locus contains a human or humanized immunoglobulin heavy chain variable region and endogenous Ig V H , D H and / or J H This includes deletions of gene segments, or combinations thereof, and optionally, in this case, upon homologous recombination between the targeting vector and a non-human Ig heavy chain locus, the recombinant nucleic acid molecule has one or more non-human V at the non-human Ig heavy chain locus. H Segment, all non-human D H Genetic segment, all non-human J H Genetic segments, and one or more non-human C H Replace the gene.

[0174] In some embodiments, the 5' homologous arm includes the sequence described as sequence number 12, and / or the 3' homologous arm includes the sequence described as sequence number 13.

[0175] In some embodiments of the targeting vector, the targeting vector comprises a recombinant nucleic acid molecule as described herein and 5' and 3' homologous arms, the arms targeting a non-human Ig light chain locus, thereby, during homologous recombination between the targeting vector and the non-human Ig light chain locus, the targeted non-human Ig light chain locus becomes a recombinant nucleic acid molecule (e.g., a modified Ig V as described herein). L Segments, and optionally Ig J L Recombinant nucleic acid molecules (including segments) are used at the non-human Ig light chain locus of the non-human Ig C L Upstream of and including therein in a operable linkage, optionally in this case, the non-human Ig light chain locus is an endogenous rodent Ig light chain locus, and / or in this case, the non-human Ig light chain locus includes a human or humanized immunoglobulin light chain variable region and endogenous Ig VL and / or J L This includes deletions of gene segments, or combinations thereof. In some embodiments, during homologous recombination between the targeting vector and a non-human Ig light chain locus, the recombinant nucleic acid molecule is recombined with non-human Ig at the non-human Ig light chain locus. L The segment is replaced. In some embodiments, during homologous recombination between the targeting vector and a non-human Ig light chain locus, the recombinant nucleic acid molecule replaces one or more non-human Ig light chain loci at the non-human Ig light chain locus. L Segments and all non-human J L The segment is replaced. In some embodiments, during homologous recombination between the targeting vector and the non-human Ig light chain locus, the recombinant nucleic acid molecule replaces all non-human Ig light chain loci at the non-human Ig light chain locus. L Segments and all non-human J H The segment is replaced. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain locus, the targeted non-human Ig heavy chain locus includes a recombinant nucleic acid molecule operably linked to a non-human Ig light chain control sequence at the Ig light chain locus.

[0176] In some embodiments, the targeting vector described herein comprises a nucleic acid molecule described herein, as well as 5' and 3' homologous arms that target a non-human Ig light chain locus, thereby, during homologous recombination between the targeting vector and the non-human Ig light chain locus, the targeted non-human Ig light chain locus becomes a recombinant nucleic acid molecule (e.g., a modified Ig V described herein). L Segments, and optionally Ig J L Segments, and / or Ig C L A recombinant nucleic acid molecule (containing a gene) is included in an operable linkage to the non-human Ig light chain regulatory sequence of the non-human Ig light chain locus, optionally in this case the non-human Ig light chain locus is an endogenous rodent Ig light chain locus, and / or in this case the non-human Ig light chain locus contains a human or humanized immunoglobulin light chain variable region and endogenous Ig V L and / or J LThis includes deletions of gene segments, or combinations thereof, and optionally, in this case, upon homologous recombination between the targeted vector and a non-human Ig light chain locus, the recombinant nucleic acid molecule is non-human V at the non-human Ig light chain locus. L Segment, J L Genetic segments, and non-human C L Replace the gene.

[0177] In some embodiments of the targeted vector, the targeted vector comprises a recombinant nucleic acid molecule as described herein and 5' and 3' homologous arms, the arms targeting a non-human Ig light chain κ locus, thereby, upon homologous recombination between the targeted vector and the non-human Ig light chain κ locus, the targeted non-human Ig light chain κ locus contains the recombinant nucleic acid molecule (e.g., a modified Ig Vκ segment as described herein, and optionally a recombinant nucleic acid molecule containing an Ig Jκ segment) upstream of the non-human Ig Cκ of the non-human Ig light chain κ locus and operably linked thereto, optionally in this case the non-human Ig light chain κ locus is an endogenous rodent Ig light chain κ locus and / or in this case the non-human Ig light chain κ locus contains a human or humanized immunoglobulin light chain variable region, contains a deletion of the endogenous Ig Vκ and / or Jκ gene segment, or a combination thereof. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain κ locus, the recombinant nucleic acid molecule replaces a non-human Vκ segment at the non-human Ig light chain κ locus. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain κ locus, the recombinant nucleic acid molecule replaces one or more non-human Vκ segments and all non-human Jκ segments at the non-human Ig light chain κ locus. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain κ locus, the recombinant nucleic acid molecule replaces all non-human Vκ segments and all non-human Jκ segments at the non-human Ig light chain κ locus. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain κ locus, the targeted non-human Ig light chain κ locus includes a recombinant nucleic acid molecule operably linked to a non-human Ig light chain κ control sequence at the Ig light chain κ locus.

[0178] In some embodiments of the targeted vector, the targeted vector comprises a nucleic acid molecule as described herein, as well as 5' and 3' homologous arms, which target a non-human Ig light chain κ locus, thereby, upon homologous recombination between the targeted vector and the non-human Ig light chain κ locus, the targeted non-human Ig light chain κ locus contains a recombinant nucleic acid molecule (e.g., a modified Ig Vκ segment as described herein, and optionally a recombinant nucleic acid molecule containing an Ig Jκ segment and / or an Ig Cκ gene) in an operable linkage to the non-human Ig light chain κ control sequence of the Ig light chain κ locus, and optionally, in this case, upon homologous recombination between the targeted vector and the non-human Ig light chain κ locus, the recombinant nucleic acid molecule replaces the non-human Vκ segment, all Jκ gene segments, and the non-human Cκ gene at the non-human Ig light chain κ locus.

[0179] In some embodiments of the targeted vector, the targeted vector comprises a recombinant nucleic acid molecule as described herein and 5' and 3' homologous arms, the arms targeting a non-human Ig light chain λ locus, thereby, in homologous recombination between the targeted vector and the non-human Ig light chain λ locus, the targeted non-human Ig light chain λ locus contains the recombinant nucleic acid molecule (e.g., a recombinant nucleic acid molecule containing a modified Ig Vλ segment and optionally an Ig Jλ segment) upstream of the non-human Ig Cλ of the non-human Ig light chain locus and operably linked thereto, optionally in this case the non-human Ig light chain λ locus is an endogenous rodent Ig light chain λ locus and / or in this case the non-human Ig light chain λ locus contains a human or humanized immunoglobulin light chain variable region, contains a deletion of the endogenous Ig Vλ and / or Jλ gene segments, or a combination thereof. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain λ locus, the recombinant nucleic acid molecule replaces a non-human Vλ segment at the non-human Ig light chain λ locus. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain λ locus, the recombinant nucleic acid molecule replaces one or more non-human Vλ segments and all non-human Jλ segments at the non-human Ig light chain locus. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain λ locus, the recombinant nucleic acid molecule replaces all non-human Vλ segments and all non-human Jλ segments at the non-human Ig light chain λ locus. In some embodiments, during homologous recombination between a targeted vector and a non-human Ig light chain λ locus, the targeted non-human Ig light chain λ locus includes a recombinant nucleic acid molecule operably linked to a non-human Ig light chain λ control sequence at the Ig light chain λ locus.

[0180] In some embodiments, the targeting vector comprises a nucleic acid molecule as described herein, as well as 5' and 3' homologous arms, which target a non-human Ig light chain λ locus, thereby, upon homologous recombination between the targeting vector and the non-human Ig light chain λ locus, the targeted non-human Ig light chain λ locus comprises a recombinant nucleic acid molecule (e.g., a recombinant nucleic acid molecule containing a modified Ig Vλ segment and optionally an Ig Jλ segment and / or an Ig Cλ gene) operably linked to a non-human Ig light chain λ control sequence at the Ig light chain λ locus. In some embodiments, upon homologous recombination between the targeting vector and the non-human Ig light chain λ locus, the recombinant nucleic acid molecule replaces the non-human Vλ segment, all non-human Jλ gene segments, and the non-human Cλ gene at the non-human Ig light chain λ locus.

[0181] In some embodiments, the targeting vectors described herein may further include nucleotide sequences adjacent to the target sequence for site-specific recombination. It is recognized that any region within the targeting vector, or individual target polynucleotides, may also be adjacent to such sites. Site-specific recombinases can be introduced into cells by any method, including by introducing a recombinase polypeptide into the cell, or by introducing a polynucleotide encoding the site-specific recombinase into a host cell. The polynucleotide encoding the site-specific recombinase may be located within the targeting vector or in a separate polynucleotide. Site-specific recombinases may be operably ligated to intracellularly active promoters, such as inducible promoters, cell-endogenous promoters, cell-external promoters, cell-specific promoters, tissue-specific promoters, or developmental stage-specific promoters. The site-specific recombinant target sequences that may be adjacent to a nucleotide sequence or any polynucleotide of interest in the targeting vector include, but are not limited to, loxP, lox511, lox2272, lox66, lox71, loxM2, lox5171, FRT, FRT11, FRT71, attp, att, FRT, rox, or combinations thereof.

[0182] In some embodiments, site-specific recombination sites are adjacent to polynucleotides encoding a selection marker within the targeting vector. In examples where the targeting vector has been integrated at the targeting locus, the nucleotide sequence between site-specific recombination sites may be removed.

[0183] In some embodiments, the targeting vector described herein includes a selection marker, which may be contained in a selection cassette. Such selection markers include, but are not limited to, neomycin phosphotransferase (neo r ), hygromycin B phosphotransferase (hyg r ), puromycin-N-acetyltransferase (puro r ), blastocydin S deaminase (bsr r Examples include xanthine / guanine phosphoribosyltransferase (GPT), herpes simplex virus thymidine kinase (HSV-K), or a combination thereof. In one embodiment, the polynucleotide encoding the selection marker is operably ligated to an active promoter in the cell. In one embodiment, the polynucleotide encoding the selection marker is flanked by a site-directed recombination target sequence.

[0184] Non-human animal genomes

[0185] In this specification, non-human animal genomes comprising recombinant nucleic acid molecules and / or targeted vectors described herein are also described. In some embodiments of non-human animal genomes, the non-human animal genome comprises recombinant nucleic acid molecules described herein at the endogenous Ig locus of the non-human animal genome, for example, the non-human animal genome comprises a targeted vector described herein, in which case the targeted vector comprises 5' and 3' homologous arms targeting the endogenous Ig locus. In some embodiments, the non-human animal genome is a rodent genome. In some embodiments, the non-human animal genome is a rat genome. In some embodiments, the non-human animal genome is a mouse genome.

[0186] In embodiments of non-human animal genomes, the genome is composed of recombinant nucleic acid molecules (e.g., modified IgV). H Segments, and optionally Ig D H Segment and / or Ig J H Recombinant nucleic acid molecules containing segments are used at the non-human Ig heavy chain locus of the non-human Ig C H Upstream of and including in a operable linkage thereto a non-human Ig heavy chain locus, optionally in this case, said non-human Ig heavy chain locus being an endogenous rodent Ig heavy chain locus, and / or in this case, said non-human Ig heavy chain locus being a human or humanized immunoglobulin heavy chain variable region, including endogenous Ig V H , D H and / or J H This includes deletions of gene segments, or combinations thereof. In some embodiments, the recombinant nucleic acid molecule contains non-human V at the non-human Ig heavy chain locus. H The segment is replaced. In some embodiments, the recombinant nucleic acid molecule has one or more non-human V at the non-human Ig heavy chain locus. H Segment, all non-human D H Segments, and all non-human J H The segment is replaced. In some embodiments, the recombinant nucleic acid molecule has one non-human V at the non-human Ig heavy chain site. H All or all non-human V segments other than the segment H Segment, all non-human D H Segments, and all non-human J H The segment is replaced. In some embodiments, the recombinant nucleic acid molecule is operably ligated to a non-human Ig heavy chain control sequence at a non-human Ig heavy chain locus.

[0187] In some embodiments, the non-human Ig heavy chain locus is a recombinant nucleic acid molecule (e.g., modified Ig V). H Segments, and optionally Ig D H Segment, Ig J H Segment and / or Ig C HA recombinant nucleic acid molecule (containing a gene) is included in an operable linkage to the non-human Ig heavy chain regulatory sequence of the non-human Ig heavy chain locus, and optionally in this case the non-human Ig heavy chain locus is an endogenous rodent Ig heavy chain locus in rodents or rodent cells (e.g., rodent embryonic stem cells), and / or in this case the non-human Ig heavy chain locus contains a human or humanized immunoglobulin heavy chain variable region and endogenous Ig V H , D H and / or J H This includes deletions of gene segments, or combinations thereof, and optionally, in this case, the recombinant nucleic acid molecule includes one or more non-human V at the non-human Ig heavy chain locus. H Segment, all non-human D H Genetic segment, all non-human J H Genetic segments, and one or more non-human C H Replace the gene.

[0188] In embodiments of non-human animal genomes, the genome is a recombinant nucleic acid molecule (e.g., modified IgV as described herein). L Segments, and optionally Ig J L Recombinant nucleic acid molecules (including segments) are used at the non-human Ig light chain locus of the non-human Ig C L Upstream of and including in a operable linkage thereto a non-human Ig light chain locus, optionally in this case, said non-human Ig light chain locus being an endogenous rodent Ig light chain locus, and / or in this case, said non-human Ig light chain locus being a human or humanized immunoglobulin light chain variable region, including endogenous Ig V L and / or J L This includes deletions of gene segments, or combinations thereof. In some embodiments, the recombinant nucleic acid molecule has a non-human V at the non-human Ig light chain locus. L The segment is replaced. In some embodiments, the recombinant nucleic acid molecule has one or more non-human V at the non-human Ig light chain locus. L Segments and all non-human J LThe segment is replaced. In some embodiments, the recombinant nucleic acid molecule replaces all non-human V at the non-human Ig light chain locus. L Segments and all non-human J H The segment is replaced. In some embodiments, the recombinant nucleic acid molecule is operably ligated to a non-human Ig light chain control sequence at the Ig light chain locus.

[0189] In embodiments of non-human animal genomes, the Ig light chain locus is located within a recombinant nucleic acid molecule (e.g., the modified IgV described herein). L Segments, and optionally Ig J L Segments, and / or Ig C L A recombinant nucleic acid molecule (containing a gene) is included in an operable linkage to the non-human Ig light chain regulatory sequence of the non-human Ig light chain locus, optionally in this case the non-human Ig light chain locus is an endogenous rodent Ig light chain locus, and / or in this case the non-human Ig light chain locus contains a human or humanized immunoglobulin light chain variable region and endogenous Ig V L and / or J L This includes deletions of gene segments, or combinations thereof, and optionally, in this case, the recombinant nucleic acid molecule contains non-human V at the non-human Ig light chain locus. L Segment, J L Genetic segments, and non-human C L Replace the gene.

[0190] In embodiments of non-human animal genomes, the genome includes a non-human Ig light chain κ locus containing a recombinant nucleic acid molecule (e.g., a modified Ig Vκ segment as described herein, and optionally a recombinant nucleic acid molecule containing an Ig Jκ segment) upstream of the non-human Ig Cκ at the non-human Ig light chain κ locus, and operably linked thereto, optionally in this case the non-human Ig light chain κ locus is an endogenous rodent Ig light chain κ locus, and / or in this case the non-human Ig light chain κ locus contains a human or humanized immunoglobulin light chain variable region, contains deletions of endogenous Ig Vκ and / or Jκ gene segments, or a combination thereof. In some embodiments, the recombinant nucleic acid molecule replaces a non-human Vκ segment at the non-human Ig light chain κ locus. In some embodiments, the recombinant nucleic acid molecule replaces one or more non-human Vκ segments and all non-human Jκ segments at the non-human Ig light chain κ locus. In some embodiments, the recombinant nucleic acid molecule replaces all non-human Vκ segments and all non-human Jκ segments at the non-human Ig light chain κ locus. In some embodiments, the recombinant nucleic acid molecule is operably ligated to a non-human Ig light chain κ control sequence at the Ig light chain κ locus.

[0191] In some embodiments, a recombinant nucleic acid molecule (e.g., a recombinant nucleic acid molecule comprising a modified Ig Vκ segment and optionally an Ig Jκ segment and / or an Ig Cκ gene as described herein) is operably ligated to a non-human Ig light chain κ regulatory sequence at the Ig light chain κ locus, and optionally the recombinant nucleic acid molecule replaces the non-human Vκ segment, all non-human Jκ gene segments, and the non-human Cκ gene at the non-human Ig light chain κ locus.

[0192] In embodiments of non-human animal genomes, the genome includes a non-human Ig light chain λ locus containing recombinant nucleic acid molecules (e.g., a modified Ig Vλ segment and optionally a recombinant nucleic acid molecule containing an Ig Jλ segment) upstream of the non-human Ig Cλ of the non-human Ig light chain locus and operably linked thereto, optionally in this case the non-human Ig light chain λ locus is an endogenous rodent Ig light chain λ locus and / or in this case the non-human Ig light chain λ locus contains a human or humanized immunoglobulin light chain variable region and endogenous Ig The recombinant nucleic acid molecule includes deletions of Vλ and / or Jλ gene segments, or combinations thereof. In some embodiments, the recombinant nucleic acid molecule replaces a non-human Vλ segment at the non-human Ig light chain λ locus. In some embodiments, the recombinant nucleic acid molecule replaces one or more non-human Vλ segments and all non-human Jλ segments at the non-human Ig light chain locus. In some embodiments, during homologous recombination between the targeting vector and the non-human Ig light chain λ locus, the recombinant nucleic acid molecule replaces all non-human Vλ segments and all non-human Jλ segments at the non-human Ig light chain λ locus. In some embodiments, the recombinant nucleic acid molecule is operably ligated to a non-human Ig light chain λ control sequence at the Ig light chain λ locus.

[0193] In some embodiments of non-human animal genomes, the non-human Ig light chain λ locus comprises a recombinant nucleic acid molecule (e.g., a recombinant nucleic acid molecule comprising a modified Ig Vλ segment and optionally an Ig Jλ segment and / or an Ig Cλ gene) operably ligated to the non-human Ig light chain λ regulatory sequence of the Ig light chain λ locus. In some embodiments, the recombinant nucleic acid molecule replaces the non-human Vλ segment, all non-human Jλ gene segments, and the non-human Cλ gene at the non-human Ig light chain λ locus.

[0194] Non-human animal cells, non-human animals, and methods for producing them. Non-human animals and non-human animal cells

[0195] For example, modified to encode anchors operably linked between the Ig leader sequence and the framework (FR) and complementarity-determining region (CDR) sequences of the germline V segment, such as the Ig heavy chain variable region (V H ) segment or Ig light chain variable region (V L Non-human animals and non-human animal cells expressing anchor-modified immunoglobulins from Ig loci modified to include recombinant nucleic acid molecules described herein, including modified Ig V segments such as the ) segment. Thus, non-human animals, embryos, and cells comprising recombinant nucleic acid molecules, targeted constructs, and / or animal genomes described herein are provided.

[0196] In some embodiments of non-human animals or non-human animal cells, the non-human animal or cell is modified to encode a recombinant nucleic acid molecule described herein (for example, an Ig heavy chain variable region (V), which is randomly placed within the genome of the animal, between the framework (FR) and complementarity-determining region (CDR) sequences of the germline V segment, and operably linked to them). H ) segment or Ig light chain variable region (V L In some embodiments, a non-human animal or cell includes a modified Ig V segment (including a modified Ig V segment such as an Ig leader sequence, and an Ig heavy chain variable region (V) segment) modified to encode an anchor operably linked between and to the framework (FR) and complementarity-determining region (CDR) sequences of the germline V segment at the endogenous Ig locus of the non-human animal. H ) segment or Ig light chain variable region (V LThis includes modified Ig V segments such as the ) segment. For example, the non-human animal includes the targeted vector described herein, in which case the targeted vector includes 5' and 3' homologous arms that target an endogenous Ig locus. In some embodiments, the non-human animal is a rodent. In some embodiments, the non-human animal cells are rodent cells. In some embodiments, the non-human animal is a rat. In some embodiments, the non-human animal cells are rat cells. In some embodiments, the non-human animal is a mouse. In some embodiments, the non-human animal cells are mouse cells.

[0197] In several embodiments, non-human animals or non-human animal cells are recombinant nucleic acid molecules (e.g., modified IgV). H Segments, and optionally Ig D H Segment and / or Ig J H Recombinant nucleic acid molecules containing segments are used at the non-human Ig heavy chain locus of the non-human Ig C H Upstream of and including in a operable linkage thereto a non-human Ig heavy chain locus, optionally in this case, said non-human Ig heavy chain locus being an endogenous rodent Ig heavy chain locus, and / or in this case, said non-human Ig heavy chain locus being a human or humanized immunoglobulin heavy chain variable region, including endogenous Ig V H , D H and / or J H This includes deletions of gene segments, or combinations thereof. In some embodiments, the recombinant nucleic acid molecule contains non-human V at the non-human Ig heavy chain locus. H The segment is replaced. In some embodiments, the recombinant nucleic acid molecule has one or more non-human V at the non-human Ig heavy chain locus. H Segment, all non-human D H Segments, and all non-human J H The segment is replaced. In some embodiments, the recombinant nucleic acid molecule has one non-human V at the non-human Ig heavy chain site. H All or all non-human V segments other than the segment H Segment, all non-human D HSegments, and all non-human J H The segment is replaced. In some embodiments, the recombinant nucleic acid molecule is operably ligated to a non-human Ig heavy chain control sequence at a non-human Ig heavy chain locus.

[0198] In some embodiments, the non-human Ig heavy chain locus is a recombinant nucleic acid molecule (e.g., modified Ig V). H Segments, and optionally Ig D H Segment, Ig J H Segment and / or Ig C H A recombinant nucleic acid molecule (containing a gene) is included in an operable linkage to the non-human Ig heavy chain regulatory sequence of the non-human Ig heavy chain locus, and optionally in this case the non-human Ig heavy chain locus is an endogenous rodent Ig heavy chain locus in rodents or rodent cells (e.g., rodent embryonic stem cells), and / or in this case the non-human Ig heavy chain locus contains a human or humanized immunoglobulin heavy chain variable region and endogenous Ig V H , D H and / or J H This includes deletions of gene segments, or combinations thereof, and optionally, in this case, the recombinant nucleic acid molecule includes one or more non-human V at the non-human Ig heavy chain locus. H Segment, all non-human D H Genetic segment, all non-human J H Genetic segments, and one or more non-human C H Replace the gene.

[0199] In some embodiments, non-human animals or non-human animal cells are recombinant nucleic acid molecules (e.g., modified IgV as described herein). L Segments, and optionally Ig J L Recombinant nucleic acid molecules (including segments) are used at the non-human Ig light chain locus of the non-human Ig C LUpstream of and including in a operable linkage thereto a non-human Ig light chain locus, optionally in this case, said non-human Ig light chain locus being an endogenous rodent Ig light chain locus, and / or in this case, said non-human Ig light chain locus being a human or humanized immunoglobulin light chain variable region, including endogenous Ig V L and / or J L This includes deletions of gene segments, or combinations thereof. In some embodiments, the recombinant nucleic acid molecule has a non-human V at the non-human Ig light chain locus. L The segment is replaced. In some embodiments, the recombinant nucleic acid molecule has one or more non-human V at the non-human Ig light chain locus. L Segments and all non-human J L The segment is replaced. In some embodiments, the recombinant nucleic acid molecule replaces all non-human V at the non-human Ig light chain locus. L Segments and all non-human J H The segment is replaced. In some embodiments, the recombinant nucleic acid molecule is operably ligated to a non-human Ig light chain control sequence at the Ig light chain locus.

[0200] In some embodiments, the Ig light chain locus is located on a recombinant nucleic acid molecule (e.g., the modified Ig V described herein). L Segments, and optionally Ig J L Segments, and / or Ig C L A recombinant nucleic acid molecule (containing a gene) is included in an operable linkage to the non-human Ig light chain control sequence of the non-human Ig light chain locus, optionally in this case the non-human Ig light chain locus is an endogenous rodent Ig light chain locus, and / or in this case the non-human Ig light chain locus contains a human or humanized immunoglobulin light chain variable region and endogenous Ig V L and / or J L This includes deletions of gene segments, or combinations thereof, and optionally, in this case, the recombinant nucleic acid molecule contains non-human V at the non-human Ig light chain locus. L Segment, J L Genetic segments, and non-human C LReplace the gene.

[0201] In some embodiments, a non-human animal or non-human animal cell includes a non-human Ig light chain κ locus containing a recombinant nucleic acid molecule (e.g., a recombinant nucleic acid molecule containing a modified Ig Vκ segment and optionally an Ig Jκ segment as described herein) upstream of the non-human Ig Cκ of the non-human Ig light chain κ locus and operably linked thereto, optionally in this case the non-human Ig light chain κ locus is an endogenous rodent Ig light chain κ locus and / or in this case the non-human Ig light chain κ locus contains a human or humanized immunoglobulin light chain variable region, contains a deletion of an endogenous Ig Vκ and / or Jκ gene segment, or a combination thereof. In some embodiments, the recombinant nucleic acid molecule replaces a non-human Vκ segment at the non-human Ig light chain κ locus. In some embodiments, the recombinant nucleic acid molecule replaces one or more non-human Vκ segments and all non-human Jκ segments at the non-human Ig light chain κ locus. In some embodiments, the recombinant nucleic acid molecule replaces all non-human Vκ segments and all non-human Jκ segments at the non-human Ig light chain κ locus. In some embodiments, the recombinant nucleic acid molecule is operably ligated to a non-human Ig light chain κ control sequence at the Ig light chain κ locus.

[0202] In some embodiments, a recombinant nucleic acid molecule (e.g., a recombinant nucleic acid molecule comprising a modified Ig Vκ segment and optionally an Ig Jκ segment and / or an Ig Cκ gene as described herein) is operably ligated to a non-human Ig light chain κ regulatory sequence at the Ig light chain κ locus, and optionally the recombinant nucleic acid molecule replaces the non-human Vκ segment, all non-human Jκ gene segments, and the non-human Cκ gene at the non-human Ig light chain κ locus.

[0203] In some embodiments, a non-human animal or non-human animal cell includes a non-human Ig light chain λ locus containing a recombinant nucleic acid molecule (e.g., a recombinant nucleic acid molecule containing a modified Ig Vλ segment and optionally an Ig Jλ segment) upstream of the non-human Ig Cλ of the non-human Ig light chain locus and operably linked thereto, optionally in this case the non-human Ig light chain λ locus is an endogenous rodent Ig light chain λ locus and / or in this case the non-human Ig light chain λ locus contains a human or humanized immunoglobulin light chain variable region, contains deletions of endogenous Ig Vλ and / or Jλ gene segments, or a combination thereof. In some embodiments, the recombinant nucleic acid molecule replaces a non-human Vλ segment at the non-human Ig light chain λ locus. In some embodiments, the recombinant nucleic acid molecule replaces one or more non-human Vλ segments and all non-human Jλ segments at the non-human Ig light chain locus. In some embodiments, during homologous recombination between a targeting vector and a non-human Ig light chain λ locus, the recombinant nucleic acid molecule replaces all non-human Vλ segments and all non-human Jλ segments at the non-human Ig light chain λ locus. In some embodiments, the recombinant nucleic acid molecule is operably ligated to a non-human Ig light chain λ control sequence at the Ig light chain λ locus.

[0204] In some embodiments, the non-human Ig light chain λ locus is operably linked to the non-human Ig light chain λ control sequence of the Ig light chain λ locus by recombinant nucleic acid molecules (e.g., modified Ig Vλ segments as described herein, and optionally Ig Jλ segments, and / or Ig This includes a recombinant nucleic acid molecule containing the Cλ gene. In some embodiments, the recombinant nucleic acid molecule replaces the non-human Vλ segment, all non-human Jλ gene segments, and the non-human Cλ gene at the non-human Ig light chain λ locus.

[0205] Methods for producing non-human animals or non-human animal cells

[0206] Furthermore, methods for producing non-human cells and / or non-human animals, such as non-human embryos, in vitro using recombinant nucleic acid molecules, such as targeted vectors, as described herein. In some embodiments, the in vitro method for modifying isolated cells includes introducing recombinant nucleic acid molecules, as described herein, into the isolated cells by contacting the cells with, for example, a targeted vector, as described herein. In some embodiments of the method, the cells are host cells. In some embodiments, the cells are embryonic stem (ES) cells. In some embodiments, the cells described herein, or cells produced according to the methods described herein, are rodent cells, for example, in this case, rat cells or mouse cells.

[0207] Methods for producing anchor-modified antigen-binding proteins using nucleic acid molecules, non-human cells, and / or non-human animals described herein are also described. Non-human animal embryos and non-human animals that may include and / or can be developed (e.g., produced) from embryonic stem cells described herein are also described. Such embryos or non-human animals may be developed by methods including transplanting ES cells described herein into an embryo and / or transplanting an embryo containing ES cells into a suitable host, and maintaining the host under suitable conditions to produce viable offspring during the development of the ES cells or the embryo.

[0208] As described herein, targeted vectors may be used to target Ig loci having human or humanized immunoglobulin variable regions. Immunoglobulin loci containing human variable region gene segments are known in the art, for example, U.S. Patents No. 5,633,425, 5,770,429, 5,814,318, 6,075,181, 6,114,598, 6,150,584, 6,998,514, 7,795,494, 7,910,798, 8,232,449, 8,502,018, 8,697,940, 8,703,485, and 8,754,28 Patent Nos. 7, 8,791,323, 8,809,051, 8,907,157, 9,035,128, 9,145,588, 9,206,263, 9,447,177, 9,551,124, 9,580,491, and 9,475,559, each of which is incorporated herein by reference in whole, and published in the United States Patent Application Publications. Applications Nos. 20100146647, 20110195454, 20130167256, 20130219535, 20130326647, 20130096287, and 2015 / 0113668, each of which is incorporated herein by reference in its entirety, and applications found in PCT publications Nos. 2007117410, 2008151081, 2009157771, 2010039900, 2011004192, 2011123708, and 2014093908, each of which is incorporated herein by reference in its entirety.

[0209] In some embodiments, the non-human animals disclosed herein include exogenous fully human immunoglobulin transgenes containing the modified Ig V segment described herein, which has the ability to be reconstituted in mouse progenitor B cells (Alt et al., 1985, Immunoglobulin genes in transgenic mice, Trends Genet 1:231-236, incorporated herein by reference in its entirety). In these embodiments, the fully human immunoglobulin transgene containing the modified Ig V segment described herein may be inserted (randomly), and the endogenous immunoglobulin gene may be knocked out (Green et al., 1994, Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs, Nat Genet 7:13-21; Lonberg et al., 1994, Antigen-specific human antibodies from mice comprising four distinct genetic modifications, Nature 368:856-859; Jakobovits et al., 2007, From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice, Nat Biotechnol 25:1134-1143. Each of these publications is incorporated herein by reference in its entirety). For example, in this case, the loci of endogenous immunoglobulin heavy chain and κ-light chain are inactivated, for example, by targeting and deleting small but essential portions of each endogenous locus, and then introducing human immunoglobulin gene loci as randomly integrated giant transgenes or minichromosomes (Tomizuka et al., 2000, Double). trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and Expression of fully human antibodies, PNAS USA 97:722-727. (The entire article is incorporated herein by reference.)

[0210] In some embodiments, the heavy and light chain loci of human or humanized immunoglobulins containing the modified Ig V segment described herein are located at the heavy and light chain loci of endogenous immunoglobulins, respectively. H Genetic segments and human V H It has been shown that even gene segment substitutions can result in immune responses containing humanized immunoglobulin variable domains. See, for example, Tien et al., (2016) Cell 166:1471-84, the entire work of which is incorporated herein by reference.

[0211] Methods for large-scale in situ gene substitution between mouse germline immunoglobulin variable gene loci and human germline immunoglobulin variable gene loci while maintaining the mouse's ability to reproduce have already been reported. See, for example, U.S. Patents 6,596,541 and 8,697,940, each of which is incorporated herein by reference in whole. Specifically, precise substitution of six megabases in both the mouse heavy chain and κ-light chain immunoglobulin variable gene loci with their human counterparts has been described, while preserving the mouse constant region. As a result, mice were generated that retained the mouse constant region while having precise substitution of the entire germline immunoglobulin variable repertoire with equivalent human germline immunoglobulin variable sequences. The human variable region is bound to the mouse constant region, reconstructed, and forms a chimeric human-mouse immunoglobulin gene locus expressed at physiologically appropriate levels. The expressed antibodies are “reverse chimeric,” meaning they contain both the human variable region sequence and the mouse constant region sequence.

[0212] In some embodiments, mice possessing humanized immunoglobulin variable regions that express antibodies having human or humanized variable regions and mouse constant regions are referred to as VELOCIMMUNE® mice. VELOCIMMUNE® humanized mice exhibit a complete, fully functional humoral immune system that is essentially indistinguishable from wild-type mice. They exhibit normal cell populations at all stages of B cell development. They exhibit normal lymphoid organ morphology. The antibody sequences of VELOCIMMUNE® mice exhibit normal V(D)J rearrangements and normal somatic hypermutation frequencies. The antibody populations in these mice reflect isotype distributions resulting from normal class switches (e.g., normal isotype cis-switches). Immunizing VELOCIMMUNE® mice results in a stable humoral immune response that generates a large and diverse antibody repertoire with human immunoglobulin variable domains suitable for use as therapeutic candidates. This platform provides a rich source of naturally affinity-matured human immunoglobulin variable region sequences for producing pharmaceutically acceptable antibodies and other antigen-binding proteins. By precisely substituting a mouse immunoglobulin variable sequence with a human immunoglobulin variable sequence, the human immunoglobulin variable sequence is operably bound to an endogenous non-human constant region gene sequence in a reverse chimeric manner, thereby creating the VELOCIMMUNE® mouse.

[0213] Examples of mice modified in a reverse chimeric manner include, but are not limited to, mice modified to include a human (humanized) variable region (e.g., including (D), J, and one or more human V gene segments) operably bound to an endogenous constant region at an endogenous immunoglobulin locus, such locus being, (a) Endogenous heavy chain position is one example, (i) A modified mouse comprising a non-reconstituted human (humanized) immunoglobulin heavy chain variable region operably linked to an endogenous heavy chain constant region, wherein the non-reconstituted human (humanized) immunoglobulin heavy chain variable region comprises a plurality of non-reconstituted human heavy chain variable regions V HGene segment (e.g., all functional human non-reconstructed human V H (Genetic segment), one or more unreconstituted immunoglobulin heavy chains D H Gene segments, and one or more unreconstituted immunoglobulin heavy chains J H Includes gene segments, In this case, optionally, one or more unreconstituted immunoglobulin heavy chains D H Gene segments and one or more unreconstituted immunoglobulin heavy chains J H The gene segment is one or more unreconstituted human immunoglobulin heavy chains D H Gene segment (for example, all functional human D H (Genetic segment) and / or one or more unreconstituted human immunoglobulin heavy chains J H Gene segment (e.g., all functional human J H (Genetic segment) (ii) A mouse modified to include a limited non-reconstituted human (humanized) heavy chain variable region operably linked to an endogenous heavy chain constant region, wherein the limited non-reconstituted human (humanized) heavy chain variable region comprises one or more non-reconstituted immunoglobulin heavy chains D H Gene segments and one or more unreconstituted immunoglobulin heavy chains J H A single unreconstructed human heavy chain variable region V operably linked to a gene segment H Essentially consisting of gene segments, and optionally in this case one or more unreconstituted immunoglobulin heavy chains D H Gene segments and one or more unreconstituted immunoglobulin heavy chains J H Each gene segment contains one or more unreconstituted human immunoglobulin heavy chains D H Gene segments and / or one or more unreconstituted human immunoglobulin heavy chains J H Gene segment, (iii) A mouse modified to include a histidine-modified non-reconstructed human (humanized) heavy chain variable region operably linked to an endogenous heavy chain constant region, wherein the histidine-modified non-reconstructed human (humanized) heavy chain variable region includes a non-reconstructed immunoglobulin heavy chain variable gene sequence that includes, in the complementarity-determining region 3 (CDR3) coding sequence, a substitution of at least one non-histidine codon with a histidine codon or an insertion of at least one histidine codon. (iv) A mouse modified to include a heavy chain-only immunoglobulin coding sequence comprising an unreconstructed human (humanized) heavy chain variable region operably linked to an endogenous heavy chain constant region, wherein the endogenous heavy chain constant region comprises (1) an intact endogenous IgM gene encoding an IgM isotype that associates with the light chain, and (2) a non-IgM gene, such as an IgG gene, that lacks a sequence encoding a functional CH1 domain, wherein the non-IgM gene encodes a non-IgM isotype that lacks a CH1 domain and can covalently bind to the light chain constant domain. and / or (b) Endogenous light chain position is one example, (i) A mouse modified to include a non-reconstituted human (humanized) immunoglobulin light chain variable region operably linked to an endogenous light chain constant region, wherein the non-reconstituted human (humanized) immunoglobulin light chain variable region comprises a plurality of non-reconstituted human light chain variable regions V L Gene segment (e.g., all functional human non-reconstructed human V L Genetic segments, and one or more unreconstituted immunoglobulin heavy chains J L Includes gene segments, In this case, optionally, one or more non-reconstituted immunoglobulin light chains J L The gene segment is one or more unreconstituted human immunoglobulin light chains J L Gene segment (e.g., all functional human J H (L gene segment) In this case, optionally, the endogenous immunoglobulin light chain locus is the endogenous immunoglobulin light chain kappa (κ) locus, and the non-reconstituted human (humanized) immunoglobulin light chain variable region is the human variable κ (V) locus. κ ) and bond κ(J κ ) comprising a gene segment, and in this case the endogenous light chain constant region is an endogenous κ chain constant region sequence, and / or in this case the endogenous immunoglobulin light chain locus is an endogenous immunoglobulin light chain lambda (λ), and the non-reconstituted human (humanized) immunoglobulin light chain variable region is a human variable λ (V λ ) Gene segment and binding λ(J λ ) comprising a gene segment, the endogenous light chain constant region being an endogenous λ chain constant region sequence, and optionally in this case the endogenous immunoglobulin light chain λ locus being (a) one or more human V λ (b) gene segment, one or more human J λ (c) gene segment, and (c) one or more human C λ Includes gene segments, in this case (a) and (b) are (c) and rodent immunoglobulin light chain constant (C λ ) operably bound to a gene segment, and in this case, the endogenous immunoglobulin λ light chain locus comprises one or more rodent immunoglobulin λ light chain enhancers (Eλ) and one or more human immunoglobulin λ light chain enhancers (Eλ), optionally comprising three human Eλ. (ii) A mouse modified to include a common light chain coding sequence that includes a reconstituted human (humanized) light chain variable region sequence operably bound to the endogenous light chain constant region, wherein the reconstituted human (humanized) light chain variable region sequence is an immunoglobulin light chain J L Gene segment and reconstituted human light chain variable region V L Including gene segments, (iii) A mouse modified to include a limited non-reconstituted human (humanized) light chain variable region operably linked to an endogenous light chain constant region, wherein the limited non-reconstituted human (humanized) light chain variable region is linked to one or more non-reconstituted human immunoglobulin light chain binding (JL ) Two or fewer non-reconstituted human immunoglobulin light chain variable (V) operably linked to a gene segment L ) including gene segments, (iv) A mouse modified to include a histidine-modified non-reconstructed human (humanized) light chain variable region operably linked to an endogenous light chain constant region, wherein the histidine-modified non-reconstructed human (humanized) light chain variable region includes a non-reconstructed human (humanized) immunoglobulin light chain variable gene sequence comprising, in the complementarity-determining region 3 (CDR3) coding sequence, a substitution of at least one non-histidine codon with a histidine codon, or an insertion of at least one histidine codon. (v) A mouse modified to include a histidine-modified reconstituted human (humanized) light chain variable region operably linked to an endogenous light chain constant region, wherein the histidine-modified reconstituted human (humanized) light chain variable region includes a reconstituted human (humanized) immunoglobulin light chain variable gene sequence, which includes at least one substitution of a non-histidine codon to a histidine codon, or at least one insertion of a histidine codon, in the complementarity-determining region 3 (CDR3) coding sequence. The mouse can optionally further: (i) The mouse contains a human (humanized) immunoglobulin heavy chain locus containing the functional ADAM6 gene, thereby exhibiting the wild-type reproductive capacity of a non-human animal; and / or (ii) Includes an exogenous terminal deoxynucleotidyltransferase (TdT) gene to increase antigen receptor diversity, and optionally, at least 10% of the variable region genes rearranged thereby include additions not present in the template, This mouse has been reported in the past. For example, U.S. Patent Nos. 8,697,940, 8,754,287, 9,204,624, 9,334,334, 9,801,362, 9,332,742, and 9,516,868; U.S. Patent Application Publications 20110195454, 20120021409, 20120192300, 20130045492, 20150289489, 20180125043, 20180244804; PCT Patent Application Publications 2019 / 113065, 2017210586, and 2011163314; Lee et al., (2014) Nature See Biotechnology 32:356. Each of those publications is incorporated herein in its entirety by reference.

[0214] Those skilled in the art will know that any mouse or mouse cells (e.g., mouse ES cells modified in a reverse chimeric manner) may be modified to include the modified IgV segment described herein. In some embodiments herein, genetically modified non-human animals are described, and the genome of such animals, such as the germline genome, Modification V of the present invention H Gene segment, Human D H Gene segment, and human J H It includes an endogenous immunoglobulin locus containing a variable immunoglobulin heavy chain region containing a gene segment, wherein the variable immunoglobulin heavy chain region is operably linked to a constant region, and / or Modification V of the present invention L Segments, and human J L The system includes an endogenous chain locus containing a variable immunoglobulin light chain region that includes a gene segment, wherein the variable immunoglobulin light chain region is operably linked to a constant region.

[0215] In some embodiments, non-human animals, such as rodents, such as rats or mice, have one or more human V genes in their genome. H , D H , and J HThe segment and one or more endogenous V of the endogenous immunoglobulin heavy chain loci H , D H , and J H This includes segment substitution, in which case one or more human V H , D H , and J H The segment is a modified human V as described herein. H It includes a gene segment and is operably linked to an endogenous immunoglobulin heavy chain gene, and is optionally unreconstituted or reconstituted human V L Segments and human J L The segment is, for example, an endogenous non-human light chain locus, and is a non-human or human immunoglobulin light chain constant (C) locus, such as in rodents such as mice and rats. L It is functionally linked to the ) region gene.

[0216] In certain embodiments, a genetically modified non-human animal includes an immunoglobulin locus (exogenous or endogenous) in its genome, such as a germline genome, which contains an immunoglobulin variable region comprising one or more non-reconstructed human immunoglobulin variable region gene segments comprising a modified Ig V gene segment as described herein, and an immunoglobulin constant region comprising an immunoglobulin constant region gene. In this case, the one or more non-reconstructed human immunoglobulin variable region gene segments are operably ligated to the immunoglobulin constant region gene.

[0217] Generally, a genetically modified immunoglobulin locus includes an immunoglobulin variable region (including an immunoglobulin variable region gene segment) operably linked to an immunoglobulin constant region. In some embodiments, the genetically modified immunoglobulin locus includes a modified Ig V gene described herein operably linked to a heavy chain constant region gene. HThe modified immunoglobulin locus includes one or more human unreconstructed immunoglobulin heavy chain variable region gene segments, including a gene segment. In some embodiments, the modified immunoglobulin locus includes a human unreconstructed immunoglobulin variable region κ gene segment, which includes a modified Ig Vκ gene segment described herein, operably linked to a κ chain constant region gene. In some embodiments, the modified immunoglobulin locus includes a human unreconstructed immunoglobulin variable region λ gene segment, which includes a modified Ig Vλ gene segment described herein, operably linked to a κ chain constant region gene. In some embodiments, the modified immunoglobulin locus includes a human unreconstructed immunoglobulin variable region λ gene segment, which includes a modified Ig Vλ gene segment described herein, operably linked to a λ chain constant region gene.

[0218] In certain embodiments, a non-human animal is operably linked to the endogenous heavy chain steady region at the endogenous heavy chain locus, and is equipped with the modified Ig V described herein. H The non-reconstructed human (humanized) immunoglobulin heavy chain variable region includes a gene segment, in which case the immunoglobulin variable region contains one or more non-reconstructed human Ig heavy chain variable region gene segments. In some embodiments, one or more non-reconstructed human Ig variable region gene segments are modified Ig V as described herein. H Gene segment, one or more immunoglobulin heavy chain diversities (D H ) segment, and one or more immunoglobulin heavy chain binding (J H ) segment (one or more unreconstructed human J selected at random) H (including segments). In some embodiments, modified Ig V described herein H The gene segment is the only Ig V located in the heavy chain variable region. H It is a segment. In some embodiments, the non-reconstructed human Ig gene segment is a functional human D H Includes all gene segments. In some embodiments, the non-reconstructed human Ig gene segment is a functional human J HThis includes all gene segments. Examples of variable regions containing Ig heavy chain gene segments are outlined, for example, in Macdonald et al., Proc. Natl. Acad. Sci. USA 111:5147-52 and in the supplementary information. This literature is incorporated herein by reference in its entirety.

[0219] In some embodiments, the non-human animals provided herein include a limited non-reconstructed human (humanized) heavy chain variable region operably linked to an endogenous heavy chain constant region containing at least a non-human IgM gene at an endogenous heavy chain locus, wherein the limited non-reconstructed human (humanized) heavy chain variable region is a single human V H Gene segment (e.g., a single modified Ig V as described herein) H Gene segment), multiple D H Gene segment (e.g., human D H (gene segment) and multiple J H Gene segment (e.g., human J H Characterized by a gene segment, in this case the limited immunoglobulin heavy chain locus can undergo rearrangement and form multiple individual rearrangements, in this case the rearrangement is a single human V H Gene segment, D H One of the segments, and D H Derived from one of the segments, in which case the reconfiguration encodes a different heavy chain variable domain (described in U.S. Patent Publication 20130096287, which is incorporated herein by reference in its entirety). In some embodiments, a single modified human V H The gene segment is V H 1-2 or V H The number is 1-69.

[0220] In certain embodiments, a non-human animal is operably linked to the endogenous light chain locus steady region, and is equipped with the modified IgV described herein. LThe non-reconstructed human (humanized) immunoglobulin light chain variable region includes segments. In some embodiments, the non-reconstructed human (humanized) immunoglobulin light chain variable region includes a non-reconstructed human Igκ variable region gene segment. In some embodiments, the non-reconstructed human (humanized) immunoglobulin variable region includes one or more non-reconstructed human Vκ segments, which may include the modified Ig Vκ segments and one or more non-reconstructed human Jκ segments described herein. In some embodiments, the non-reconstructed human immunoglobulin variable region gene segment includes all human Jκ segments. In some embodiments, the immunoglobulin variable region gene segment includes four functional Vκ segments and all human Jκ segments. In some embodiments, the immunoglobulin variable region gene segment includes 16 functional Vκ segments and all human Jκ segments (e.g., all functional human Vκ and Jκ segments). In some embodiments, the non-reconstructed human immunoglobulin variable region gene segment includes all human Vκ segments and all human Jκ segments. Examples of variable regions containing the Ig κ gene segment are provided, for example, in Macdonald et al, Proc. Natl. Acad. Sci. USA 1 11:5147-52 and Supplementary Information, which are incorporated herein by reference in their entirety.

[0221] In some embodiments, a limited non-reconstructed human (humanized) light chain variable region operably linked to the endogenous light chain constant region is a non-reconstructed human (humanized) light chain variable region having two or fewer human V L Gene segments and multiple J L Characterized in that it contains a gene segment (for example, a dual light chain mouse, or DLC, as described in U.S. Patent No. 9,796,788, the whole of which is incorporated herein by reference), and has two or fewer human V L One of the gene segments is a modified Ig V as described herein. L It may be a segment. In some embodiments, V LThe gene segment is the Vκ gene segment. In some embodiments, V L The gene segment is the Vλ gene segment. In some embodiments, the Vκ gene segments are IGKV3-20 and IGKV1-39. In some embodiments, the non-human animal strictly comprises two unreconstructed human Vκ gene segments and five unreconstructed human Jκ gene segments operably linked to the mouse light chain constant region at the mouse endogenous κ light chain locus, optionally in this case the two strictly unreconstructed human Vκ gene segments are the human Vκ1-39 gene segment and the human Vκ3-20 gene segment, and the five unreconstructed human Jκ gene segments are the human Jκ1 gene segment, the human Jκ2 gene segment, the human Jκ3 gene segment, the human Jκ4 gene segment, and the human Jκ5 gene segment, wherein the unreconstructed human kappa light chain gene segments are capable of reconstructing and encoding the human variable domain of an antibody, and optionally further, the non-human animal does not include an endogenous Vκ gene segment capable of reconstructing so that an immunoglobulin light chain variable region is formed.

[0222] In certain embodiments, a non-reconstructed human (humanized) immunoglobulin light chain variable region operably linked to an endogenous light chain constant region contains a non-reconstructed human Igλ variable region gene segment, including a modified Igλ segment as described herein. In some embodiments, the non-reconstructed human immunoglobulin variable region gene segment includes a plurality of human Vλ segments and one or more human Jλ segments. In some embodiments, the non-reconstructed human immunoglobulin variable region gene segment includes one or more human Vλ segments, one or more human Jλ segments, and one or more human Cλ constant region sequences. In some embodiments, the non-reconstructed human immunoglobulin variable region gene segment includes all of the human Vλ segments. In some embodiments, the non-reconstructed human immunoglobulin variable region gene segment includes all of the human Jλ segments. Examples of variable regions containing Igλ gene segments are provided, for example, in U.S. Patents 9,035,128 and 6,998,514, which are incorporated herein by reference in their entirety. In some embodiments, an unreconstructed human (humanized) immunoglobulin light chain variable region operably linked to an endogenous light chain constant region comprises (a) one or more human Vλ gene segments, (b) one or more human Jλ gene segments, and (c) one or more human Cλ gene segments, wherein (a) and (b) are operably linked to (c) and an endogenous (e.g., rodent) Cλ gene segment, and wherein the endogenous immunoglobulin λ light chain locus further comprises one or more rodent immunoglobulin λ light chain enhancers (Eλ) and one or more human immunoglobulin λ light chain enhancers (Eλ), optionally comprising three human Eλ.

[0223] In certain embodiments, a non-reconstructed human (humanized) immunoglobulin light chain variable region operably linked to an endogenous light chain constant region includes a non-reconstructed human Igλ variable region gene segment, such as a modified Igλ segment described herein, operably linked to an endogenous (e.g., rodent, rat, or mouse) Cκ gene, thereby causing the non-human animal to express an immunoglobulin light chain containing human λ variable domain sequences derived from Vλ and Jλ gene segments fused to an endogenous κ constant domain. See, for example, U.S. Patent No. 9,226,484, which is incorporated herein by reference in its entirety.

[0224] In some embodiments, the humanized immunoglobulin κ light chain locus, for example, the humanized immunoglobulin endogenous κ locus, comprises one or more human Vλ gene segments (e.g., modified human Vλ segments as described herein) and one or more human Jλ gene segments upstream of the Cλ gene (e.g., operably linked), which may, for example, substitute for the endogenous Cκ gene. In some embodiments, the Cλ gene is a rodent (e.g., rat or mouse) Cλ gene. In some embodiments, the Cλ gene is a mouse Cλ1 gene. In some embodiments, the Cλ gene comprises one or more human Cλ genes. In some embodiments, one or more human Jλ gene segments and one or more Cλ genes of such a humanized immunoglobulin κ light chain locus reside in a Jλ-Cλ cluster. In some embodiments, the genetically modified rodent (e.g., rat or mouse) is homozygous for such a humanized immunoglobulin κ light chain locus. In some embodiments, genetically modified rodents (e.g., rats or mice) are heterozygous to such humanized immunoglobulin κ light chain loci. In some embodiments, genetically modified rodents (e.g., rats or mice) containing such humanized immunoglobulin κ light chain loci produce antibodies containing λ light chains, particularly in response to antigen stimulation, for example, in which case each λ light chain contains a human λ light chain variable domain operably linked to a human λ light chain constant domain.

[0225] In some embodiments, the immunoglobulin variable region, including a non-reconstructed human immunoglobulin variable region gene segment, also includes human immunoglobulin variable region intergene sequences. In some embodiments, the immunoglobulin variable region includes non-human (e.g., rodent, rat, mouse) Ig variable region intergene sequences. In some embodiments, the intergene sequences are endogenous species-derived intergene sequences.

[0226] In some embodiments, the immunoglobulin variable region is a reconstituted light chain variable region (a general light chain variable region). In some embodiments, the reconstituted Ig light chain variable region gene is a human reconstituted Ig light chain variable region gene. Typical reconstituted Ig light chain variable regions are provided, for example, in U.S. Patents 9,969,814, 10,130,181, and 10,143,186, and U.S. Patent Publications 20120021409, 20120192300, 20130045492, 20130185821, 20130302836, and 20150313193, the entirety of which is incorporated herein by reference. In some embodiments, a non-human organism containing a general light chain variable region ("general light chain" organism) is used to produce a bispecific antibody. In some embodiments, the common light chain coding sequence includes a single reconstituted human immunoglobulin light chain Vκ / Jκ sequence operably linked to the endogenous light chain constant region. In some embodiments, the Vκ / Jκ sequence of the single reconstituted human immunoglobulin light chain is modified so that the single reconstituted human immunoglobulin light chain sequence codes for an anchor described herein that is operably linked to the universal light chain. In some embodiments, the single reconstituted human immunoglobulin light chain Vκ / Jκ sequence is either (i) a human Vκ1-39 / Jκ5 sequence containing a human Vκ1-39 gene segment fused to a human Jκ5 gene segment, or (ii) a human Vκ3-20 / Jκ1 sequence containing a human Vκ3-20 gene segment fused to a human Jκ1 gene segment.

[0227] In some embodiments, the immunoglobulin variable region is a light-chain and / or heavy-chain immunoglobulin variable region including the insertion and / or substitution of a histidine codon, the codon designed to introduce pH-dependent binding properties to antibodies produced in such non-human organisms. In some of these embodiments, the histidine codon is inserted into and / or substituted into a nucleic acid sequence encoding CDR3. Various such light-chain and / or heavy-chain immunoglobulin loci are provided in U.S. Patents 9,301,510, 9,334,334, and 9,801,362, and U.S. Patent Application Publication 20140013456, the entirety of which is incorporated herein by reference. In some embodiments, the histidine-modified reconfigured human (humanized) light chain variable region operably linked to the endogenous light chain constant region comprises a single reconfigured human immunoglobulin light chain variable region gene sequence including human Vκ and Jκ segment sequences, wherein optionally, in this case, the Vκ segment sequence is derived from the human Vκ1-39 or Vκ3-20 gene segment, and in this case, the single reconfigured human immunoglobulin light chain variable region gene sequence comprises the substitution of at least one non-histidine codon with a histidine codon in the Vκ segment sequence, expressed at a position selected from the group consisting of 105, 106, 107, 108, 109, 111 and combinations thereof (according to IMGT numbering). In some embodiments, the histidine-modified non-reconfigured human (humanized) heavy chain variable region operably linked to the endogenous heavy chain constant region comprises a complementarity-determining region 3 (CDR3) coding sequence (e.g., modified (human) V as described herein). H The gene segment includes a non-reconstructed human (humanized) immunoglobulin heavy chain variable gene sequence comprising at least one substitution of a non-histidine codon with a histidine codon, or at least one insertion of a histidine codon. In some embodiments, the non-reconstructed human (humanized) immunoglobulin heavy chain variable gene sequence is non-reconstructed human V H (For example, modified (human) V as described herein) H (segment), non-reconstructed human D HH , or synthetic D H , and non-reconstructed human J HIncluding gene segments, optionally in this case the non-reconstructed human V H Segment (e.g., modified (human) V as described herein) H The segment includes the substitution of at least one non-histidine codon with a histidine codon, or the insertion of at least one histidine codon. In some embodiments, the histidine-modified, unreconstituted human (humanized) light chain variable region operably linked to the endogenous heavy chain constant region is unreconstituted V L and non-reconstructed J L Includes gene segments. In some embodiments, the histidine-modified non-reconstructed human (humanized) light chain variable regions are two or fewer non-reconstructed human V L (For example, two or fewer Vκ gene segments) and one or more non-reconstructed human J L (For example, containing the Jκ) gene segment, and containing two or fewer human V L Each gene segment contains, in its CDR3 coding sequence, a substitution of at least one non-histidine codon with a histidine codon, or an insertion of at least one histidine codon. In some embodiments, two or fewer non-reconstructed human Vκ gene segments are human Vκ1-39 and human Vκ3-20 gene segments, each containing one or more substitutions of non-histidine codons with histidine codons, and in this case, the human Vκ and Jκ gene segments are capable of reconstruction, and the human Vκ and human Jκ gene segments encode a human light chain variable domain containing one or more histidines at a position selected from the group consisting of 105, 106, 107, 108, 109, 111 (according to IGMT numbering) and combinations thereof, in this case, the one or more histidines are derived from one or more substitutions.

[0228] In some embodiments, the immunoglobulin constant region includes a heavy chain constant region gene. In some embodiments, the heavy chain constant region is a human heavy chain constant region gene. In some embodiments, the heavy chain constant region gene is an endogenous species-derived heavy chain constant region gene. In some embodiments, the heavy chain constant region gene is a mouse or rat constant region gene. In some embodiments, the constant region gene is a mixture of human and non-human sequences. For example, in some embodiments, the constant region gene encodes a human CH1 region as well as non-human (e.g., endogenous species-derived, mouse, rat) CH2 and / or CH3 regions. In some embodiments, the heavy chain constant region gene is a constant region gene for Cμ, Cδ, Cγ (Cγ1, Cγ2, Cγ3, Cγ4), Cα, or Cε. In some embodiments, the constant region gene is an endogenous constant region gene. In some embodiments, the constant region gene encodes a mutated CH1 region so that non-human animals express antibodies of the heavy chain only (see, for example, U.S. Patent No. 8,754,287, U.S. Patent Application Publication 2015 / 0289489, which is incorporated herein by reference in its entirety). In some embodiments, for example, where the objective is to generate a heavy chain to produce a bispecific antibody (in common or dual light-chain organisms), the Fc domain of the heavy chain includes modifications to promote heavy chain heterodimerization and / or inhibit heavy chain homodimerization. Such modifications are provided, for example, in U.S. Patents No. 5,731,168, 5,807,706, 5,821,333, 7,642,228 and 8,679,785, and U.S. Patent Application Publication 2013 / 0195849, which is incorporated herein by reference in its entirety.

[0229] In some embodiments, the immunoglobulin constant region includes a light chain constant region gene. In some embodiments, the light chain constant region gene is a κ constant region gene. In some embodiments, the light chain constant region gene is a λ constant region gene. In some embodiments, the light chain constant region gene is an endogenous species-derived light chain constant region gene. In some embodiments, the light chain constant region gene is a mouse constant region gene or a rat constant region gene. In some embodiments, the light chain constant region gene is a mixture of human and non-human sequences.

[0230] In some embodiments, the immunoglobulin variable region containing the human variable region gene segment, and the immunoglobulin constant region gene to which the variable region gene segment is operably linked, are located at an endogenous immunoglobulin locus. In some embodiments, the endogenous immunoglobulin locus is the endogenous heavy chain locus. In some embodiments, the endogenous immunoglobulin locus is the endogenous κ locus. In some embodiments, the endogenous immunoglobulin locus is the endogenous λ locus. In some embodiments, the constant region gene to which the human variable region gene segment is operably linked is the endogenous constant region gene.

[0231] In some embodiments, one or more endogenous immunoglobulin loci in the genome of a non-human animal provided herein, or a portion of one or more endogenous loci (e.g., a variable region and / or a constant region), are inactivated. Endogenous immunoglobulin variable region gene agents and portions thereof may be inactivated using any method known in the art, including, but not limited to, deletion of the loci or a portion thereof from the genome of an organism, substitution of the loci or a portion thereof with a different nucleic acid sequence, inversion of a portion of the loci, and / or relocation of a portion of the loci to another location in the genome of a non-human organism. In some embodiments, the inactivation of the loci is only partial inactivation. In some embodiments, the variable region of the loci is inactivated, but the constant region retains its functionality (e.g., because it is operably bound to a non-endogenous variable region gene segment).

[0232] In some embodiments, the genetically modified non-human animal contains an inactivated endogenous immunoglobulin heavy chain locus. In some embodiments, the endogenous immunoglobulin heavy chain locus or a portion thereof is inactivated by deletion, substitution, migration and / or inversion of at least a portion of the endogenous variable region of the endogenous heavy chain locus. In some embodiments, at least a portion of the variable region of the endogenous heavy chain locus that is deleted, substituted, migrated and / or inverted includes the J segment of the variable region. In some embodiments, the endogenous immunoglobulin heavy chain locus or a portion thereof is inactivated by deletion, substitution, migration and / or inversion of at least a portion of the endogenous constant region of the endogenous heavy chain locus. In some embodiments, at least a portion of the constant region of the endogenous heavy chain locus that is deleted, substituted, migrated and / or inverted includes the Oμ gene of the endogenous constant region.

[0233] In some embodiments, the genetically modified non-human animal contains an inactivated endogenous immunoglobulin κ chain locus. In some embodiments, the endogenous immunoglobulin κ chain locus or a portion thereof is inactivated by deletion, substitution, migration and / or inversion of at least a portion of the endogenous variable region of the endogenous κ chain locus. In some embodiments, at least a portion of the variable region of the endogenous κ chain locus that is deleted, substituted, migrated and / or inverted includes the J segment of the variable region. In some embodiments, the endogenous immunoglobulin κ chain locus or a portion thereof is inactivated by deletion, substitution, migration and / or inversion of at least a portion of the endogenous constant region of the endogenous κ chain locus. In some embodiments, at least a portion of the constant region of the endogenous κ chain locus that is deleted, substituted, migrated and / or inverted includes the Cκ gene of the endogenous constant region.

[0234] In some embodiments, the genetically modified non-human animal contains an inactivated endogenous immunoglobulin λ-chain locus. In some embodiments, the endogenous immunoglobulin λ-chain locus or a portion thereof is inactivated by deletion, substitution, migration, and / or inversion of at least a portion of the endogenous variable region of the endogenous λ-chain locus. In some embodiments, at least a portion of at least one VJC gene cluster in the endogenous λ-chain locus is deleted, substituted, migrated, and / or inverted. In some embodiments, the endogenous immunoglobulin λ-chain locus or a portion thereof is inactivated by deletion, substitution, migration, and / or inversion of at least a portion of the endogenous constant region of the endogenous λ-chain locus. In some embodiments, at least a portion of the constant region of the endogenous λ-chain locus that is deleted, substituted, migrated, and / or inverted contains the C gene of the endogenous constant region.

[0235] In various embodiments, modification of immunoglobulin loci does not affect the reproductive capacity of non-human animals. In some embodiments, the heavy chain loci include functional loci, e.g., endogenous ADAM6a gene, ADAM6b gene, or both, and the gene modification does not affect the expression and / or function of endogenous ADAM6a gene, ADAM6b gene, or both. In some embodiments, the genome of the genetically modified non-human animal further includes ectopically located functional loci, e.g., endogenous ADAM6a gene, ADAM6b gene, or both. Typical non-human animals expressing exogenous ADAM6a and / or ADAM6b are described in U.S. Patents 8,642,835 and 8,697,940, each of which is incorporated herein by reference in whole.

[0236] In some embodiments, genetically modified non-human animals further contain and express exogenous terminal deoxynucleotidyltransferase (TdT) genes due to increased antigen receptor diversity. A typical non-human animal expressing exogenous TdT is described in PCT Patent Application Publication 2017210586, which is incorporated herein by reference in its entirety.

[0237] In some embodiments, the transcription factors include RAG1 transcription factors, RAG2 transcription factors, immunoglobulin heavy chain transcription factors, immunoglobulin κ light chain transcription factors, immunoglobulin λ light chain transcription factors, or any combination thereof.

[0238] In some embodiments, the genome of the non-human animal provided further comprises one or more human immunoglobulin heavy and / or light chain genes (see, for example, U.S. Patent Nos. 8,502,018, 8,642,835, 8,697,940, 8,791,323, and U.S. Patent Publication Nos. 2013 / 0096287A1 and 2018 / 0125043A1, and PCT Patent Publication No. 2019 / 113065, each incorporated herein by reference in whole). Alternatively, recombinant nucleic acid molecules comprising the modified Ig V segment described herein may be introduced into embryonic stem cells of different modified strains, such as the VELOCIMMUNE® strain (see, for example, U.S. Patent No. 8,502,018 or U.S. Patent No. 8,642,835, each incorporated herein by reference in whole). In some embodiments, the non-human animals described herein may be prepared by introducing the targeted vector described herein into cells derived from a modified strain. For example, the targeted vector described herein may be introduced into a non-human animal described in U.S. Patents 8,642,835 and 8,697,940, the entire vector of which is incorporated herein by reference, and the non-human animal expresses an antibody having a complete human variable region and a mouse constant region. In some embodiments, the non-human animals described herein are prepared to further include a human immunoglobulin gene (variable region gene and / or constant region gene). In some embodiments, the non-human animals described herein, including the modified Ig V segment described herein, include the manipulated DH region described herein and heterologous (e.g., human) genetic material, the genetic material encoding one or more human heavy chain variable regions and / or light chain variable regions, in whole or in part.

[0239] The non-human animals described herein may, in many cases, be prepared as described above or by methods known in the art to include additional human or humanized genes, depending on the intended use of the non-human animal. Such additional human or humanized gene genetic material may be introduced through further modification of the genome of genetically modified cells (e.g., embryonic stem cells) by breeding techniques known in the art, as described above or by using other desired genetically modified strains.

[0240] For example, non-human animals containing the modified Ig V segment described herein, as described herein, are incorporated herein by reference in their entirety by U.S. Patent Publications 2011-0195454 A1, 2012-0021409 A1, 2012-0192300 A1, 2013-0045492 A1, 2013-0185821 A1, 2013-0198880 A1, and 2013-0302836. A1, No. 2015-0059009 A1; further including one or more modifications (e.g., via hybridization or multiple gene targeting strategies) described in International Patent Application Publication Nos. 2011 / 097603, 2012 / 148873, 2013 / 134263, 2013 / 184761, 2014 / 160179, and 2014 / 160202.

[0241] Transgenic founder non-human animals can be identified based on the presence of a modified IgV segment in their genome and / or based on the expression of an anchored modified antibody containing amino acids corresponding to the receptor-binding portion of a non-immunoglobulin polypeptide that binds to a congener receptor. The transgenic founder non-human animals can then be crossed with another non-human animal carrying a modified IgV segment, thereby generating a series of non-human animals, each carrying one or more copies of the modified IgV segment. Furthermore, transgenic non-human animals carrying modified IgV segments can be further crossed with other transgenic non-human animals carrying other desired transgenes (e.g., human immunoglobulin genes).

[0242] Transgenic non-human animals may also be generated to contain selective systems that allow for the control or direction of transgene expression. Typical systems include the Cre / loxP recombinase system of bacteriophage P1 (see, e.g., Lakso, M. et al., 1992, Proc. Natl. Acad. Sci. USA 89:6232-6236, the whole of which is incorporated herein by reference) and the FLP / Frt recombinase system of budding yeast (O'Gorman, S. et al., 1991, Science This includes 251:1351-1355 (the entirety of which is incorporated herein by reference). Such animals may be provided by constructing a “dual” transgenic animal by crossing two transgenic animals, for example, one containing a transgene containing a selected modification (e.g., a modified Ig V segment) and the other containing a transgene encoding a recombinase (e.g., Cre recombinase).

[0243] Mouse (i.e., modified human V) H Segment, D H , and J HEmbodiments utilizing modified IgV segments in mice containing gene segments (all of which are operably linked to one or more mouse heavy chain constant region genes) are discussed extensively herein, but other non-human animals containing modified IgV segments are also provided. Such non-human animals include any non-human animals that can be genetically modified to express the anchor-modified immunoglobulins described herein, e.g., mammals such as mice, rats, rabbits, pigs, cattle (e.g., cows, uncastrated males, buffalo), deer, sheep, goats, chickens, cats, dogs, ferrets, and primates (e.g., marmosets, rhesus monkeys). For example, in non-human animals for which suitable genetically modifiable ES cells are not readily available, other methods may be used to produce non-human animals containing gene modifications. Such a method includes, for example, the steps of modifying a non-ES cell genome (e.g., fibroblasts or induced pluripotent cells), introducing the modified genome into suitable cells, such as enucleated oocytes, using somatic cell nuclear transfer (SCNT), and implanting the modified cells (e.g., modified oocytes) into a non-human animal under conditions suitable for embryo formation.

[0244] Methods for modifying non-human animal genomes (e.g., pigs, cows, rodents, chickens, etc.) include, for example, modifying the genome to include the modified IgV segment described herein using zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), or Cas proteins (i.e., the CRISPR / Cas system). Guidelines for methods for modifying germline genomes of non-human animals can be found, for example, in U.S. Patent Publication Nos. 2015-0376628 A1, 2016-0145646 A1, and 2016-0177339 A1, which are incorporated herein by reference in their entirety.

[0245] In some embodiments, the non-human animals described herein are mammals. In some embodiments, the non-human animals described herein are small mammals, e.g., small mammals of the superfamily Dormoidea or Muroidea. In some embodiments, the genetically modified animals described herein are rodents. In some embodiments, the rodents described herein are selected from mice, rats, and hamsters. In some embodiments, the rodents described herein are selected from the superfamily Muroidea. In some embodiments, the genetically modified animals described herein are derived from families selected from the families of the family Myctophidae (e.g., mouse-like hamsters), Cricetidae (e.g., hamsters, New World rats and mice, voles), Muridae (purebred mice and rats, gerbils, spiny mice, maned mice), Dolichophidae (tree mice, rock mice, white-tailed rats, Madagascar rats and mice), Glididae (e.g., spiny dormice), and Muridae (e.g., blind mice, bamboo mice, and highland mole mice). In some embodiments, the genetically modified rodents described herein are selected from purebred mice or rats (Muridae), gerbils, spiny mice, and maned mice. In some embodiments, the genetically modified mice described herein are derived from members of the Muridae family. In some embodiments, the non-human animals described herein are rodents. In some embodiments, the rodents described herein are selected from mice and rats. In some embodiments, the non-human animals described herein are mice.

[0246] In some embodiments, the non-human animals described herein are rodents that are C57BL strain mice selected from C57BL / A, C57BL / An, C57BL / GrFa, C57BL / KaLwN, C57BL / 6, C57BL / 6J, C57BL / 6ByJ, C57BL / 6NJ, C57BL / 10, C57BL / 10ScSn, C57BL / 10Cr, and C57BL / Ola. In some embodiments, the mice of the present invention are 129 strains selected from the group consisting of strains 129P1, 129P2, 129P3, 129X1, 129S1 (e.g., 129S1 / SV, 129S1 / SvIm), 129S2, 129S4, 129S5, 129S9 / SvEvH, 129 / SvJae, 129S6 (129 / SvEvTac), 129S7, 129S8, 129T1, and 129T2 (see, for example, Festing et al., 1999, Mammalian Genome 10:836; Auerbach, W. et al., 2000, Biotechniques 29(5):1024-1028,1030,1032; the whole is incorporated herein by reference). In some embodiments, the genetically modified mice described herein are a mixture of the aforementioned 129 strain and the aforementioned C57BL / 6 strain. In some embodiments, the mice described herein are a mixture of the aforementioned 129 strain or a mixture of the aforementioned BL / 6 strain. In some embodiments, the 129 strain in the mixture described herein is the 129S6(129 / SvEvTac) strain. In some embodiments, the mice described herein are the BALB strain, for example, the BALB / c strain. In some embodiments, the mice described herein are a mixture of the BALB strain and another of the aforementioned strains.

[0247] In some embodiments, the non-human animal described herein is a rat. In some embodiments, the rat described herein is selected from Wistar rat, LEA strain, Sprague Dawley strain, Fisher strain, F344, F6, and Dark Agouti. In some embodiments, the rat strain described herein is a mixture of two or more strains selected from the group consisting of Wistar, LEA, Sprague Dawley, Fisher, F344, F6, and Dark Agouti.

[0248] Method for producing anchor-modified immunoglobulins, and anchor-modified immunoglobulins Several in vitro and in vivo technologies have been developed to generate antibody-based therapeutics. In detail, in vivo technologies have characterized the generation of transgenic animals (i.e., rodents) possessing human immunoglobulin genes, where the genes are either randomly integrated into the animal's genome (see, e.g., U.S. Patent No. 5,569,825, the entirety of which is incorporated herein by reference) or precisely positioned at endogenous immunoglobulin loci operably linked to the animal's endogenous immunoglobulin constant region (see, e.g., U.S. Patents No. 8,502,018, 8,642,835, 8,697,940, and 8,791,323, the entirety of which is incorporated herein by reference). Both approaches have yielded good results in generating antibody therapeutic candidates that are promising for human use. Furthermore, both of these approaches are superior to in vitro approaches in that antibody candidates are selected from an in vivo antibody repertoire, and this selection involves the selection of affinity and specificity to the antigen within the internal environment of the host immune system. Thus, the antibodies bind to naturally presented antigens (within the relevant biological epitopes and on the surface) rather than to artificial environments or in silico predictions that may accompany in vitro technologies. Despite the robust antibody repertoire obtained from in vivo technologies, antibodies against complexes (e.g., viruses, channel polypeptides) or cytoplasmic antigens remain challenging. Moreover, the development of antibodies against polypeptides that share a high degree of sequence identity between species (e.g., humans and mice) due to immune tolerance also remains a challenge.

[0249] Therefore, the present invention is particularly based on the understanding that the present invention constructs an in vivo system characterized by the creation of antibodies that increase affinity to an antigen by having an anchor to assist the immunoglobulin in anchoring to a target antigen (e.g., a cognate receptor of the anchor) and by contributing to the avidity of the molecule by affinity to the cognate receptor, and / or by performing somatic hypermutation of a large repertoire of immunoglobulins that have the ability to recognize the cognate receptor.

[0250] The non-human animals provided may be used to produce human antibodies, which include variable domains derived from one or more variable region nucleic acid sequences encoded by the genetic material of the cells of the non-human animals described herein. For example, the non-human animals provided are immunized with a target antigen (e.g., a receptor homologous to the anchor) under conditions and for a sufficient amount of time to induce an immune response against the target antigen. The antibodies are isolated from the non-human animals (or one or more cells, e.g., one or more B cells) and characterized using various assays to measure, for example, affinity, specificity, epitope mapping, ability to inhibit ligand-receptor interaction, inhibitory receptor activity, etc. In some embodiments, the antibodies produced by the non-human animals provided include one or more human variable domains derived from one or more human variable region nucleotide sequences isolated from the non-human animals.

[0251] The non-human animals described herein provide improved in vivo systems and sources of biological materials (e.g., cells) for producing human antibodies useful for various assays. In some embodiments, the provided non-human animals are used to develop therapeutic agents targeting one or more receptors of the ligand receptor pairs described herein. In some embodiments, the provided non-human animals are used to identify, screen, and / or develop candidate therapeutic agents (e.g., antibodies) that bind to one or more G protein-coupled receptor (GPCR) polypeptides. In some embodiments, the provided non-human animals are used to screen and develop candidate therapeutic agents (e.g., antibodies) that interfere with the activity of one or more receptor tyrosine kinases, one or more human GPCR polypeptides, one or more Notch receptors, one or more of CD28, CTLA4, and PD1, plexin receptors, LDLR, LILR, KIR, and integrins, or NPRs such as NPR3. In some embodiments, the binding profiles of one or more human GPCR polypeptides, one or more Notch receptors, one or more CD28, CTLA4, and PD1, plexin receptors, LDLR, LILR, KIR, and integrins, or antagonists and / or agonists of NPRs such as NPR3 are determined using the provided non-human animals. In some embodiments, the epitopes of one or more candidate therapeutic antibodies that bind to one or more human GPCR polypeptides, one or more Notch receptors, one or more CD28, CTLA4, and PD1, plexin receptors, LDLR, LILR, KIR, and integrins, or NPRs such as NPR3 are determined using the provided non-human animals.

[0252] In some embodiments, the pharmacokinetic profile of the antibody is determined using a provided non-human animal. In some embodiments, one or more provided non-human animals and one or more control or reference non-human animals are each exposed to one or more candidate therapeutic antibodies at various doses (e.g., 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 7.5 mg / kg, 10 mg / kg, 15 mg / kg, 20 mg / kg, 25 mg / kg, 30 mg / kg, 40 mg / kg, or 50 mg / kg or more). The candidate therapeutic antibody may be administered via any preferred route of administration, including parenteral and oral routes. Parenteral routes include, for example, intravenous, intra-arterial, intra-portal, intramuscular, subcutaneous, intraperitoneal, intrathecal, subarachnoid, lateral ventricle, intracranial, intrathoracic, or other routes of administration. Oral routes include, for example, oral, nasal, transdermal, pulmonary, rectal, oral cavity, vaginal, and ocular. Administration may also be by continuous infusion, local administration, sustained release from implants (gel, membrane, etc.), and / or intravenous injection, for example, using intravenous fluid bags. Blood is isolated from non-human animals (humanized and control) at various time points (e.g., 0 hours, 6 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, or up to 30 days or more). Various assays, including but not limited to total IgG, anti-therapeutic antibody response, and agglutination, may be used to determine the pharmacokinetic properties of the administered candidate therapeutic antibody using feed obtained from the non-human animals described herein.

[0253] In some embodiments, the non-human animals provided express antibodies, and therefore cells, cell lines, and cell cultures may be generated to serve as a source of antibodies for use in binding and function assays, for example, to assay for the binding or function of an antagonist or agonist, the antagonist or agonist being specific to a human polypeptide sequence or epitope, or specific to a human polypeptide sequence or epitope that functions in ligand-receptor interaction (binding). In some embodiments, the epitope to be bound by the candidate therapeutic antibody or siRNA can be determined using cells isolated from the non-human animals provided.

[0254] In some embodiments, the non-human animal-derived cells provided may be isolated ad-hoc and used, or maintained in culture over multiple generations. In some embodiments, the non-human animal-derived cells provided may be immortalized (e.g., via the use of a virus) and maintained indefinitely in culture (e.g., in a continuous culture).

[0255] In some embodiments, the non-human animals described herein provide an in vivo system for generating antibody variants that bind to human target antigens. Such variants include antibodies that have desired functionality, specificity, and low cross-reactivity to a common epitope shared by two or more human target antigens. In some embodiments, the provided non-human animals are used to generate a panel of antibodies for producing a series of antibody variants that are screened for desired or improved functionality.

[0256] In some embodiments, the non-human animals described herein provide an in vivo system for generating antibody libraries. Such libraries provide a source of heavy and light chain variable region sequences that can be transplanted into different Fc regions based on desired effector function and / or used as a source for affinity maturation of variable region sequences using techniques known in the art (e.g., site-directed mutagenesis, error-prone PCR, etc.).

[0257] kit The present invention further provides a pack or kit comprising one or more containers filled with at least one non-human animal, non-human cell, DNA fragment, and / or targeted vector as described herein. The kit may be used in any applicable method (e.g., a research method). A notice in the form prescribed by a government agency regulating the manufacture, use, or sale of pharmaceutical and biological products may optionally be associated with such containers, the notice reflecting (a) an approval by the authority for manufacture, use, or sale relating to human administration, (b) instructions for use, or both, or a contract governing the transfer of substances and / or biological products (e.g., non-human animals or non-human cells as described herein) between two or more entities.

[0258] Non-limiting embodiments are described below. Embodiment 1. A recombinant nucleic acid molecule comprising a modified immunoglobulin (Ig) variable (V) segment encoding an anchor-modified Ig polypeptide, The modified Ig V segment includes a nucleic acid sequence encoding an anchor between the nucleic acid sequence encoding the Ig signal peptide and the nucleic acid sequences encoding the framework region (FR)1, complementarity-determining region (CDR)1, FR2, CDR2, FR3, and CDR3 of the germline Ig V segment or its variant. Anchor-modified Ig polypeptides are functionally linked. (i) Ig signal peptide, (ii) anchors, and (iii) comprising germline Ig V segment or its variants FR1, CDR1, FR2, CDR2, FR3, and CDR3, The anchor comprises a receptor-binding portion of the target non-immunoglobulin polypeptide that binds to a congener receptor, and A recombinant nucleic acid molecule in which the nucleic acid molecule is selectively devoid of all other V segments. Embodiment 2. The recombinant nucleic acid molecule according to Embodiment 1, wherein the Ig signal peptide is an Ig signal peptide of the germline Ig V segment or a variant thereof. Embodiment 3. The germline Ig V segment or its variants are germline Ig heavy chain variable (V H ) is a segment or a variant thereof, thereby, The modified IgV segment contains a nucleic acid sequence encoding an Ig signal peptide and germline IgV H Modified IgV containing a nucleic acid sequence encoding an anchor between the nucleic acid sequence encoding the framework region (FR) 1, complementarity-determining region (CDR) 1, FR2, CDR2, FR3, and CDR3 of the segment or its variant. H It is a segment, and Anchor-modified Ig polypeptides are functionally linked. (i) Ig signal peptide, (ii) anchors, and (iii) germline Ig V H A recombinant nucleic acid molecule according to Embodiment 1 or Embodiment 2, comprising FR1, CDR1, FR2, CDR2, FR3, and CDR3 of the segment or its variant. Embodiment 4. The germline Ig V segment or its variant is germline human (h)V H 1-2 segments, germline hV H 1-3 segments, germline hV H 1-8 segments, germline hV H 1-18 segments, germline hV H 1-24 segments, germline hV H 1-45 segments, germline hV H Segments 1-46, germline hV H 1-58 segments, germline hV H Segments 1-69, germline hV H 2-5 segments, germline hV H 2-26 segments, germline hV H 2-70 segments, germline hV H3-7 segments, germline hV H 3-9 segments, germline hV H 3-11 segments, germline hV H 3-13 segments, germline hV H 3-15 segments, germline hV H 3-16 segments, germline hV H 3-20 segments, germline hV H 3-21 segments, germline hV H 3-23 segments, germline hV H 3-30 segments, germline hV H 3-30-3 segment, germline hV H 3-30-5 segment, germline hV H 3-33 segments, germline hV H 3-35 segments, germline hV H 3-38 segments, germline hV H 3-43 segments, germline hV H 3-48 segments, germline hV H 3-49 segments, germline hV H 3-53 segments, germline hV H 3-64 segments, germline hV H 3-66 segments, germline hV H 3-72 segments, germline hV H 3-73 segments, germline hV H 3-74 segments, germline hV H 4-4 segment, germline hV H 4-28 segments, germline hV H 4-30-1 segment, germline hV H 4-30-2 segment, germline hV H 4-30-4 segment, germline hV H 4-31 segments, germline hV H 4-34 segments, germline hV H 4-39 segments, germline hV H 4-59 segments, germline hV H 4-61 segments, germline hV H5-51 segments, germline hV H 6-1 segment, germline hV H 7-4-1 segment, germline hV H A recombinant nucleic acid molecule according to any one of Embodiments 1 to 3, which is a 7-81 segment or a variant thereof. Embodiment 5. The germline IgV segment or its variant is germline hV H A recombinant nucleic acid molecule according to any one of Embodiments 1 to 4, comprising 1-69 segments or their variants, wherein the Ig signal peptide optionally comprises the sequence MDWTWRFLFVVAAATGVQS (SEQ ID NO: 7). Embodiment 6. In a movable link, from 5' to 3', (I) Modified Ig V H segment, (II) One or more Ig heavy chain diversity (D H ) segments, and (III) Mono-Ig heavy chain bond (J H A recombinant nucleic acid molecule according to any one of embodiments 3 to 5, comprising a segment. Embodiment 7. (II) One or more Ig D H The segment may be one, multiple, or all human IgD H Includes segments and / or (III) One or more Ig J H The segment may be one, multiple, or all human IgJ. H A recombinant nucleic acid molecule according to Embodiment 6, comprising a segment. Embodiment 8. (II) One or more Ig D H Segment, and one or more Ig J of (III) H The gene segment is rejoined, and the IgD is rearranged. H / J H It forms a sequence, thereby enabling the recombinant nucleic acid molecule to operate in a functional linkage from 5' to 3'. Modified Ig V Hgene segment, and Reconstituted IgD H / J H A recombinant nucleic acid molecule comprising a sequence, as described in Embodiment 6 or Embodiment 7. Embodiment 9. Modified Ig V H Gene segments and rearranged IgD H / J H The sequence is rejoined, and the reconstructed Ig V encodes an anchor-modified Ig heavy chain variable domain. H / D H / J H Forming an array, The anchor-modified Ig heavy chain variable domain is functionally linked. (i) Ig signal peptide, (ii) anchors, and (iii) Reconstituted Ig V H / D H / J H A recombinant nucleic acid molecule according to Embodiment 8, comprising FR1 encoded by a sequence, complementarity-determining region (CDR) 1, FR2, CDR2, FR3, CDR3, and FR4. Embodiment 10. Modified Ig V H The segment is non-reconstructed modified Ig V H A recombinant nucleic acid molecule according to any one of embodiments 3 to 8, which is a gene segment. Embodiment 11. Ig heavy chain constant region (C H It further includes nucleic acid sequences encoding ), Ig C H The nucleic acid sequence that codes for (I) Modified Ig V H segment, (II) One or more Ig D H Segments, and (III) One or more Ig J H A recombinant nucleic acid molecule according to any one of embodiments 6 to 10, located downstream of segments and operably coupled thereto. Embodiment 12. Ig C HThe recombinant nucleic acid molecule according to Embodiment 11, wherein the nucleic acid sequence encoding includes an Igμ gene encoding an IgM isotype, an Igδ gene encoding an IgD isotype, an Igγ gene encoding an IgG isotype, an Igα gene encoding an IgA isotype, and / or an Igε gene encoding an IgE isotype. Embodiment 13. It contains a nucleic acid sequence encoding an anchor-modified Ig heavy chain, and the anchor-modified Ig heavy chain is operable in a ligation. (i) Ig signal peptide, (ii) Anchor, (iii) Reconstituted Ig V H / D H / J H Ig heavy chain variable domains including FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 encoded by the sequence, (iv) Ig C H A recombinant nucleic acid molecule according to any one of embodiments 3 to 12, including , Embodiment 14. Ig C H is non-human Ig C H A recombinant nucleic acid molecule according to any one of embodiments 11 to 13. Embodiment 15. Non-human Ig C H is rodent Ig C H The recombinant nucleic acid molecule described in Embodiment 14. Embodiment 16. Non-human Ig C H Rat Ig C H The recombinant nucleic acid molecule described in Embodiment 15. Embodiment 17. Non-human Ig C H This is mouse Ig C H The recombinant nucleic acid molecule described in Embodiment 15. Embodiment 18. The germline Ig V gene segment or its variants are germline Ig light chain variable (V L ) is a segment or a variant thereof, thereby, The modified IgV segment contains a nucleic acid sequence encoding an Ig signal peptide and germline IgV L Modified IgV containing a nucleic acid sequence encoding an anchor between the nucleic acid sequence encoding the framework region (FR) 1, complementarity-determining region (CDR) 1, FR2, CDR2, FR3, and CDR3 of the segment or its variant. L It is a segment, and Anchor-modified Ig polypeptides are functionally linked. (i) Ig signal peptide, (ii) anchors, and (iii) germline Ig V L A recombinant nucleic acid molecule according to Embodiment 1 or Embodiment 2, comprising FR1, CDR1, FR2, CDR2, FR3, and CDR3 of the segment or its variant. Embodiment 19. In a movable link, from 5' to 3', (I) Modified Ig V L Segments, and (II) One or more Ig light chain bonds (J L A recombinant nucleic acid molecule according to Embodiment 18, comprising a segment. Embodiment 20. Modified Ig V L Gene segment and one or more IgJ L The segments are recombined, and the reconstructed Ig V encodes an anchor-modified Ig light chain variable domain. L / J L Forming an array, The anchor-modified Ig light chain variable domain is functionally linked. (i) Ig signal peptide, (ii) anchors, and (iii) Reconstituted Ig V L / J L A recombinant nucleic acid molecule according to Embodiment 19, comprising FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 encoded by sequences. Embodiment 21. Ig light chain constant region (C LIt further includes nucleic acid sequences encoding ), Ig C L The nucleic acid sequence that codes for (I) Modified Ig V L Segments, and (II) One or more Ig light chain bonds (J L A recombinant nucleic acid molecule according to Embodiment 19 or Embodiment 20, which is downstream of and operably coupled to the segments. Embodiment 22. It contains a nucleic acid sequence encoding an anchor-modified Ig light chain, and the anchor-modified Ig light chain is operable in a ligation. (i) Ig signal peptide, (ii) Anchor, (iii) Reconstituted Ig V L / J L Ig light chain variable domains including FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 encoded by the sequence, (iv) Ig C L A recombinant nucleic acid molecule according to any one of embodiments 18 to 21, including , Embodiment 23. Ig C L is non-human Ig C L The recombinant nucleic acid molecule described in Embodiment 21 or Embodiment 22. Embodiment 24. Non-human Ig C L is rodent Ig C L The recombinant nucleic acid molecule described in Embodiment 23. Embodiment 25. Non-human Ig C L Rat Ig C L The recombinant nucleic acid molecule described in Embodiment 23. Embodiment 26. Non-human Ig C L This is mouse Ig C L The recombinant nucleic acid molecule described in Embodiment 23. Embodiment 27. Germline Ig V LThe segment or its variant is a germline Ig light chain variable kappa (Vκ) segment or its variant, thereby, The modified Ig V segment is a modified Ig Vκ segment that includes a nucleic acid sequence encoding an anchor between the nucleic acid sequence encoding the Ig signal peptide and the nucleic acid sequences encoding the framework region (FR)1, complementarity-determining region (CDR)1, FR2, CDR2, FR3, and CDR3 of the germline Ig Vκ segment or its variant, and Anchor-modified Ig polypeptides are functionally linked. (i) Ig signal peptide, (ii) anchors, and (iii) A recombinant nucleic acid molecule according to any one of Embodiments 18 to 26, comprising germline Ig Vκ segment or a variant thereof FR1, CDR1, FR2, CDR2, FR3, and CDR3. Embodiment 28. In a movable link, from 5' to 3', (I) Modified Ig Vκ segment, and (II) The recombinant nucleic acid molecule according to Embodiment 27, comprising one or more Ig light chain-bound kappa (Jκ) segments. Embodiment 29. It further includes a nucleic acid sequence encoding the constant kappa region (Cκ) of the Ig light chain, The nucleic acid sequence encoding Ig Cκ (I) Modified Ig Vκ segment, and (II) Recombinant nucleic acid molecules according to Embodiment 28, which are located downstream of and operably linked to one or more Ig Jκ segments. Embodiment 30. Germline Ig V L The segment or its variant is a germline Ig light chain variable lambda (Vλ) segment or its variant, thereby, The modified Ig V segment is a modified Ig Vλ segment that includes a nucleic acid sequence encoding an anchor between the nucleic acid sequence encoding the Ig signal peptide and the nucleic acid sequences encoding the framework region (FR)1, complementarity-determining region (CDR)1, FR2, CDR2, FR3, and CDR3 of the germline Ig Vλ segment or its variant, and Anchor-modified Ig polypeptides are functionally linked. (i) Ig signal peptide, (ii) anchors, and (iii) A recombinant nucleic acid molecule according to any one of Embodiments 18 to 26, comprising germline Ig Vλ segment or a variant thereof FR1, CDR1, FR2, CDR2, FR3, and CDR3. Embodiment 31. In a movable link, from 5' to 3', (I) Modified Ig Vλ segment, and (II) The recombinant nucleic acid molecule according to Embodiment 30, comprising one or more Ig light chain-bound lambda (Jλ) segments. Embodiment 32. It further includes a nucleic acid sequence encoding the constant lambda region (Cλ) of the Ig light chain, The nucleic acid sequence encoding Ig Cλ (I) Modified Ig Vλ segment, and (II) Recombinant nucleic acid molecules according to Embodiment 31, which are located downstream of and operably linked to one or more Ig Jλ segments. Embodiment 33. A recombinant nucleic acid molecule according to any one of Embodiments 1 to 32, wherein the anchor includes a linker, the linker linking the receptor-binding portion of the target non-immunoglobulin polypeptide to FR1, CDR1, FR2, CDR2, FR3, and CDR3 of the germline Ig V segment or a variant thereof. Embodiment 34. The linker is a recombinant nucleic acid molecule according to Embodiment 33, comprising the sequence GGGGS (SEQ ID NO: 5). Embodiment 35. The anchor is a recombinant nucleic acid molecule according to any one of Embodiments 1 to 34, comprising a natriuretic peptide (NP) receptor (NPR) binding moiety. Embodiment 36. The recombinant nucleic acid molecule according to Embodiment 35, wherein the NPR-binding portion of NP includes the C-terminal tail of NP. Embodiment 37. NP is an atrial natriuretic peptide (ANP), a recombinant nucleic acid molecule according to Embodiment 35 or Embodiment 36. Embodiment 38. The anchor is a recombinant nucleic acid molecule according to any one of Embodiments 1 to 37, comprising the sequence NSFRY (SEQ ID NO: 3). Embodiment 39. A recombinant nucleic acid molecule according to any one of Embodiments 1 to 38, comprising a sequence selected from the group consisting of the sequence described as SEQ ID NO: 8 or a degenerate variant thereof, the sequence described as SEQ ID NO: 10 or a degenerate variant thereof, SEQ ID NO: 11 or a degenerate variant thereof, and SEQ ID NO: 12 or a degenerate variant thereof. Embodiment 40. The targeting vector further includes 5' and 3' homologous arms, which target non-human Ig heavy chain loci, thereby enabling homologous recombination between the targeting vector and the non-human Ig heavy chain loci to recombinate the recombinant nucleic acid molecule with the non-human Ig C at the non-human Ig heavy chain loci. H Upstream of and including in a operable linkage thereto, optionally the non-human Ig heavy chain locus is the endogenous rodent Ig heavy chain locus, and / or the non-human Ig heavy chain locus includes the human or humanized immunoglobulin heavy chain variable region, and the endogenous Ig V H , D H and / or J H A targeted vector comprising a recombinant nucleic acid molecule according to any one of embodiments 1 to 10 and 33 to 39, comprising a deletion of a gene segment or a combination thereof. Embodiment 41. During homologous recombination between the targeting vector and the non-human Ig heavy chain locus, the recombinant nucleic acid molecule is recombined with non-human Ig heavy chain locus. HA targeted vector according to embodiment 40, which replaces a segment. Embodiment 42. During homologous recombination between the targeting vector and the non-human Ig heavy chain locus, the recombinant nucleic acid molecule has one or more non-human Ig heavy chain loci. H Segment, all non-human D H Segments, and all non-human J H A targeted vector according to Embodiment 40 or Embodiment 41, which replaces a segment. Embodiment 43. During homologous recombination between the targeting vector and the non-human Ig heavy chain locus, the recombinant nucleic acid molecule is one non-human V at the non-human Ig heavy chain locus. H All or all non-human V segments other than the segment H Segment, all non-human D H Segments, and all non-human J H A targeted vector according to any one of embodiments 40 to 42, which replaces a segment. Embodiment 44. The targeted vector according to any one of Embodiments 40 to 43, wherein, in homologous recombination between the targeted vector and a non-human Ig heavy chain locus, the targeted non-human Ig heavy chain locus comprises a recombinant nucleic acid molecule operably linked to a non-human Ig heavy chain control sequence at the non-human Ig heavy chain locus. Embodiment 45. A targeted vector according to any one of embodiments 40 to 44, wherein the 5' homologous arm contains the sequence described as sequence number 11, and / or the 3' homologous arm contains the sequence described as sequence number 12. Embodiment 46. The targeting vector further includes 5' and 3' homologous arms, which target a non-human Ig heavy chain locus, thereby, upon homologous recombination between the targeting vector and the non-human Ig heavy chain locus, the targeted non-human Ig heavy chain locus contains the recombinant nucleic acid molecule in an operable linkage to the non-human Ig heavy chain control sequence of the non-human Ig heavy chain locus, optionally the non-human Ig heavy chain locus being an endogenous rodent Ig heavy chain locus and / or the non-human Ig heavy chain locus containing a human or humanized immunoglobulin heavy chain variable region, and endogenous Ig VH , D H and / or J H A targeted vector comprising a recombinant nucleic acid molecule according to any one of Embodiments 1-17 and 33-39, comprising deletions of gene segments or combinations thereof. Embodiment 47. During homologous recombination between the targeting vector and the non-human Ig heavy chain locus, the recombinant nucleic acid molecule has one or more non-human Ig heavy chain loci. H Segment, all non-human D H Genetic segments, and all non-human J H Genetic segments, and one or more non-human C H A targeted vector according to embodiment 46, which replaces a gene. Embodiment 48. The targeting vector further includes 5' and 3' homologous arms, which target a non-human Ig light chain locus, thereby, during homologous recombination between the targeting vector and the non-human Ig light chain locus, the targeted non-human Ig light chain locus recombinates the recombinant nucleic acid molecule with the non-human Ig C at the non-human Ig light chain locus. L Upstream of and including therein in a operable linkage, optionally in this case, the non-human Ig light chain locus is the endogenous rodent Ig light chain locus, and / or in this case, the non-human Ig light chain locus includes the human or humanized immunoglobulin light chain variable region and endogenous Ig V L and / or J L A targeted vector comprising a recombinant nucleic acid molecule according to any one of embodiments 1-2, 18-20, 27-28, 30-31, and 33-38, comprising deletions of gene segments or combinations thereof. Embodiment 49. During homologous recombination between the targeting vector and the non-human Ig light chain locus, the recombinant nucleic acid molecule is recombined with the non-human Ig light chain locus. L A targeted vector according to embodiment 48, which replaces a segment. Embodiment 50. During homologous recombination between the targeting vector and the non-human Ig light chain locus, the recombinant nucleic acid molecule has one or more non-human Ig light chain loci. LSegments and all non-human J L A targeted vector according to Embodiment 48 or Embodiment 49, which replaces a segment. Embodiment 51. During homologous recombination between the targeting vector and the non-human Ig light chain locus, the recombinant nucleic acid molecule is recombined with all non-human Ig light chain loci. L Segments and all non-human J H A targeted vector according to any one of embodiments 48 to 50, which replaces a segment. Embodiment 52. The targeted vector according to any one of Embodiments 48 to 51, wherein, in homologous recombination between the targeted vector and a non-human Ig light chain locus, the targeted non-human Ig heavy chain locus comprises a recombinant nucleic acid molecule operably linked to a non-human Ig light chain control sequence at the Ig light chain locus. Embodiment 53. The targeting vector further comprises 5' and 3' homologous arms, which target a non-human Ig light chain locus, thereby, upon homologous recombination between the targeting vector and the non-human Ig light chain locus, the targeted non-human Ig light chain locus contains the recombinant nucleic acid molecule in an operable linkage to the non-human Ig light chain control sequence of the non-human Ig light chain locus, optionally in this case the non-human Ig light chain locus is an endogenous rodent Ig light chain locus, and / or in this case the non-human Ig light chain locus contains a human or humanized immunoglobulin light chain variable region and an endogenous Ig V L and / or J L A targeted vector comprising a recombinant nucleic acid molecule according to any one of embodiments 1-2, 18-38, which includes deletions of gene segments or combinations thereof. Embodiment 54. During homologous recombination between the targeting vector and the non-human Ig light chain locus, the recombinant nucleic acid molecule is the non-human Ig light chain locus. L Segment, all non-human J L Segments, and non-human C L A targeted vector according to embodiment 53, which replaces a gene. Embodiment 55. The targeted vector further comprises 5' and 3' homologous arms, the arms targeting a non-human Ig light chain κ locus, thereby, upon homologous recombination between the targeted vector and the non-human Ig light chain κ locus, the targeted non-human Ig light chain κ locus contains the recombinant nucleic acid molecule upstream of the non-human Ig Cκ of the non-human Ig light chain κ locus and operably linked thereto, optionally in this case the non-human Ig light chain κ locus is an endogenous rodent Ig light chain κ locus and / or in this case the non-human Ig light chain κ locus contains a human or humanized immunoglobulin light chain variable region, contains a deletion of an endogenous Ig Vκ and / or Jκ gene segment, or a combination thereof, the targeted vector containing the recombinant nucleic acid molecule according to any one of Embodiments 1-2, 18-20, 27-28, and 33-38. Embodiment 56. The targeted vector according to Embodiment 55, wherein, during homologous recombination between the targeted vector and the non-human Ig light chain κ locus, the recombinant nucleic acid molecule replaces the non-human Vκ segment at the non-human Ig light chain κ locus. Embodiment 57. The targeted vector according to Embodiment 55 or Embodiment 56, wherein, during homologous recombination between the targeted vector and the non-human Ig light chain κ locus, the recombinant nucleic acid molecule replaces one or more non-human Vκ segments and all non-human Jκ segments at the non-human Ig light chain κ locus. Embodiment 58. A targeted vector according to any one of embodiments 55 to 57, wherein, during homologous recombination between the targeted vector and the non-human Ig light chain κ locus, the recombinant nucleic acid molecule replaces all non-human Vκ segments and all non-human Jκ segments at the non-human Ig light chain κ locus. Embodiment 59. The targeted vector according to any one of embodiments 55 to 58, wherein, in homologous recombination between the targeted vector and a non-human Ig light chain κ locus, the targeted non-human Ig light chain κ locus comprises a recombinant nucleic acid molecule operably linked to a non-human Ig light chain κ control sequence at the Ig light chain κ locus. Embodiment 60. A targeted vector comprising a recombinant nucleic acid molecule according to any one of embodiments 1-2 and 18-29, wherein the targeted vector further comprises 5' and 3' homologous arms, the arms targeting a non-human Ig light chain κ locus, thereby, upon homologous recombination between the targeted vector and the non-human Ig light chain κ locus, the targeted non-human Ig light chain κ locus contains the recombinant nucleic acid molecule in an operable linkage to the non-human Ig light chain κ control sequence of the Ig light chain κ locus. Embodiment 61. The targeted vector according to Embodiment 60, wherein, during homologous recombination between the targeted vector and the non-human Ig light chain κ locus, the recombinant nucleic acid molecule replaces the non-human Vκ segment, all non-human Jκ gene segments, and the non-human Cκ gene of the non-human Ig light chain κ locus. Embodiment 62. A targeted vector comprising a recombinant nucleic acid molecule according to any one of Embodiments 1-2, 18-20, 30-31, and 33-38, wherein the targeted vector further comprises 5' and 3' homologous arms, the arms targeting a non-human Ig light chain λ locus, thereby, in homologous recombination between the targeted vector and the non-human Ig light chain λ locus, the targeted non-human Ig light chain λ locus containing the recombinant nucleic acid molecule upstream of the non-human Ig Cλ of the non-human Ig light chain locus and operably linked thereto, optionally in this case the non-human Ig light chain λ locus is an endogenous rodent Ig light chain λ locus and / or in this case the non-human Ig light chain λ locus contains a human or humanized immunoglobulin light chain variable region, contains a deletion of an endogenous Ig Vλ and / or Jλ gene segment, or a combination thereof. Embodiment 63. The targeted vector according to Embodiment 62, wherein, during homologous recombination between the targeted vector and the non-human Ig light chain λ locus, the recombinant nucleic acid molecule replaces the non-human Vλ segment at the non-human Ig light chain λ locus. Embodiment 64. The targeted vector according to Embodiment 62 or Embodiment 63, wherein, during homologous recombination between the targeted vector and the non-human Ig light chain λ locus, the recombinant nucleic acid molecule replaces one or more non-human Vλ segments and all non-human Jλ segments at the non-human Ig light chain locus. Embodiment 65. A targeted vector according to any one of embodiments 62 to 64, wherein, during homologous recombination between the targeted vector and the non-human Ig light chain λ locus, the recombinant nucleic acid molecule replaces all non-human Vλ segments and all non-human Jλ segments at the non-human Ig light chain λ locus. Embodiment 66. The targeted vector according to any one of embodiments 62 to 65, wherein, in homologous recombination between the targeted vector and a non-human Ig light chain λ locus, the targeted non-human Ig light chain λ locus comprises a recombinant nucleic acid molecule operably linked to a non-human Ig light chain λ control sequence at the Ig light chain λ locus. Embodiment 67. A targeting vector comprising a recombinant nucleic acid molecule according to any one of Embodiments 1-2, 18-26, and 30-38, further comprising 5' and 3' homologous arms, the arms targeting a non-human Ig light chain λ locus, thereby, in homologous recombination between the targeting vector and the non-human Ig light chain λ locus, the targeted non-human Ig light chain λ locus comprises a recombinant nucleic acid molecule operably linked to a non-human Ig light chain λ control sequence at the Ig light chain λ locus. Embodiment 68. The targeted vector according to Embodiment 67, wherein, during homologous recombination between the targeted vector and the non-human Ig light chain λ locus, the recombinant nucleic acid molecule replaces the non-human Vλ segment, all non-human Jλ gene segments, and the non-human Cλ gene at the non-human Ig light chain λ locus. Embodiment 69. A non-human animal genome comprising a recombinant nucleic acid molecule according to any one of Embodiments 1 to 39, or a targeted vector according to any one of Embodiments 40 to 68, wherein the non-human animal is optionally a rodent, and the rodent is optionally a rat or a mouse. Embodiment 70. The non-human animal genome according to Embodiment 69, wherein the recombinant nucleic acid is located at the endogenous Ig gene locus of the non-human animal genome. Embodiment 71. A non-human animal or non-human animal cell comprising a recombinant nucleic acid molecule according to any one of Embodiments 1 to 39, a targeted vector according to any one of Embodiments 40 to 68, or a non-human animal genome according to Embodiment 69 or Embodiment 70. Embodiment 72. The non-human animal or non-human animal cell according to Embodiment 71, wherein a recombinant nucleic acid molecule, a targeted vector, or a non-human animal genome is present in the germline of a non-human animal or non-human animal cell. Embodiment 73. A method for modifying isolated cells in vitro, comprising introducing a recombinant nucleic acid molecule described in any one of Embodiments 1 to 39 into the isolated cells. Embodiment 74. An in vitro method according to Embodiment 73, wherein the introduction involves contacting cells with a targeted vector according to any one of Embodiments 40 to 68. Embodiment 75. The in vitro method according to Embodiment 73 or Embodiment 74, wherein the cell is a host cell. Embodiment 76. The in vitro method according to Embodiment 73 or Embodiment 74, wherein the cells are embryonic stem (ES) cells. Embodiment 77. An in vitro method according to any one of embodiments 73 to 76, wherein the cells are rodent cells, and optionally the rodent cells are rat cells or mouse cells. Embodiment 78. A non-human animal embryo produced from embryonic stem cells as described in Embodiment 76. Embodiment 79. A non-human animal produced from embryonic stem cells as described in Embodiment 76. Embodiment 80. A method for producing a non-human animal, comprising transplanting ES cells or an embryo containing ES cells as described in Embodiment 76 into a suitable host, and maintaining the host under suitable conditions to produce viable offspring during the development of the ES cells or embryo. Embodiment 81. Non-human animals, compared to control non-human animals, (a) an equal number of mature B cells in the spleen, (b) an equivalent number of kappa-positive B cells in the spleen, (c) An equivalent number of lambda-positive B cells in the spleen, (d) Equivalent levels of serum IgG, and / or (e) A non-human animal according to any one of Embodiments 71-72 and 79, or a non-human animal prepared according to the method of Embodiment 80, containing an equivalent level of serum IgM. Embodiment 82. The non-human animal is a non-human animal described in any one of embodiments 71-72, 79, and 81, or a non-human animal prepared according to the method described in embodiment 80, which can elicit an immune response equivalent to that of a control non-human animal. Embodiment 83. It contains multiple antigen-binding proteins, each of which contains an anchor-modified Ig polypeptide, and optionally, The mass of each antigen-binding protein supports the presence of anchor-modified Ig polypeptides. The mass of each antigen-binding protein is determined by matrix-assisted laser desorption / ionization-time-of-flight mass spectrometry, or The mass of each antigen-binding protein supports the presence of an anchor-modified Ig polypeptide, and the mass of each antigen-binding protein is determined by matrix-assisted laser desorption / ionization-time-of-flight mass spectrometry in any one of embodiments 71-72, 79, and 81-82, or in a non-human animal prepared according to the method of embodiment 80. Embodiment 84. The non-human animal is a non-human animal according to any one of embodiments 71-72, 79, and 81-83, further comprising a congener receptor of the non-immunoglobulin polypeptide of interest, or a non-human animal prepared according to the method of embodiment 80. Embodiment 85. It comprises multiple antigen-binding proteins, each of which contains an anchor-modified Ig polypeptide, and specifically binds to the homologous receptor of the target non-immunoglobulin polypeptide, and selectively, The mass of each antigen-binding protein supports the presence of anchor-modified Ig polypeptides. The mass of each antigen-binding protein is determined by matrix-assisted laser desorption / ionization-time-of-flight mass spectrometry, or The mass of each antigen-binding protein supports the presence of an anchor-modified Ig polypeptide, and the mass of each antigen-binding protein is determined by matrix-assisted laser desorption / ionization-time-of-flight mass spectrometry in any one of embodiments 71-72, 79, and 81-84, or in a non-human animal prepared according to the method of embodiment 80. Embodiment 86. The homogeneous receptor is a natriuretic peptide receptor (NPR) in the non-human animal according to any one of embodiments 84 to 85. Embodiment 87. Each of the multiple antigen-binding proteins is 1X10 9 KD less than 30 minutes, and / or more than 30 minutes 1 / 2 A non-human animal according to any one of embodiments 84 to 86, comprising the above. Embodiment 88. A non-human animal according to any one of embodiments 84 to 87, wherein at least 15% of the multiple antigen-binding proteins block the binding of the congener receptor to the non-immunoglobulin polypeptide of interest. Embodiment 89. A non-human animal according to any one of embodiments 84 to 88, wherein more than 50% of the multiple antigen-binding proteins bind to a congener receptor expressed on the cell surface. Embodiment 90. A non-human animal according to any one of embodiments 71-72, 79, and 81-89, wherein the non-human animal is a rodent, and optionally the rodent is a rat or a mouse, or a non-human animal prepared according to the method of embodiment 80. Embodiment 91. A method for producing an antigen-binding protein, or a method for obtaining a nucleic acid encoding said antigen-binding protein, Immunizing a non-human animal described in any one of embodiments 71-72, 79, and 81-90, or a non-human animal prepared according to the method described in embodiment 80, with an antigen. This includes causing non-human animals to produce antigen-binding proteins containing anchor-modified Ig polypeptides that bind to antigens, or to produce nucleic acids encoding such proteins, optionally, The mass of the antigen-binding protein supports the presence of an anchor-modified Ig polypeptide. The mass of the antigen-binding protein is determined by matrix-assisted laser desorption / ionization-time-of-flight mass spectrometry, or The mass of the antigen-binding protein supports the presence of an anchor-modified Ig polypeptide, and the mass of the antigen-binding protein is determined by matrix-assisted laser desorption / ionization-time-of-flight mass spectrometry. Embodiment 92. The method according to Embodiment 91, further comprising recovering an antigen-binding protein, or a nucleic acid encoding an antigen-binding protein, from a non-human animal or non-human animal cell. Embodiment 93. The method according to Embodiment 92, wherein the non-human animal cells are B cells or hybridomas. Embodiment 94. Non-human animal cells recovered according to the method described in Embodiment 91. Embodiment 95. The non-human animal cell is a B cell, as described in Embodiment 94 of the non-human animal. Embodiment 96. The B cells are mouse B cells, as described in Embodiment 94 or 95, which are non-human animal cells. Embodiment 97. Hybridoma cells comprising a non-human animal cell according to any one of embodiments 94-95 fused with a myeloma cell. Embodiment 98. An anchor-modified Ig polypeptide, which is encoded by a recombinant nucleic acid molecule according to any one of Embodiments 1 to 39, a targeted vector according to any one of Embodiments 40 to 68, or a non-human animal genome according to any one of Embodiments 69 to 70, expressed by a non-human animal or non-human animal cell according to any one of Embodiments 71 to 72 and 81 to 90, and expressed by a non-human animal or non-human animal cell prepared according to the method of any one of Embodiments 73 to 76 and 80 or prepared according to the method of any one of Embodiments 91 to 93, optionally, The mass of each antigen-binding protein supports the presence of anchor-modified Ig polypeptides. The mass of each antigen-binding protein is determined by matrix-assisted laser desorption / ionization-time-of-flight mass spectrometry, or The mass of each antigen-binding protein supports the presence of anchor-modified Ig polypeptides, and the mass of each antigen-binding protein is determined by matrix-assisted laser desorption / ionization-time-of-flight mass spectrometry. Embodiment 99. The anchor-modified Ig polypeptide according to Embodiment 98, comprising the amino acid sequence described as Sequence ID No. 3 at its N-terminus.

[0259] Other features of the embodiments described will become apparent in the course of describing the exemplary embodiments below, which are given for illustrative purposes only and are not intended to be limiting. [Examples]

[0260] The following examples are provided to those skilled in the art to illustrate how the methods and compositions disclosed herein are prepared and used, and are not intended to limit the scope of what the inventors consider to be their invention. Unless otherwise indicated, temperatures are given in Celsius and pressures are atmospheric pressure or near atmospheric pressure.

[0261] Example 1. Construction of an immunoglobulin variable region containing an ANP-modified immunoglobulin variable region gene segment. This non-limiting embodiment illustrates the construction of a targeted vector for integrating an anchor-modified immunoglobulin (Ig) variable region (V) gene segment into the immunoglobulin variable region of an immunoglobulin locus. As described below, the coding sequence of the C-terminal tail of ANP is operably ligated and positioned with the Ig V gene segment. The modified Ig V segment may also be operably ligated and positioned with the Ig-binding (J) gene segment and, if necessary, the Ig-diversity (D) gene segment, thereby expressing an antibody containing the C-terminal tail of ANP at the N-terminus of an immunoglobulin polypeptide chain during V(D)J recombination.

[0262] ANP modification V, intended for insertion into the variable region of immunoglobulin heavy chains. H Targeted vectors containing gene segments were prepared using VELOCIGENE® technology (e.g., U.S. Patent No. 6,586,251, and Valenzuela et al., 2003, Nature Biotech. 21(6):652-659, which are incorporated herein by reference) and molecular biotechnologies known in the art. Non-limiting strategic examples for constructing targeted vectors using sequences encoding the C-terminal tail of ANPs are shown in Figures 1-2.

[0263] via the sequence encoding the peptide linker, germline V H Donor DNA fragments containing the C-terminal tail of ANP inserted into gene segments 1-69 were prepared by de novo DNA synthesis (Blue Heron Biotech, Bothell, Washington). Figure 1 shows "p466090" ANP-V. H Figure 1 shows the Cas9 donor fragment. Plasmid p46685 was constructed by ligating the EcoRI and AvrII sites of donor plasmid p46609 with the spectinomycin-resistant cassette "SPEC" (Figure 1). Figure 2 shows a detailed view of the obtained donor plasmid p46609.

[0264] The BAC clone VI504 was modified using the donor fragment (MAID6211). See Figure 2. BAC clone VI504 contains, from 5' to 3', an approximately 20 kb 5' homology arm, an approximately 15 kb I-CeuI-AscI fragment containing the mouse Adam6a gene "a", the Frt-Ub-Hyg-Frt cassette, and the mouse Adam6a gene "b", the germline human V H an approximately 9 kb AscI-AsiSI fragment containing the 1-69 gene, human D H and human J H an approximately 60 kb fragment containing the gene, and an approximately 8 kb 3' mouse homology arm containing the mouse IgH intron enhancer (black oval), the IgM switch region, and a portion of the mouse IgM gene (Figure 3).

[0265] In Step 1, VI504 was digested in vitro with Cas9 complexed with a mixture of two gRNAs to cleave 5' and 3' of the human germline V H 1-69 gene. The resulting 3' end and 5' end have a 60 bp overlap with the ends of p46685. Next, the XhoI fragment of p46685 was assembled with VI504 (MAID6211) by Gibson Assembly to generate VI738. In Step 2, VI738 was digested with MreI to remove the spectinomycin resistance cassette. The BAC was then repaired by joiner oligo-mediated Gibson Assembly, leaving a seamless junction (ΔMreI) to generate the final LTVEC VI748 (MAID6833). The LTVEC was identical to VI504 except that VI748 had an ANP-G4S codon inserted.

[0266] The correct assembly of the described donor fragments, and the germline (GL) V of the BAC clone VI504 described herein H 1-69 gene segment and the NP-modified V HTargeted replacement of the 1-69 gene segment was confirmed by sequence analysis and polymerase chain reaction using the primers listed in Table 1 throughout the entire construction of the targeting vector. [Table 3-1] [Table 3-2]

[0267] Example 2. Generation of Rodents Comprising NP-Modified V H Gene Segments This Example demonstrates the generation of a non-human animal (e.g., a rodent) that comprises an immunoglobulin heavy chain variable region, whose genome comprises an NP-modified V H gene segment, for example, a V that comprises the C-terminal tail of ANP H gene segment.

[0268] The VI748 targeting vector was linearized, and electroporated into mouse embryonic stem cells that have a genome homozygous for the endogenous Ig heavy chain variable region locus (1115KO) in which all endogenous V H , D H , H and J H segments except for most of the 5' V 1-86 segment are deleted, and homozygous for the endogenous Ig light chain variable region κ locus in which all endogenous Vκ and Jκ segments are replaced by the complete repertoire of human Vκ and Jκ segments. The Ig heavy chain locus of the ES cells (with a background of 50% Balb, 25% C57BL / 6, and 25% 129) used for electroporation of each targeting vector is shown in Figure 4. After electroporation, the electroporated cells were cultured in selective medium. Drug-resistant colonies were picked 10 days after electroporation, and screened by TAQMAN™ to identify anchor-modified V HUsing primers / probes that detect the proper integration of 1-69 gene segments, chromosomal analysis was performed to assess the accuracy of targeting, as previously reported (Valenzuela et al., cited above; Frendewey, D. et al., 2010, Methods Enzymol. 476:295-307, the relevant literature is incorporated herein by reference in its entirety). Forward primer: TGTGTCCTGTCCACAGGTG (SEQ ID NO: 34) Probe: CCAGTCCAACAGTTCCGGTACG (Sequence ID 35) Reverse primer: CAGCTGGACCTGGCTACC (SEQ ID NO: 36)

[0269] The VELOCIMOUSE® method (DeChiara,™ et al., 2010, Methods Enzymol. 476:285~294; DeChiara,™, 2009, Methods Mol. Biol., 530:311~324; Poueymirou et al., 2007, Nat. Biotechnol., 25:91~99, the entire text of which is incorporated herein by reference) was used. In this method, target ES cells were injected into non-compaction 8-cell stage Swiss Webster embryos to generate healthy, fully ES cell-derived F0 generation mice. These mice were given an anchor (ANP) modified V H The segment is heterozygous and expresses an anchor (ANP) modified antibody. This modified mouse is referred to herein as ANP-V H This is referred to as the 1-69 modified mouse.

[0270] For example, to remove any lox-addition selection cassette introduced by an unremoved targeting construct at the ES cell stage or in the embryo, the drug selection cassette may be optionally removed by subsequent addition of a recombinase (e.g., by Cre treatment) by mating with a Cre-deficient mouse line (e.g., see International Patent Application Publication 2009 / 114400, which is incorporated herein by reference in its entirety). Optionally, the selection cassette may be retained within the mouse.

[0271] Example 3. Analysis of rodent immunophenotypes by flow cytometry. ANP-V H To determine the immunophenotype of the 1-69 modified mice, bone marrow and spleen B cells were analyzed by flow cytometry. This study included two VELOCIMMUNE® control mice (see, for example, U.S. Patents 8,502,018, 8,642,835, and 8,697,940, each of which is incorporated herein by reference in its entirety) and three ANP-V mice described in Example 2. H Modified mice (1-69) were euthanized, and their spleens and bone marrow were collected. Bone marrow was collected from the femur by centrifugation at 8,000 rpm for 2 minutes. The spleen was dissociated and prepared as a single-cell suspension. Red blood cells from the spleen and bone marrow preparations were lysed with ACK lysis buffer and subsequently washed with DPBS containing 2% FBS. Isolated cells (total 1 × 10⁶) 6 The cells were incubated with anti-mouse CD16 / CD32 (clone 2.4G2, BD) on ice for 10 minutes, and then labeled with the antibody panel listed in Table 2 on ice for 30 minutes. [Table 4]

[0272] After staining, cells were washed and fixed with 2% formaldehyde. Data acquisition was performed using a BD LSRFortessa flow cytometer and analyzed using FlowJo. Cell subsets were identified using the following strategies: Bone marrow maturation: immature B cells (B220int IgM+), mature B cells (B220high IgM+), pro-B cells (IgM- B220int, c-KitintCD43high), pre-B cells (IgM- B220int, c-Kit-CD43int). Spleen and bone marrow kappa / lambda: B cells (CD19+ CD3-), T cells (CD3+ CD19-), IgK+ B cells (CD19+ IgK+ IgL-), IgL+ B cells (CD19+ IgK- IgL+). Spleen maturation: Mature B cells (CD19+, B220+, CD93-), follicular B cells (CD19+, B220+, CD93-, CD21 / 35int IgMint / +), marginal zone B cells (CD19+, B220+, CD93-, CD21 / 35+ IgM+), transitional B cells (CD19+, B220+, CD93+), T1 B cells (CD19+, B220+ T2 B cells (CD93+, IgM+ CD23-), T3 B cells (CD19+, B220+ CD93+, IgM+ CD23+), and T3 B cells (CD19+, B220+ CD93+, IgMint CD23+).

[0273] As shown in Figures 5A-5F, in the spleen, ANP-V H In the 1-69 modified mice, similar levels of B cells were present compared to the VELOCIMMUNE® control mice. ANP-V H The frequency of mature B cells in 1-69 modified mice appears to be similar to that observed in VELOCIMMUNE® control mice, but ANP-V H Immature cells in 1-69 modified mice were slightly reduced compared to VELOCIMMUNE® control mice. In the spleen, the frequency of lambda and kappa-positive B cells was reduced in ANP-V H The 1-69 modified mouse is similar to the VELOCIMMUNE® control mouse.

[0274] As shown in Figures 6A-6F, in the bone marrow, ANP-V H In the 1-69 modified mice, similar levels of B cells were present compared to the VELOCIMMUNE® control mice. In the bone marrow, ANP-V was present compared to the VELOCIMMUNE® control mice. H 1-69 modified mice had more pro-B cells and fewer pre-B cells. Compared to VELOCIMMUNE® control mice, ANP-V H In the bone marrow of the 1-69 modified mice, there were fewer mature B cells and more immature B cells.

[0275] ANP-V H To further analyze the immunophenotype of the 1-69 modified mice, mouse IgG levels were analyzed by Western blotting. For this assay, ANP-V H Blood samples were collected from 1-69 modified mice and a subset of VELOCIMMUNE® control mice. Serum was collected in serum separators (BD), incubated for 30 minutes, and separated from blood by centrifugation at 9000 rcf for 5 minutes at 4°C. Mouse serum was diluted 1:25 in PBS and then electrophoresed on 4-20% Novex Tris-Glycine gel under non-reducing conditions. Manufacturer: BioRad Trans-Blot Following the instructions from Transfer System, the gel was transferred to a polyvinylidene difluoride (PVDF) membrane. The blot was then blocked overnight in 10% nonfat milk in Tris-buffered saline (TBST, Sigma) containing 0.05% Tween®-20. The PVDF membrane was incubated at room temperature for 1 hour with anti-mouse IgG-HRP (Thermo / Pierce, Cat #31432) diluted 1:20,000 in a 4% skim milk powder TBST solution. The blot was then washed five times for 5 minutes each, followed by color development for 1 minute using Amersham ECL Western Blotting Detection Reagent (GE Healthcare Life Sciences) according to the manufacturer's instructions. The blot was then imaged using a GE Healthcare ImageQuant LAS-4000 Cooled CCD Camera Gel Documentation System. Images were acquired at 15-second intervals until 20 images were obtained or until the image was fully exposed, whichever came first.

[0276] As shown in Figure 7, when measured by Western blotting, serum IgG levels are ANP-V H The 1-69 modified mice and the VELOCIMMUNE® control mice were comparable. This result suggests that the ANP mouse designer V mouse has normal Ab levels compared to the VELOCIMMUNE® control mouse.

[0277] ANP-V H To further analyze the immunophenotype of the 1-69 modified mice, total serum IgM and IgG levels were measured by ELISA. For the ELISA, plates were coated overnight at 4°C with 1 μg / mL anti-mouse IgM+IgG+IgA (clone Ab102445, Abcam). The plates were then washed in DPBS containing 0.1% Tween-20 and blocked in 1% BSA DPBS solution at room temperature for 1 hour. ANP-V HSerum from either a 1-69 modified mouse or a VELOCIMMUNE® control mouse, along with a mouse IgM standard (Biolegend, catalog number 401604) or a mouse IgG standard (Sigma, catalog number I8765), were serially diluted in 1% BSA DPBS solution and incubated at room temperature for 1 hour. After incubation, plates were washed in DPBS containing 0.1% Tween-20, and IgM or IgG was detected using either anti-mouse IgM-HRP (Southern Biotech, catalog number 1021-05) or anti-mouse IgG-HRP (Southern Biotech, catalog number 1030-05). Further washing was performed, followed by the addition of TMB substrate (BD). After color development, the reaction was stopped with 1N sulfuric acid, and absorbance was measured at 450 nm using a SpectraMax plate reader. Standard plots were created in GraphPad Prism using standard nonlinear regression (curve fitting, 4 parameters) of IgM or IgG, and serum IgM and IgG levels were quantified.

[0278] As shown in Figures 8A-8B, serum IgG levels measured by ELISA are ANP-V H The 1-69 modified mice and VELOCIMMUNE® control mice were comparable. Serum IgM levels measured by ELISA were also comparable to ANP-V. H The results were comparable between the 1-69 modified mice and the VELOCIMMUNE® control mice. Both results suggest that ANP mice have normal Ab levels compared to VELOCIMMUNE® control mice.

[0279] Antibody-mediated anchor retention was verified by matrix-assisted laser desorption / ionization-time-of-flight mass spectrometry (MALDI-TOF MS). Immunoglobulins isolated from mouse serum using Protein A magnetic beads (Thermo Scientific) were electrophoresed on an SDS-PAGE gel under reducing conditions to separate the heavy and light chains of immunoglobulins. The immunoglobulin heavy chains were removed and digested overnight with Lys-C enzyme (Promega). Salts were removed from the digest using a C18 Ziptip (Millipore) according to the manufacturer's protocol. The peptides were eluted from each zip tip in 2.5 µl of 70% ACN / 0.1% TFA containing 10 mg / mL α-cyano-4-hydroxycinnamic acid (CHCA) and directly applied to Bruker Anchorchip Targets (Bruker Daltonics) mixed with α-cyano-4-hydroxycinnamic acid (Protea) dissolved in 70% acetonitrile + 0.1% trifluoroacetic acid (TFA). After drying, each target was analyzed by matrix-assisted laser desorption / ionization-time-of-flight mass spectrometry (MALDI-TOF MS) using a Bruker Ultraflextreme MALDI MS (Bruker Daltonics) in reflextron-positive mode.

[0280] According to MALDI-TOF MS, ANP-modified immunoglobulins are ANP-V H‐ The study suggested that the intact state of the gene was maintained in the serum of 1-69 modified mice (data not shown).

[0281] Example 4. Production of antibodies in rodents containing a manipulated immunoglobulin variable region gene segment. This example demonstrates antibody production in rodents whose genome contains an immunoglobulin heavy chain variable region including the engineered immunoglobulin variable region gene segment described herein. Using the methods described herein and / or immunization methods known in the art, rodents containing the engineered immunoglobulin variable region gene segment described herein can be immunized with the polypeptides or fragments thereof (e.g., peptides derived from a desired epitope) or, if desired, a combination of polypeptides or fragments thereof.

[0282] In short, a cohort of mice containing the modified immunoglobulin variable region gene segments described herein is challenged with a target antigen, such as a receptor for a target non-immunoglobulin polypeptide that binds to a congener receptor, using immunization methods known in the art. The antibody immune response is monitored by an ELISA immunoassay (i.e., serum titer).

[0283] immunization

[0284] VELOCIMMUNE® control (n=3) mice and ANP-V H 1-69 modified (n=4) mice were immunized with a protein immunogen (referred to as human NPR3 ecto-mFc) consisting of the extracellular domain of NPR3 fused to a C-terminal mFc tag, using a standard immunization protocol. Blood was collected from the mice before the start of immunization and after immunogen boosting. Mice were euthanized after the final blood collection to isolate antibodies. Titer analysis was performed against human NPR3 protein (consisting of the extracellular domain of NPR3 fused to a myc-myc-hexahistidine tag; referred to as human NPR3 ecto-MMH) and engineered human NPR3-expressing cells (HEK293 cells engineered to overexpress full-length human NPR3; referred to as 293 / hNPR3).

[0285] Determination of antiserum titer

[0286] Antibody titers in serum against NPR3 were determined using ELISA. 96-well microtiter plates (Pierce) were coated overnight at 4°C with 2 μg / mL human NPR3 ecto-MMH antigen in phosphate-buffered saline (PBS, Irvine Scientific). The plates were washed with PBS-T (Sigma-Aldrich) containing 0.05% Tween 20 and blocked at room temperature for 1 hour with 250 μl of PBS solution of 0.5% bovine serum albumin (BSA, Sigma-Aldrich). The plates were washed with PBS-T, and pre-immunoantiserum and immunoantiserum were added to the plates at room temperature for 1 hour after being serially diluted 3-fold in 0.5% BSA-PBS. The plates were washed, and goat anti-mouse IgG-Fc-horseradish peroxidase (HRP) conjugate secondary antibody (Jackson Immunoresearch) was added to the plates at a 1:5000 dilution and incubated at room temperature for 1 hour. The plates were washed again, and color development was achieved by incubation for 15-20 minutes using TMB / H2O2 as the substrate. The reaction was stopped with acid, and the plates were read on a 450 nm spectrophotometer (Victor, Perkin Elmer). Antibody titers were calculated using Graphpad PRISM software. Titer was defined as the interpolated serum dilution factor, and the binding signal was 2 times the background.

[0287] Antibody titer against cells

[0288] Anti-NPR3 antibody titers against manipulated cells were determined using the Meso Scale Discovery (MSD) MULTI-ARRAY® method. 96-well carbon electrode plates (MSD) were coated with 40,000 cells per well of either 293 / hNPR3 or HEK293 cells in PBS at 37°C for 1 hour. The cell coating solution was discarded, and the plates were blocked by incubation at room tempera...

Claims

1. A composition for use as a pharmaceutical, comprising an anchor-modified antibody, wherein the anchor-modified antibody is in a functionally linked manner. (i) Anchors, and (ii) An immunoglobulin (Ig) variable (V) domain comprising a framework region (FR) 1, a complementarity-determining region (CDR) 1, FR2, CDR2, FR3, and a portion of CDR3, which is encoded by a germline Ig V segment or a variant thereof, wherein the variant is selected from the group consisting of its polymorphic variant, its somatic hypermutant variant, its recombinant variant, and its degenerate variant. Includes, The anchor comprises a receptor-binding portion of the target non-immunoglobulin polypeptide that binds to a congener receptor, and A composition in which the IgV domain specifically binds to the homologous receptor.

2. The germline Ig V segment or its variant is germline Ig heavy chain variable (V H The composition according to claim 1, which is a segment, or a polymorph thereof, somatic hypermutation, recombinant, or degenerate variant.

3. Said germline Ig V segment or said variant thereof is a germline human (h) V H 1-2 segment, germline hV H 1-3 segment, germline hV H 1-8 segment, germline hV H 1-18 segment, germline hV H 1-24 segment, germline hV H 1-45 segment, germline hV H 1-46 segment, germline hV H 1-58 segment, germline hV H 1-69 segment, germline hV H 2-5 segment, germline hV H 2-26 segment, germline hV H 2-70 segment, germline hV H 3-7 segment, germline hV H 3-9 segment, germline hV H 3-11 segment, germline hV H 3-13 segment, germline hV H 3-15 segment, germline hV H 3-16 segment, germline hV H 3-20 segment, germline hV H 3-21 segment, germline hV H 3-23 segment, germline hV H 3-30 segment, germline hV H 3-30-3 segment, germline hV H 3-30-5 segment, germline hV H 3-33 segment, germline hV H 3-35 segment, germline hV H 3-38 segment, germline hV H 3-43 segment, germline hV H 3-48 segment, germline hV H 3-49 segment, germline hV H 3-53 segment, germline hV H 3-64 segment, germline hV H 3-66 segment, germline hV H 3-72 segments, germline hV H 3-73 segments, germline hV H 3-74 segments, germline hV H 4-4 segment, germline hV H 4-28 segments, germline hV H 4-30-1 segment, germline hV H 4-30-2 segment, germline hV H 4-30-4 segment, germline hV H 4-31 segments, germline hV H 4-34 segments, germline hV H 4-39 segments, germline hV H 4-59 segments, germline hV H 4-61 segments, germline hV H 5-51 segments, germline hV H 6-1 segment, germline hV H 7-4-1 segment, germline hV H The composition according to claim 2, which is a 7-81 segment; or a polymorph, somatic hypermutation, recombinant, or degenerate variant thereof.

4. The germline IgV segment or its variant is germline hV H The composition according to claim 2 or 3, which is a 1-69 segment, or a polymorph thereof, somatic hypermutation, recombinant, or degenerate variant.

5. The FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 of the anchor-modified antibody are reconstituted IgV H / D H / J H A composition according to any one of claims 2 to 4, encoded by an array.

6. The anchor-modified antibody has an Ig heavy chain constant region (C H A composition according to any one of claims 1 to 5, comprising )

7. The IgC H The composition according to claim 6, wherein the isotype is IgM, IgD, IgG, IgA, or IgE.

8. The germline Ig V segment or its variant is germline Ig light chain variable (V L The composition according to claim 1, which is a segment, or a polymorph thereof, somatic hypermutation, recombinant, or degenerate variant.

9. The germline Ig V L The composition according to claim 8, wherein the segment or the variant thereof is a germline Ig light chain variable kappa (Vκ) segment, or a polymorph, somatic hypermutation, recombinant, or degenerate variant thereof.

10. The germline Ig V L The composition according to claim 8, wherein the segment or the variant thereof is a germline Ig light chain variable lambda (Vλ) segment, or a polymorph, somatic hypermutation, recombinant, or degenerate variant thereof.

11. The FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 of the anchor-modified antibody are reconstituted IgV L / J L Array, arbitrarily, reconfigured V L / Jκ sequence or reconstituted V L The composition according to claim 8, encoded by the Jλ sequence.

12. The aforementioned anchor-modified antibody has a constant Ig light chain (C L The composition according to any one of claims 8 to 11, comprising the region of )

13. The composition according to any one of claims 1 to 12, wherein the anchor comprises a linker, the linker links the receptor-binding portion of the target non-immunoglobulin polypeptide to the FR1, CDR1, FR2, CDR2, FR3, and CDR3 of the germline Ig V segment or a variant thereof, and optionally the linker comprises the sequence GGGGS (SEQ ID NO: 5).

14. The composition according to any one of claims 1 to 13, wherein the anchor comprises a natriuretic peptide receptor (NPR) binding portion of a natriuretic peptide (NP), optionally the NPR binding portion of the NP comprises the C-terminal tail of the NP, and / or the NP is an atrial natriuretic peptide (ANP), and optionally the anchor comprises the sequence NSFRY (SEQ ID NO: 3).

15. The composition according to any one of claims 1 to 14, wherein the anchor-modified antibody is included in the pharmaceutical composition, and optionally the pharmaceutical composition includes a buffer, a diluent, an excipient, or any combination thereof.

Citation Information

Patent Citations

  • Secreted variant immunomodulatory proteins and engineered cell therapies

    JP2020500010A

  • Product and process for targeting an immune response

    US5698679A

  • Chimeric activators: quantitatively designed protein therapeutics and uses thereof

    WO2008124086A2